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Abstract
The rise of the Anthropocene has seen more global pollution than before in history. With
the explosion of consumer electronics in the last half century, the rise of metal pollution
from their extraction and disposal results in the unnatural introduction of heavy and rare
metals into the ecosystem. Organisms have a metal defense protein, metallothionein,
which has multiple roles in essential metal regulation and protection against toxic metal
exposure. However, these modern heavy metals prominent in electronics are not found
biologically and their interactions in the body are generally unknown. Some of these
metals are employed as therapeutic agents in the treatment of cancers, and as such this
Thesis describes an investigation of therapeutic agents as models for heavy metal
pollution to provide insight into the mechanisms of metal metabolism. Using electrospray
ionization mass spectrometry and spectroscopic techniques, the binding of human
metallothionein with the exotic metals platinum and rhodium is explored. Platinum and
rhodium bind readily to human metallothionein, raising concerns for toxicity.
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Summary for Lay Audience
Metals are everywhere. Some metals are required by humans and organisms as nutrients,
while some can be extremely toxic. These toxic metals can be deadly depending on
amount of exposure, often causing heavy damage to cells and tissues. Life has adapted to
light levels of toxic metal exposure with proteins that are involved in metal binding - a
group of proteins known as Metallothioneins. When exposed to toxic metals, cells will
increase the production of this protein, metallothionein, to counteract the increased
exposure. These metallothionein proteins capture the toxic metal and isolate it from
performing its toxic activity. This response also can occur in some cancer cells, in
response to metal-based therapy (cisplatin, a platinum-based drug), where the metal in the
drug triggers the cancer cell to have an aggressively defensive response. At the chemical
level, metallothionein acts to break apart the drug molecule and isolate the toxic metal for
safe excretion from the body. Recent research in constructing robust molecular
frameworks for these drugs to improve cancer treatment efficacy may be able to bypass
Metallothionein’s defensive nature in these aggressive cancers. Using an extremely
precise analytical methods known as mass spectrometry that show the changes in the
exact mass as the protein breaks down the metal from the drug. While metal-based drugs
are a specific type of toxic metal exposure, there is a fear of the increased impact of
human activity on ecosystems, climate, and the environment will result in toxic metal
exposure to all life in ways that has not been done before. These involve toxic metals that
have never had a biological role and are found in major electronics and consumer goods
that are now a standard of living. The implications of these cancer drug analyses with
metallothioneins are extended to address this issue of toxic metal pollution and its effects.
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Chapter 1

1

Introduction to Metallothioneins*
1.1

Metals are Ubiquitous

Living organisms are exposed to metals everywhere on Earth: from its crust and from its
bodies of water, and through particulates in the air. Essential, non-essential, and toxic
metals are consumed from fruits, vegetables and meats, and drinking water. Some of
these metals are necessary for life and play a critical role in biological processes, while
others can be extremely harmful. Where one resides geographically is a factor in the
dietary source of metals. For instance, living near an active volcano may make one more
exposed to airborne metals that settle in surrounding lands, which then become
incorporated in the surrounding vegetation. This is also the case of those living downwind
from coal power electric stations and living adjacent to landfill sites. In contrast, other
regions of the earth are so metal deficient in the soil that they cannot sustain agriculture.
Heavily urbanized cities with an abundance of vehicular traffic and industries introduce
metals through exhaust and waste products. Alarmingly, for example the effects of this
pollution can also be traced in the correlation of heavy metal content in honey in bee
farms in close proximity to urban development.1 Human exposure to heavy metals is also
related to the occupational environment, for instance industrial workers involved in raw
material processing are more likely to have higher exposure to toxic xenobiotic metals.
Metal bound proteins isolated from fish2 such as rainbow trout (Salmo gairdneri),3 show
that polluting aquatic bodies with mineral waste can result in bioaccumulation in the
tissue. Yet despite the ubiquity of heavy toxic metals, there is clearly a defense
mechanism in play that protects organisms against such constant, chronic exposures.
Even in the environmentally conscious minds of the 21st century, the trash from the past
haunts us.4 Widespread global metal poisoning events from industrial malpractices still
leave scars (for more information, google search terms like “Itai-itai Disease,” or
“Ontario Minamata Disease”). While as a whole, the human population is moving
towards “green” technology, waste generation from infrastructure materials and consumer
goods is still a major issue. In the current technological age, our love for super computers
*A version of this chapter has been submitted for publication:
In Comprehensive Coordination Chemistry III, Volume 8: Bio-coordination Chemistry, Elsevier.
Reproduced with permission from: D. L. Wong and M. J. Stillman.
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that fit in our hands demands greater quantities of rare metals. The mining, refining, and
production of materials containing these metals can be devastating on the environment.4-6
The end of product life cycles also leaves much metal behind in landfill sites. Some of
these metals being discarded have never been biologically present or played any role in
physiological chemistry yet is now well known that this pollution is being distributed
globally. As a result, all life across the globe will eventually be exposed to a host of
xenobiotic metals that are unknown to human and organismal physiology. To understand
the effects of this non-traditional metal exposure, we first must understand the metal
regulation mechanisms that Life has in play.

Figure 1-1 Dose-Response Curve (Bertrand Diagram)
Dose-response curve that shows the physiological effect (positive or negative) from
exposure to metals under essential, (green line), therapeutic (blue line), and toxic
conditions (red line).
Figure 1-1 shows a dose-response curve (more antiquatedly known as a Bertrand
Diagram, named by Bert L. Vallee).7 Its schematic description illustrates the
physiological effects as the exposure to a metal increases from zero. For all organisms,
there is a minimum requirement for the intake of essential metals (green line, examples of
which include Fe(II), Mg(II), and Zn(II)) that keep the biological machinery functioning
optimally. Not achieving that minimum results in a state is described as “Deficient” with
negative physiological effects. Like much in Life, moderation is key – saturating a system
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with metals will damage the delicate physiological chemistry when there is no mechanism
with which it can respond. There are some metals that are always toxic and play no
known physiological role, where any amount is detrimental (red line). Small exposures to
these metals may be tolerated due to inherent resistance mechanisms, but if the exposure
exceeds these levels, death results (for instance, arsenic was used as a classic
Shakespearean poison). In rare cases, a metal ion or a metal complex can act
therapeutically (blue line) but only in a narrow dosage window can the benefits outweigh
the detrimental effects. Often, these metals used for such specific applications will cause
negative side effects with long term use. This is the case with cisplatin, a platinum based
anti-cancer agent that can cause severe renal damage with long term use.8

1.1.1

Zn(II) is Essential, Cd(II) is Toxic

Zn(II) is an abundant d-block metal that is essential in humans in its Zn(II) cationic
oxidation state for physiological chemistry. It differs from most d-block metals as it
remains in a fixed 2+ oxidation state, but its role is no less exciting. Based on its
remarkable Lewis acidity and almost rigid tetrahedral geometry in structural roles, it has
been reported that Zn(II) is a required cofactor in thousands of essential metal-dependent
enzymes.9
Isomorphous to Zn(II) but deadly, Cd(II) is a poisonous metal with toxic effects that
result from its similarity to Zn(II) and Ca(II). Cd(II) exists naturally alongside Zn(II) and
it is absorbed biotically via the same mechanisms as biological Zn(II). However, any
amount of Cd(II) is toxic, with a long biological half-life of several decades in humans.10
Cd(II) can replace native Zn(II) in enzymes, can cause brittleness in bones, and causes
renal damage during excretion.11
Human cellular physiology can tolerate small amounts of Cd(II), which is good
considering many plants and the animals that feed on them can draw minute amounts
from the soil. This raises the question: how do our cells manage to sort essential metals
from those that are toxic?
The focus of this thesis is the metal-binding protein, metallothionein (MT), whose major
role has been identified as the metal chaperone for Zn(II) and Cu(I), and a source of

4

cellular Zn(II) for metal-dependent enzymes. Metallothioneins (MTs) are a large family
of small cysteine rich proteins that are found in all Life. It is through the multitude of its
cysteine residues (30% of the residue content) that it can sequester metals. MTs have
been found to be involved in a large variety of biochemical mechanisms and response
pathways. MT has an unusual structure due to its small size and flexibility. With the
general mantra that protein structure begets function, this makes MT’s function difficult
to define. The structural details of holo- and apo-MT are described further below.
What is the role of MTs in Life? Since its discovery in 1957,12 many original research
papers have had trouble strictly defining MT’s role in Life; that is, its designed purpose.
In the Proceedings of the second international meeting on metallothionein and other low
molecular weight metal-binding proteins, Vallee, one of the original discoverers of
equine MT, describes metallothionein as a “sphinx’s riddle”.13 That enigma is multiplied
by the broad genetic diversity of metallothioneins across all of Life, and questions its
evolutionary development. The multiple possible roles of MT presented a two-sided coin
in terms of how to approach its study. In vivo observation of MT activity in wildlife lets
us see the native structure in its natural role, and its response to differing environments. In
vitro observation lets us see what chemistry MT is capable of, depending on the external
factor, like metal poisoning or drug resistance.

1.1.1.1

Homeostasis and Regulation of Physiological Zn(II)

MTs are believed to be key players in d-block metal regulation through trafficking and
storage, primarily of Zn(II) and Cu(I), and cellular levels are controlled through MT
induction.14-16 However, there is basal level of MT expression, even in Zn(II) deficient
situations.17-19 MT’s ability to chelate multiple intermediate and soft metals and to donate
these ions individually to enzymes is strong evidence of this role in vivo. The stepwise
binding coefficient of each preceding metallation event selects the first metal for
donation, as the last bound.20 Factors that control stepwise metallation include the solvent
accessibility of the bound metal, which MT domain the metal is bound to, and whether
the metal ion binding site involves terminal or bridged cysteine coordination.
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Udom et al. showed that Zn(II) MT could reconstitute apo-enzymes that had lost their
essential metal cofactor and reactivate them to full activity.21 Maret and Vallee showed
that MT interacts via Zn(II) mediation between itself and the DNA binding domain of the
transcription factor Gal4.22 This Zn(II) transfer likely occurs via protein-protein
interactions between MT and the receiving peptide, as MT has been shown to transfer
metals between other MT molecules in this fashion.23, 24 When we consider that Zn(II)
makes up cofactors in every chemical class of enzymes, and is essential for gene
expression, the regulation of this metal in the cell is vital.25
The concepts of the magnitude of the binding constant strength in relation to the chelate
effect theory apply here. Metallothioneins are essentially multiligand chelators that
metallate in stepwise fashion. The rate kn with which the first metal binds is statistically
greater than the next kn+1 such that the last metal bound (7th for M(II)) is the slowest to
bind. When describing this in terms of binding constants, the stepwise reaction with the
greatest KF is most favourable and most stable, from which we can identify the
cooperative cluster formation, from its greater KF. The last metals to bind are, therefore,
the weakest bound, and most likely to dissociate first (lowest KF, highest KD).20 It is clear
that these most labile metals are those that are involved in metal donation to enzymes and
biological targets. Corresponding NMR studies show that the most labile metals are
bound to the more solvent accessible cysteines, which may explain their lability.26
Figure 1-2 illustrates how the 7 stepwise binding constants for Zn1-7MT overlap the
binding constant of apo carbonic anhydrase (CA), with the last two Zn(II) ions bound to
MT shared or donated to apo-CA. Competition studies showed that the MT does not
donate a Zn(II) ion to the apo-CA until after the fifth metal has bound to the MT. This
indicates that the last two metals to bind for fully metallated Zn7MT are the most labile
and available for donation.27
The most effective technique for analyzing the binding constants of the individual
metallation steps is by using the resolving power of native electrospray ionisation mass
spectrometry (ESI-MS), discussed further in this Chapter.
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Figure 1-2 Donation of Zn(II) in Zn-MT to apo carbonic anhydrase
Zn(II)5-7MT, the most labile ions in terms of the stepwise binding constants, are the first
metals donated to carbonic anhydrase. This figure is adapted from T. B. J. Pinter and M.
J. Stillman (2015). 28

1.1.1.2

Cadmium and Heavy Metal Toxicity

Without a doubt, the initial discovery of MT as a Cd-binding protein presented a bias
towards its perceived role in heavy metal detoxification. MTs are excellent at
accumulating toxic heavy metals. Soft heavy metals like Hg(II) and Cd(II) bind to MT in
vivo, which induces the synthesis of new MT protein. Accumulation of MT in response to
elevated metal ion concentrations, combined with its association with these ions, indicates
a role in the sequestration of any excess metal ion.29 Importantly, heavy, toxic metal ions
including, but not limited to, Hg(II), Cd(II), Pb(II), As(III), Pt(II), Pd(II), Rh (I,II), only
are present in the body as a result of external intake. These soft heavy metals have no
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known biological role. Man-made industrial practices as described above have literally
dug up these metals and through consumerism, introduced these metals into the
ecosystem of the Earth’s surface, with the nightmare scenario being a catastrophic
pollution event (for example, Aznalcóllar Disaster, Donana Park, Spain30). These
electron-rich d-block metals displace natively bound essential metals (e.g. Zn(II), Cu(I)),
destroying enzymatic activity, or disrupting biological structures, often irreversibly. The
presence of these metal ions can also establish a pro-oxidant environment, where redox
reactions and resulting reactive oxygen species can affect cellular and genetic structures.31
The induction of MT synthesis has been correlated to external Cd(II) and Cu(I) tolerance
in both a variety of cultured cells and animal studies.32 Heavy metals like Hg(II) and
Mn(II) are known to accumulate in thiol rich fractions of cells in marine fish.3 Use of
trace metal analysis of fish to understand the extent of pollution in a marine source is
based on the idea of bioaccumulation. During the life of a fish, metals accumulate within
their body and are neither metabolized nor excreted. Biomagnification is a related
principle that extends bioaccumulation through the predators of the food chain; those at
the top of the food chain consume not only the metals of those within the fish of the rung
below, but also the fish that was consumed by that fish, and the fish below that, etc.
Animal studies show that after exposure, Cd(II) binds to albumin in the blood plasma, and
is transported to the liver.11 Initially, Cd(II) levels rise in the liver as a result. The arrival
of Cd(II) in the liver signals MT synthesis, which chelates the Cd(II) to form Cd-bound
MT (Cd-MT), which in turn, circulates the body via blood plasma towards the kidneys.10
In mammals, the small molecular weight (MW) of Cd-MT allows it to be filtered by the
proximal tube of the glomerulus, excreted though the renal system and exits the body in
urine. Unfortunately, this process is not rapid. Cd-MT can be reabsorbed by the tubular
cells, and subsequently release relatively large concentrations of Cd(II) upon Cd-MT
degradation, leading to renal damage. Friberg et al. reported that the half-life of Cd(II) in
the blood on the order of hundreds of days, and several years to decades in the kidneys.11
High levels of Cd-MT in the urine are markers for toxicity, as was established in Japan
following the mass “Itai-Itai Disease” outbreak from Cd(II) poisoning caused by
malpractices of Mitsui Mining & Smelting Co. Itai-Itai disease is one of the Four Major
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Pollution Diseases of Japan.33 Industrial waste from the smelting plant entered the Jinzu
River Basin, where downstream citizens relied on the river ecosystem to provide fish,
fresh water, and irrigation for rice crops. Over time, crippling physiological effects
related to the poisoned ecosystem became evident in the affected population. Side effects
included brittle bones, and severe renal damage with Cd-MT prevalent as a urinary
marker for the affliction.34
More recently, similar damage to other ecosystems occurred both in Japan23 and Canada
24

from industrial mercury waste,35, 36 which became incorporated in the marine

ecosystem including fish that were essential to the local diet. This caused the severe
neurological effects of Minamata disease in the affected population.

1.2

Metallothioneins are Ubiquitous

The metallothionein family is remarkable in that it appears that every phylum in Life has
an MT or MT-like protein involved in metal regulation. About one-third of its short, ~61
amino acid sequence comes from phylogenetically conserved cysteine regions. These
cysteines, often in the sequence as –C-C-, -C-X-C- or -C-X-X-C- repeat regions, have
soft, reactive thiolates involved in metal binding, but do not form disulfide bonds
natively. MTs are present in all mammalian tissues, with more pronounced expression in
the liver, kidney, brain, and during fetal development.37 These proteins exist in the
cytosol and in the nucleus, as well as in extracellular fluids like bile, plasma, and urine.38
MTs are unorthodox in their high metal loading capabilities, and their promiscuous
nature: one protein molecule is capable of multiple and variable stoichiometric metal
binding.13 Class 1 MTs do not form a single, specific metal –loaded species, unless
through strictly controlled metal exposure. We see this heterogeneous binding property in
the simultaneous binding of Zn(II), Cu(I), and Cd(II) in a single protein molecule.
Because of these wildly adaptive behaviors, the biological role of MT was a subject of
great debate in the years following its discovery.39 Was it involved in detoxification?
Could MT reactivate apo-enzymes? Why could MT be induced by such a variety of
external agents?
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The discovery of other low MW, cysteine rich proteins demonstrated their evolutionary
necessity, but through natural divergence, the purpose and functions have become
optimized by their amino acid structure. These sulfur rich metal binding proteins are
given the family name of, “metallothioneins,” and are divided among 3 class types, based
on their similarities of their cysteine homologies.
Class 1 MT: polypeptide with a highly conserved sequence: cysteine residues are
congruent with those in the equine renal cortex sequence (e.g. mammalian, vertebrate)
Class 2 MT: polypeptide that is also rich in cysteine residues, though not entirely in the
same location as equine renal cortex. (e.g. fungi, plant, invertebrate)
Class 3 MT atypical, non-translationally synthesized metal thiolate polypeptides e.g.
cadystins, phytochelatins

Figure 1-3 Mammalian MT isoforms
Representative single amino acid code sequences of mammalian MTs. Conserved cysteine
motifs highlighted with black. Sequences obtained from the UniProt Database, with the
respective protein ID in parenthesis.
Within each class, there are 4 major isoforms characterized by their cysteine topology
(e.g. MT1, MT2, MT3, MT4, Figure 1-3, Figure 1-4), that represents a protein category
within a species’ MT gene expression. A representative sequence of mammalian MTs
representing each isoform is shown in Figure 1-4. These isoforms themselves may have
sub-isoforms (e.g. MT1A,-1B, -1C etc.). These sub-isoforms exhibit single residue
variation in their amino acid sequence that affects the charge of the overall protein. This
leads to the question of whether sequence-specific MT in higher level eukaryotes
expressing these multiple MT genes have their own have specific metal binding
properties. The majority of the studies described in this Thesis concern Class 1 MTs, with
the experiments performed utilizing recombinant human metallothionein 1a.
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1.2.1

Human Metallothioneins

Human metallothioneins are understandably the most relatable of the vertebrate MTs.
Humans MTs are divided into four main subtypes, and each display slightly varied
characteristics.

Figure 1-4 Human MT1 and MT2 protein sequence
Single amino acid code sequences of human MT isoforms 1-4 displaying MT1 with its
multiple sub-isoforms. Cysteine residues are highlighted in black. Sequences obtained
from the UniProt Database, with the respective protein ID preceding the isoform.
MT1 and MT2 are the major isoforms present in all species but are highly expressed in
the liver and kidneys. These isoforms are generally found in vivo bound to Zn(II) and
some Cd(II). While MT2 is expressed homogenously, MT1 can exist in several
subisoforms as shown in Figure 1-4. MT 3 is expressed in the brain and is known to
favour Cu(I)/Zn(II) binding. This particular isoform has been linked to mitigation of
protein misfolding and aggregation in neural cells, leading to neurodegenerative diseases.
MT 4 is expressed in squamous epithelial cells, which line the outside of organs to afford
external protection.
Along with their metal binding properties, MTs are associated with oxidative stress
remediation. Compared to glutathione, another prominent cellular antioxidant, MT is
shown to have a twenty times greater protective power against peroxide radical
damage.40, 41 This makes MT an indirect player in many roles of cellular regulation, and
protection against generic cellular damage, sparking interest especially in MTs role in
diseases, aging, and drug resistance.
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1.3

Structural Elements of Metallothioneins

Protein structure defines its function. This is a dogma that is difficult to apply to the
flexible nature of MT. The structural properties of MTs are enigmatically elusive; the
most easily observable form being the fully metallated MTs. Complete metallation forms
the two characteristic metal-thiolate clusters; an observable feature that can be readily
identified using a number of instrumental techniques, once it has completely formed.
Even with full metallation, crystallization of MT has proven hard. In many proteins, their
secondary structural features provide stability such that crystals can be isolated and
structurally analyzed, but with MT this is not the case. To our knowledge, just one X-ray
diffraction study is reported for mammalian MT, that is, for Cd,Zn-MT1 from rat liver.42
The structural parameters were greatly extended by 1H NMR studies subsequent to this
report.43 The presence of a two domain structure in mammalian MT was established from
111/113

Cd NMR studies pioneered by the Armitage group, starting in 1980. The 1H NMR

and X-ray diffraction results were discussed together in a single paper giving great detail
to the protein structure and linker region.43
MT is a cytoplasmic protein and relies heavily on the solution environment for the native
structure it adopts. MT in vivo is not fully metallated. Cd7MT and Zn7MT are not easily
found, unless under extreme Cd(II) or Zn(II) exposure. Conversely, the metal-free apoprotein, or partially metallated protein long eluded isolation, until Maret and workers
reported the use of Förster Resonance Energy Transfer (FRET) imaging to establish the
presence of free thiols in MT.44-46 This new discovery led to a significant paradigm shift:
what was originally believed to be fully holo (fully metallated) was now known to exist in
a partially metallated state. Therefore, metallation of MT is a post-translational
modification.47 The MT structure is significantly more dynamic and variegated than
traditional elucidation techniques could determine.

1.3.1

Metal-Induced Structure

The formation of the many metal-thiolate bonds in MT is the driving force for its
subsequent folding and structural order. MT has few hydrophobic residues, implying that
the major intramolecular forces at play are electrostatics, hydrogen bonding, and the key
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element: formation of the metal-thiolate bond in tetrahedral beads,48 as we continue in our
discussion below. The stepwise metallation sequence itself, has revealed most unusual
binding site properties for a protein, in that the metal induced folding depends on the
metal loading status. Early spectroscopic studies involving MT metal binding focused on
finding the stoichiometry at which the observed signal for metallation became saturated.
This provided in essence, a “frozen” state that could be examined for its properties. Thus
the idea of “magic numbers” based on the stoichiometry of signal saturation was
popularized for defining the metal binding properties of MT.49 These golden numbers
were identified with the metals that had been found in MTs of living organisms, including
Zn(II), Cd(II), Cu(I), and Hg(II). These metals were studied extensively for their possible
role in MT’s function. For the purpose of this Chapter we will refer to these as the
classical metals. As we will see further in the Chapter, metals that do not belong in this
category or are encased in coordination complexes do not follow these magic numbers.
These metals are never found physiologically. Their metal binding chemistries are
governed by the flexibility of the MT protein, and the geometry of the incoming metal
complex. We will describe these metals as non-traditional, when we discuss their
metallation of MTs further below.

1.3.2

Non-Traditional Metallation of Metallothioneins

All cells have a basal level of MT expression. Increased protein production can be
induced by external pressures, such as oxidation, or the presence of heavy metals as
described above. In certain cancer types, MT expression has been correlated to developed
resistance against therapeutic action. MT can break down metal complexes to their metal
ion. Platinum based drugs and other cytotoxic agents face this drug resistance, which has
been associated with an increase in gene expression or protein production of MT,
particularly in cancerous cells. The combination of the abhorrent and uncontrolled growth
of cancerous cells plus the ability to increase production of this multi-protective peptide
provides a formidable defense against chemotherapeutic agents. As we will discuss
further, the acidic conditions of a cancerous cell50 promotes the protective effect of MT,
particularly against the electron rich transition metals being used in these medicines.
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Because of their propensity to bind soft d10 metals (e.g. the aforementioned Cu(I), Zn(II),
Cd(II), Pt(II) etc.), MTs are suspected of playing a role in the developed resistance to
cisplatin and as such, the protein’s ability to possibly bind any metal has been of interest
when considering therapeutic agents that can withstand this resistance.
As we will see in Chapter 2, the general metallation mechanism in vivo involves
tetrahedral cysteine M(II) coordination, with the onset of clusters at high metal loading or
a lower pH environment. We can see a variety of different coordination behaviors with
M(I), e.g. Cu(I) can bind MT with a variety of metal stoichiometries (6, 12, 20), and each
of these may involve different coordination modes. With 6 mol. eq. of Cu(I), a Cu6S9
cluster forms. With 12-13 mol. eq., a combination of a Cu6 and Cu7 cluster forms. In both
cases, trigonal coordination was assigned. However, at 20 eq.of Cu(I), the metal
conformation requires digonal cysteine thiolate coordination. The reaction with Cu(I)
shows the great degree of flexibility that MT binding can take on, and that in vitro, we
can push the envelope of possible binding modes to explore what could happen. The
flexible nature of hydrogen bonding in MT allows for a variety of unexpected interactions
to occur. For example, N and O donors are known to be involved in binding some metals
and may tune the soft/hard nature of the chelating MT.
In the following section we describe the mechanism of this metal sequestration, how the
structures adopted from the metallation relates to MT function, and how the resulting
protein depends on the conditions involved.

1.4
1.4.1

Techniques Used in this Thesis
Expression and Purification of Recombinant Human
Metallothionein 1a

Model species are “models” because they have rapid production times and can be
observed easily. What grows faster than bacteria? Recombinant expression involves
employing bacterial machinery to over express translation of a desired protein, in our case
MT. This technique is ideal for plant and human MTs, as Escherichia coli can grow in
large quantities with short life cycles and faster growth periods, without the need for
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animal decapitation. The technique used in this Thesis was developed by Peter Kille and
Ian Watt at Cardiff university.51 The general procedure is summarized as:
Complementary DNA (cDNA) of the metallothionein mRNA is cloned into a plasmid.
Typical plasmids will also include coding for proteins “tags” or short amino acid
sequences that can assist in protein purification that are later removed. Other important
elements of the plasmid include a transcriptase, a resistance marker to aid in cell
selection, and an inducible repressor (such as the Lac I repressor) to induce expression.
Once these plasmids are prepared, they are transformed, or transferred into the host E.
coli cells.
These cells now carry a resistance to the antibiotic defined in its plasmid sequence, and
we can take advantage of antibiotics to ensure the growth of only the transformed cells. A
small preparation is made on LB Agar plates with the antibiotic kanamycin, according to
the protocol in Figure 1-5(Left). These cells are inoculated in a liquid LB Broth culture
(prepared according to the protocol in Figure 1-5(Right) and grown until they reach a “lag
phase” (the bacterial growth plateau), at which point the maximum number of viable cells
is present. In the case of the Lac I repressor, Isopropyl β-D-1-thiogalactopyranoside
(IPTG) turns on this repressor and is added externally to initiate MT expression.
A difficulty with metalloprotein overexpression is the maintenance of structure upon
synthesis, as once formed, proteins are vulnerable to protease and other regulatory
actions. To properly isolate large quantities of the induced protein, extra metal is added to
the medium to prevent protein degradation by the bacterial proteases. The cells are then
harvested usually by centrifugation and can be kept frozen in a glycerol solution prior to
purification.
To purify the protein from the bacteria, the cells must be lysed with high pressure.
Generally, with the addition of that protein tag, described earlier, the desired protein can
be isolated using a chromatographic column that complements the protein tag properties.
The extra residues are then removed with a protease reaction. In the case of the MT
produced in the Stillman Group, the 15 amino acid S-tag is attached to the N-terminus.52
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The recombinant human MT1A used in the experiments described in this Thesis were all
prepared using the following method:
Preparation of Recombinant Human Metallothionein I: Recombinant human
metallothionein I (rh-MT1) was expressed in BL21(DE3) E. coli cells that were
transformed using a pET-29a plasmid containing an S-tag for protein stability during the
purification. The cells were grown in LB broth with 0.5 mL 50 mg/mL kanamycin. MT
expression was induced with IPTG and metallated with CdSO4 (Figure 1-5). Cells were
lysed using a cell disruption system (Constant Systems, UK), and then centrifuged to
separate the MT- containing supernatant from unwanted cellular components. Further
purification was performed using High Performance Liquid Chromatography (HPLC,
Dionex UltiMate 3000, Thermo Fischer Scientific). Elution through a 5 mL HiTrap SP
HP ion exchange column was achieved using 10 mM tris(hydroxymethyl)aminomethane
(Tris-HCl) at pH 7.4 (Fisher) was monitored by UV-visible absorption (Cary UV 50 Bio,
Varian, Toronto) at the characteristic Cd-MT wavelengths of 300-200 nm. Fractions that
contained metallated MT were collected, and the S-tag removed using a Thrombin
CleanCleave™ Kit (Sigma Aldrich). The thrombin resin beads were recovered,
regenerated, and stored for later use. The purified MT protein was evacuated and purged
with Argon prior to storage in -80°C, with individual experimental preparations as further
described in each Chapter.
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Figure 1-5 LB agar and LB broth preparation
LB agar (Left) and LB broth (Right) preparation instructions for the preparation of
kanamycin-resistant, human MT expressing E. coli cells.

1.4.2

Spectroscopic Methods

Spectroscopic analysis of metallothioneins has been generally restricted to UV-visible
absorption, Circular Dichroism (CD), and proton and metal Nuclear Magnetic Resonance
(NMR) techniques. This is because the nd10 metals that traditionally are used in vitro and
are recovered from MTs in vivo, exhibit only ligand-to-metal-charge-transfer (LMCT) in
the absorption spectrum and the peptide, with its absence of aromatic amino acids,
exhibits a very restricted band envelope below 220 nm. In addition, the lack of native
secondary or tertiary structure for the apo-MT means that the CD spectrum in the absence
of metals, is also uninformative. In a sense, this absence of spectroscopic signatures for
the apo-protein has allowed the metallation reaction to be followed readily from changes
in the absorption spectrum centred on the LMCT band of the specific metal, for example,
at 250 nm for Cd-MT. In parallel with the increase in absorption, and red shifted from the
apo-MT edge at 220 nm, is the development of CD spectral properties related to the
metal-induced folding of the peptide backbone. This technique is used especially in
Chapters 4 and 5.

1.4.2.1

Absorption Spectroscopy

Bioinorganic complexes can exhibit spectral properties arising from charge transfer
absorption bands that are characteristic of certain bonds, such as the one for S→ Cd
described above.53 Comparing isosbestic changes in absorption patterns during metal
titrations provides important information on metal binding stoichiometries of MT.54 Care
must be taken to avoid the interference of buffers and metals to exclude side reactions;
and significantly, to avoid oxidative conditions due to the sulfur rich nature of MTs.

1.4.2.2

Circular Dichroism Spectroscopy

The absorption of circularly polarized light of the CD experiment is modified by the
presence of chiral environments. The structural properties of α helices and β pleated
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sheets commonly found in proteins exhibit specific CD spectral signatures. These spectral
features can be used to analyze the consequences of structural modifications in proteins.
The MT peptide, however, does not adopt well-formed secondary or tertiary structural
elements, and as a result, the CD spectrum for apo-MT is devoid of these spectral
signatures. However, metal binding to apo-MT imparts metal-induced structural
properties, which results in strong CD spectral envelopes in the LMCT region. These CD
envelopes arise from metal-induced chiral environments, and are stoichiometrically
dependent, allowing the quantitation of the metal-induced structural properties of the
metallated MT.48 These spectroscopic properties are useful for monitoring structural
changes during metal titrations. Good examples have been reported for titrations of MT
with Ag(I), Au(I), Cu(I), Pt(II), Cd(II), and Co(II).55
Prior to the common use of native ESI-MS, the changes in the CD spectral envelopes
provided by far the greatest detail about the structural properties of the MT peptide. This
is because for there to be significant changes in the CD spectrum there had only to be an
absorption band related to the metal that was sensitive to a major influence of the
coordination geometry on the structure of the metallated MT.53, 56 The focus on the use of
CD spectroscopy was specifically important for the metallation of MT because of the
number of metals that bind in almost identical environments, meaning that the absorption
chromophore does not distinguish between each metal. It is not possible to resolve
changes that takes place as a function of the metal bound. This issue became most
apparent when the use of native ESI-MS was common and metallation titrations became
available, showing a wide distribution of species during titration for each mol. eq. added
except for saturation.27

1.4.3

Electrospray Ionization Mass Spectrometry (ESI-MS)

Mass spectrometers ionize species in a solution and separate those ions based on their
mass. All mass spectrometers Figure 1-6A) have the following components: (a) sample
inlet ionization source, (b) ion optics, (c) mass analyzer and ion detector, (d) data
analyzer, and (e) vacuum pump system.57 There are many methods of ionization possible,
but the method most useful for metalloprotein studies uses direct sample solution infusion
into an electrospray ionization atmospheric interface. The sample solution is passed
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through a fine, highly charged capillary, which results in charged molecules in solution
either from the ionization of the solvent or from a redox reaction directly with the
molecule. The central feature of the ESI-MS approach is that the wet droplets of protein
must rapidly dry to form the ionized protein efficiently Figure 1-6(B). High temperature
N2 gas evaporates the solvent until nothing remains but the charged molecular ion. There
are two common mass analyzers: (i) quadrupole and (ii) time-of-flight (TOF).58 Recently,
a third mass analyzer based on the quantized ion trap has become an emerging player
(Orbitrap ™).59 For a wider range of mass speciation in metalloproteins and with greater
resolution, the TOF is most useful, because it has a wider and almost linear range of
detection allowing a greater variety of metallated species to be analyzed. The charged
particles are accelerated through a time-of-flight mass analyzer; all ions are given the
same kinetic energy but are then separated by their different distributions of mass. The
charge distribution of the protein species leaving the atmospheric interface is not singular;
rather a multiplet of charged species exists. The range of the multiplet can be from two or
three charges to up to 25 components. It is now generally accepted that the charge
distribution depends on the surface area that will contain the charged ions, which, for
positive, protonated, species will be diagnostic for the extent of the instantaneous folding
or unfolding of the protein under the solution conditions.60, 61 This multiplet consists
therefore, of several m/z species where m is the mass of the protein plus the number of
protons and z is the total charge introduced by the number of protons bound. The
deconvolution of the series of multiplet masses, knowing their charge, can be determined
mathematically to give the parent protein mass. This is illustrated in Figure 1-7. The
structural power of this requirement is that as the surface area increases (for e.g. with a
denaturant or by unfolding) the multiplet number increases. This provides a fine measure
of the degree of folding under any solution conditions that exceeds the typical
quantitation of folding provided by the CD experiment described earlier. The specific
structures involved though, have not been associated to date, with the different multiplets
observed. I will describe the value of this experimental technique below when I discuss
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the structural properties of apo-MT.

Figure 1-6 An ESI-TOF-MS and its ionization mechanism
A) Schematic of a basic ESI-MS instrument. B) As the analyte solution droplets move
through the charged capillary, the surface tension of the solution becomes overcome by
the repulsive force of the charged particles, known as a “Coulombic explosion.”62
An analytical method like this can precisely describe the composition of a protein
mixture, showing the masses of all the individual components. Data from native ESI-MS
experiments can be used to account for the species in an averaged spectroscopic signal by
defining the individual contributions. ESI-MS methods have been used widely in drugprotein interaction studies, enzymatic reactions, and elucidative applications.
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Figure 1-7 Charge state and deconvoluted mass spectra
Apo α-MT fragment at pH 2. Screenshot of the acquired spectrum window in the Bruker
DataAnalysis 4.2 software with the m/z spectra shown top with major charge states +5,
+4, +3, +2, labelled, with the bottom showing the deconvoluted spectrum showing the
mass in Da of the species resolved from the m/z spectra.

1.4.3.1

Electrospray Ionization Mass Spectrometry (ESI-MS) in MT
studies

Fenselau’s group was a leader in the realm of ESI-MS analysis of metallothioneins. At
the time in the early 1990’s, mass spectrometry was being recognized as a high resolution
technique for analysing protein complexes.63 Fenselau and coworkers used ESI-MS to
identify the many partially metallated species of MT that accompany metal titration,
while showing the ease of use especially in the case of direct solution infusion. Their
work highlighted the delicacies of the pH environment in metallation, suggesting the pH
dependence of cooperativity that is now widely understood,64 while also demonstrating
the power of ESI-MS in drug—protein complex analysis.65 They pioneered work in
cysteine alkylation studies using therapeutic alkylating agents to probe the structure of
MT, which we will expand on further in this section. With Fenselau and others now
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illustrating the ease with which ESI-MS can be used to analyze solution samples,
Lobinski introduced the idea of coupling techniques for high resolution metal binding
analysis.66 Since ESI-MS allows for direction infusion of the sample, attaching a high
performance liquid chromatography (HPLC) system with an acidification column prior to
ESI analysis allowed for the absolute identification of rabbit liver MT isoforms and
subisoforms, that could previously only be postulated through chromatographic
separation. ESI-MS then took off as the best way to quantify metallation of MTs, and was
used to compare different MT species,67 compare polymorphisms in plant MTs,68 and to
further question the cluster formation properties of MTs.69

Structural studies with MS using Cysteine Modification by Alkylation
Because of its cysteine rich structure, MT is prone to react with alkylating agents. This
was postulated as a method of drug induced resistance by Fenselau, who used alkylating
therapeutic agents like chlorambucil, melphalan, and dexamethasone to probe the cysteine
structure.64, 65, 70-72 These alkylating methods were also used to demonstrate the effects of
alkylation on metal ion flux between enzymes, as these therapeutic agents reacted in
small stoichiometric ratios without dissociating seven divalent metals, but that
modification did increase rates of Zn(II) donation to apo CA, suggesting that the
modification had distorted the native structure.65 Depending on the size and charge
density of the alkylating agent, differential binding patterns could be resolved, and used
to infer structural information.65 For instance, the smaller alkylating agents penetrate and
bind free cysteines differentially based on their solvent exposed surface area. This is
combined with ESI-MS to show that the structure of the protein may define the
metallation mechanism (cluster vs. bead, described in Chapter 2) that dominates
metallation. These alkylating reactions show that not only are the cysteine residues buried
within the protein structure, but also that they are differentially accessible by solvent. It
supported the idea that not all 7 binding sites can be considered equal, emphasising that
the pseudo first order generalizations of these early MT studies were not adequate
assumptions.
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Figure 1-8 Various cysteine alkylating agents
Reactions of various small alkylating agents with free thiols. (A) the reaction of parabenzoquinone. (B) the reaction of n-ethyl maleimide. (C) the reaction of iodoacetamide.
(D) the reaction with 5,5'-Disulfanediylbis(2-nitrobenzoic acid).
As we have seen in the variety of metallation reactions that MT can partake in, the
richness of its cysteine thiols imparts great reactivity. These thiolates can act as
nucleophiles in substitution reactions. For instance Ellman’s Reagent (5,5'disulfanediylbis(2-nitrobenzoic acid), DTNB, Figure 1-8(D)), has been historically used
to quantify thiols in solution, with stoichiometric reaction depicted in the Figure 1-8
above.73 Iodoacetamide (IAM, Figure 1-8(C)) is used as well, but it benefits from a small
spatial size, allowing it to fully penetrate most protein structures. Para-benzoquinone
(pBQ, Figure 1-8(A)) is a useful agent that is easy to prepare but is photo-reactive and
works best below neutral pH. This is a difficulty when trying to analyze proteins at
neutral, physiological pH. N-ethyl maleimide (NEM, Figure 1-8(B)) can work under
those conditions, albeit it is not as small and penetrating as IAM. Depending on the
conditions used, the alkylation is so favourable that it can displace native bound metals.
Regardless, both pBQ and NEM (Figure 1-8A, B) differentially bind MT and provide
information about the solution structure under controlled conditions. Their differential
mass spectrometric profiles of species distribution can give clues about the shape of the
protein solvent surface. This technique and its related principles are used to analyze the
native structure of apo-MT in Chapter 2, and to probe Rh-bound MT in Chapter 5.

1.4.3.2

ESI-MS for Quantitative Analysis of Stepwise Metallation

The binding constants of each metallation event depict the metal donation properties of
MT. With the advent of ESI-MS, quantitative studies involving metal titrations into MT
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could be equilibrated and measured with ESI-MS to find the resulting equilibrium
constants K, from the relative intensities of the products.

Kinetic rate constant determination
Another advantage with ESI-MS is the ability to monitor reactions in real time up to
hours (or however long the sample solution lasts at a particular flow rate). With MT
however, the metallation is generally rapid and complete before the dead time of the
instrument. As such, the kinetic analysis of metallation to MTs was mostly constrained to
inferring results from competition reactions.
Ngu et al. took advantage of the differential rates of metallation depending on metal type,
using arsenic metallation of MT.74 As(III) is known to bind in vitro to MT with a
maximum stoichiometry of As6MT. This binding is slow enough that it can be monitored
using ESI-MS and was used as a model for the metallation by more naturally found Zn(II)
and Cd(II). The highly detailed time-dependent, temperature-resolved results show that
the each metallation event is faster than its subsequent metallation event (k1> k2 and so
on). This is true for both the whole protein and the metallation of the individual domains,
shown in Figure 1-9.
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Figure 1-9 Decreasing rate constants shown in the stepwise metallation of βαMT and its
individual domains.
Comparison of the rate constants calculated from the time-resolved ESI-MS
measurements for As3+-metallation of βhMT, αhMT, and βαhMT, the trend in rate
constant values for six equivalent sites where k1 = 28.8 M-1s-1 and the rate constants
reported for βhMT-S-tag and αhMTS-tag.1 The red dashed line represents rate constant
data for the βhΜΤ redrawn with the value of n shifted by three to illustrate the similarity
to the rate constant trend for the final three As3+ binding to βαhMT. Reproduced from
Ngu et al.74 Copyright 2008 American Chemical Society.

Equilibrium Constant determination
The early studies of MT were focused on observed optical signals, but now the focus
resides on numerically assigning properties to MTs to distinguish isoforms and their
specific functions. Historically, the metallation reaction of MT can be described as a
bimolecular reaction with metals binding at a single rate with a single binding constant.
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Mn + MT = Mn+1MT
MT + 7M = M7MT
This simplification of the metallation mechanism was to compensate for the lack of detail
in the instrumental method. Often the metallation reaction was complete within the dead
time of the instrument, resulting in an apparent cooperative reaction. Because metals like
Cd(II), Zn(II), and Cu(I) bind so rapidly, the individual steps cannot be visualized.
However, the lability of Zn(II) and Cu(I) bound to MT is linked to the thermodynamic
stability of the bond and this defines MT’s metal donation properties. As the metallation
reaction progresses, the last metals to bind have the weakest binding affinity. If the
binding affinity of the last metallation reaction of MT is close to the binding constant for
a protein’s Zn(II) binding site, metal donation to the apoenzyme occurs. Otherwise, the
MT harvests Zn(II) from sites with lower KF than it. As such, these numerical values are
requisite for understanding MT’s metallation and metal donation processes.20, 28
Kenzyme > K(Zn7MT) = MT donates Zn to enzyme
Knon-specific Zn site < KZn(0-7)MT = MT harvests Zn

1.4.4

Computational Studies of Metallothionein

Because protein structures are not limited to the rigid dimensions defined by their crystal
structure, the dynamic nature of proteins is hard to visualize. Computer simulations and
molecular dynamics (MD) can predict what might happen to a truly dynamic protein
system on small timescales (fs to ps). In the case of MT, studies on the fluxional apo
structure showed the position of the cysteines in the native structure prior to metallation,
as a model for the de novo synthesized protein. By doing so with MD, we can also watch
the energy of the system until it reaches a minimum, resting state. A combination of
molecular mechanics (MM) and MD were used by Rigby et al. to watch the effect on
protein folding that each M(II) metallation event imparted on the structure. This showed
the metal dependent folding mechanism emphasized the importance of the native apo
structure. The study showed that initially, cysteines were partially solvent exposed, and as
metallation progressed, the metal cysteine bonds coalesced into the protein center. When
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the reverse (demetallation) was performed, the cysteines moved to the exterior of the
protein chain.75 This structural rearrangement is evident in the models of Rh2MT in
Chapter 5. The early ESI-MS work by Fenselau identified alkylating agents that reacted
readily and selectively with MT. To determine the position of the cysteine residues
involved in the selective alkylation, the eight most solvent accessible cysteines were
simulated bound to drug molecules and the energies and distances were compared,
identifying Cys 33 and Cys 48 as the most favourable for complexation,70 giving
information on metal binding sites.
The challenge with applying computational chemistry to metallothioneins actually begins
when metallating the protein. The complexity of transition metals is still computationally
expensive compared to simple MM, MD, or Newtonian based calculations. In order to
consider the electronic effects of orbitals, Time Dependent Density Functional theory is
used to apply models for forces that are present with the diffuse electronic orbitals of dblock metals. This is because the inclusion of the d and higher orbitals introduces electron
movements that are not included in the MM theory and creates complications when
calculating structures. A way to deal with this is by both defining a fixed geometry and
assuming it, or separating the sections involved in the calculations. However this greatly
limits the affordable calculations that can be performed. Returning to the concept of
models and modelling reactions, the binding of glutathione, a small peptide with a
cysteine thiolate, is used to mimic a single thiolate binding event in the metallation of
MT, as is discussed in Chapter 6.

1.5

Scope

To understand the possible binding mechanisms of xenobiotic metals in vivo, it is
necessary to first understand what we have now defined as traditional metal binding to
MT.
In Chapter 2, I provide an overview of the metallation of M(II) to MTs by exploring
millisecond timescale reactions of Cd(II) binding to apo-MT. Particularly, the partially
metallated forms are of interest as they are the most probabilistic form of the protein in
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vivo, and as they are known to exist in multiple conformations, either terminally bound or
in complex metal thiolate networks involving bridging cysteines between the metals.
With the onset of xenobiotic metal pollution and metal-based therapy (e.g., platinum
group metals), it is necessary to consider how these foreign metals bind to MT in vivo. It
is often the clustering pattern of metals in MTs that give structural features, but in the
case of these non-physiologically relevant metals, binding is anything but characteristic.
It is through these reactions with xenobiotic metals that the flexible nature of MT metal
chelation can be tested, as the world is approaching exposure to heavy metal pollution
unimaginable before.
Currently, the best model of the physiological effects of non-natural metals comes from
metal-therapeutics testing. These tests involve strictly controlled exposure and well
documented effects. By testing the metal defense protein MT with these xenobiotic
complexes, we understand our own physiological metal defense and the mechanism
behind developed drug resistance.
In Chapter 3, using cisplatin, I unravel the rapid initial reaction pathway for MT with
cisplatin, that is believed to be involved in developing cisplatin resistance. The results
show the step by step destruction of cisplatin, and ligand displacement by the MT’s
cysteine thiolates.
Following the studies with cisplatin, in Chapters 4 and 5, we explore a platinum
alternative, dirhodium(II) tetraacetate, in a model study with the β domain fragment of
MT followed by a study with the whole protein. Through this reaction we see the
sequential destructive chemistry clearly with the loss of all 4 acetate ligands, but in this
complexation geometry, the metal-metal bond remains intact. This bond strength is
analyzed with molecular modelling studies employing GSH and Rh2(OAc)4, using TDDFT methods in Chapter 6, to observe the electronic interactions and to investigate the
origin of the spectroscopic signal.
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Finally, in Chapter 7, we summarise the findings of this Thesis exploring non-traditional
metallation of metallothioneins, by introducing some examples of xenobiotic metals in
therapeutic use, and reviewing their reactions with metallothioneins.
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Chapter 2

2

Understanding Cd2+ Binding Mechanisms and its
Relation to the Intrinsically Disordered Structure of
Metallothioneins*

The 20-cysteine mammalian metallothioneins are considered to be central to the
homeostatic control of the essential metals Zn(II) and Cu(I) and, as part of their partially
metal-loaded status, play a role in reversing oxidative stress.1 Native apo-MT does not
adopt a well-known structural motif, being described as a random-coil or intrinsicallydisordered. Conclusions reached from a combination of ESI-mass spectral charge states,
As(III) metallation of apo-MT at low pH, from molecular dynamic calculations and from
metallation of the α-domain fragment, suggest that in fact the native apo-MT adopts a
structure that is highly efficient towards metallation at physiological pH. The results in
this Chapter show that the initial (M<5) Cd(II) metallation at physiological pH takes
place to rapidly form structures based on isolated Cd(SCYS)4 units, beads. At pH 5,
cysteine bridged Cd4(SCYS)11 clusters form. The ESI-mass spectral profile of cysteine
modified apo-MT at physiological pH shows that it is folded, whereas in the presence of 3
M guanidinium hydrochloride, the apo-MT is unfolded. Stopped-flow kinetic studies of
the Cd(II) metallation show that the reaction is much slower for the denatured vs. the
native apo-MT for formation of either beads or clusters. Metallation is slower for the
formation of clusters than the formation of beads. These results are the first to quantify
the presence of structure in native apo-MT in terms of the critical metallation properties.
The implications of this study suggest that disruption of apo-MT structure due to ageing
or other agents will negatively impact the metallation process for essential metals.

2.1 The Native Structure of Metallothionein
Essential metals are critical to Life’s processes. Metals that disrupt these processes are
considered toxic. Therefore, Life requires control of metal ions for necessary function,
employing regulatory control agents like metallothioneins (MT). MTs are a family of
cysteine-rich, low molecular weight proteins that coordinate, and, therefore, isolate a
*A version of this chapter has been published:
Metallomics DOI:10.1039/C8MT00347E Citation: Metallomics, 2019, Advance Article. Copyright
2019 Royal Society of Chemistry.
Reproduced with permission from: D. L. Wong, N. C. Korkola, and M. J. Stillman.
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variety of free metal ions. Despite the critical involvement of MTs in Zn(II) and Cu(I)
homeostasis, their stepwise metallation mechanisms are poorly understood. Since MT’s
discovery in 1957, as a Cd-containing protein,2 much research has focused on the metal
saturated, two-domain structure of Cd7MT and Zn7MT. When it was reported that MT
natively exists predominantly in either the reduced apo (metal free, no S-S) state, or the
partially metallated states,3-5 interest was spurred about the metallation mechanism and
the true structure of native MT in vivo.4, 6-14
Information about the apo-MT structure has remained mysteriously vague. Labelled as
“random coil,” “globular,” or “intrinsically disordered,” the structure of partially
metallated MTs have been historically difficult to elucidate due to the lack of secondary
structures, little to no aromatic residues, extreme sensitivity to oxidation, and dependence
on solution phase interactions. MT is unique in that progressive metallation imparts a
major increase in the ordered structure.15 Initially, at physiological pH, the divalent metal
ions bind tetrahedrally to terminal cysteinyl thiolates as isolated beads, which with further
metallation, progress to the formation of metal-thiolate clusters, involving metal-bridging
cysteine thiols.16 The traditional, two-domain, dumbbell-like structure is formed only
upon full metallation with 7 divalent metals at physiological pH.
Extensive advances have been made in studying partially metallated and metal-free MTs,
including in vivo fluorescence detection,5, 17 molecular dynamic simulations,18, 19 collision
induced denaturation,20 and mass spectrometric methods.14, 21 The work in this Chapter
builds on recent investigations involving denaturation,22 cysteine modification12 and mass
spectrometry,6, 23-25 in conjunction with stopped-flow kinetic analysis to provide new
detail about the first metallation steps that take place as a function of the structural status
of the apo-MT. The structures adopted initially by de novo apo-MT are critical to the
subsequent metallation steps and define the complete metallation pathway. These early
metallation steps are vital to the function of MTs in vivo.
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Figure 2-1 The many structures of metallothionein.
(A) Conceptual structures for (i) the Cd4 cluster in the α domain, (ii) the fully metallated
structure, and (iii) 5 terminally-bound (beaded) Cd(II) displaying no domain structure
based on MM3 molecular models and (B) sequence and connectivity diagrams of fully
metallated βαMT and the two partially metallated pathways. Calculations and image
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26
The confirmation of the presence of apo-MT in vivo has cemented the fact that
metallation is a post-translational modification. The connectivities of bridging cysteines
take place across the domain, Figure 2-1B (i) and (ii), and, as a result, these metal-bonds
can only be formed once the protein is fully synthesized. Therefore, the initial states of
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metallation are of great interest for the purpose of determining the properties and
influence of the structure adopted by metal free MTs.
From studies reported specifically over the last two years by Irvine et al.,8, 16 two distinct,
pH dependent, metal binding pathways or mechanisms are at play. Initially, and
especially for M≤3, the formation of “beads” involving terminally bound cysteines is
dominant, especially for Zn(II) above pH 6 and Cd(II) above pH 7. The native MT
protein structure under the beaded pathway can accommodate a maximum of 5 M(II),
with the 20 cysteines tetrahedrally coordinating each metal, Figure 2-1(iii). MT adopts a
“single domain” type globular structure, where the lack of bridging cysteines results in no
true binding domain as described previously.16, 27, 28 Figure 2-1shows these two major
conformations that MTs flexibly adopt at specific points during metallation. The ball-andstick models are displayed Figure 2-1A and the peptide sequence inFigure 2-1B, and
Figure 2-1(i) show the structure of the Cd4S11 cluster that forms favourably in the αdomain.
At metallation levels of M = “magic number 4” 1, 11, 12, 20, 29, 30 and higher, the pathway
adopted involves cooperative coalescence to a metal-thiolate cluster. This is now a
thermodynamically stable, M4Scys11 cluster formed in the C-terminal α domain,31 and
increases the stability of the MT peptide against protease digestion. The conditions for
selecting the dominant pathway are pH, temperature, and metal concentration and the
selection is element dependent. The effects of the dominating pathway can be seen in the
speciation of the metallated products using ESI-MS methods.
The rapid stepwise metallation of MTs has been difficult to observe. Due to the
spectroscopically silent nature of native Zn(II)MT, Cd(II) is used as a spectroscopic probe
because of its S → Cd(II) ligand to metal charge transfer (LMCT) that is at 250 nm; this
is well clear of protein-based absorbance because of the absence of aromatic residues.
Initial kinetic reports of MT metallation focused on rates of demetallation, or rates of
metallation of the C-terminal α-domain of this protein.14, 31 The α-domain is an 11cysteine fragment that contains the M4S11, thermodynamically stable, adamantine-like,
metal-thiolate cluster. The β-domain (“β-MT”) is a smaller, 9 cysteine peptide fragment
that forms a cluster when saturated (M3S9) but is more labile than the α-fragment. The α

38

domain has been studied previously by our group, with results that show that the
metallation kinetics are influenced by the apo-MT structure, and is flexible enough to
accommodate 5 M(II) in forced conditions.7 While studying the isolated domains gives
valuable information regarding individual cysteine coordination,31 it is now understood
that the isolated domains behave differently than the intact protein.17, 27, 32, 33
In this Chapter, the rates of the metallation by Cd(II) of the native βαMT protein in
solution are reported and discussed to understand how changes in the apo structure
influence the metal-binding pathways. The rate of the early steps in the Cd(II) metallation
of apo-βαMT depends on the folded state of the MT, and the metallation structure that
results. By using denaturing agents at physiological pH, and at pH values that favour
either beaded (pH ~8) or cluster formation (pH ~5), stopped-flow kinetic methods provide
the binding rate for the Cd(II) metallation. The extent of folding under these conditions is
obtained from the ESI-mass spectral data using cysteine modification methods. The
results show that the metallation rate at physiological pH is 10 times faster than at pH 5
for both the folded and the denatured protein. Metallation involving cluster formation is
slower than bead formation. These results indicate that at physiological pH, MT is a
highly efficient scavenger of Cd(II) and can employ its 20 cysteines with flexible binding.
The metallation properties for partially metallated Cd-MTs at both pH extremes, which
would mimic the pathways adopted specifically for zinc binding, are described below. By
selecting conditions that are known to favour either of the two pathways, and confirmed
using ESI-MS, the rates of metallation of the beaded pathway vs. the cluster pathway can
be compared. The outcomes of these experiments provide evidence that at physiological
pH, apo-MT adopts a specific native structure that is optimized for metallation.

2.2
2.2.1

Experimental Methods
Solution Preparation

Ammonium formate (J.T. Baker) and tris(hydroxymethyl)aminomethane-HCl (Tris-HCl)
(Sigma-Aldrich) buffers were prepared by dissolving solid crystals into DI water to make
a final concentration of 10 mM. The solution was then pH adjusted to 2.80, 5, 6, 7, 7.4,
7.5, or 8 using HCl and NH4OH. KCl (Fisher) was added to the ammonium formate
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buffer used in stopped flow studies to final concentration of 200 mM to maintain a
constant ionic strength.
50 mg/mL Kanamycin (Teknova), 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG)
(Fisher), and 1 M CdSO4 (J.T. Baker) for cell growth were prepared by dissolving the
appropriate amount of solid reagent in DI water. 10 mM solutions of N-ethylmaleimide
(NEM) (Eastman) and Cd(OAc)2 (Acros) were made by mixing solid crystals into the
ammonium formate buffer of the desired pH for the experiment. KCl was added to the
Cd(OAc)2 solution used in stopped flow studies to a concentration of 200 mM. 8 M
guanidinium chloride (GdmCl) was prepared by mixing solid GdmCl crystals (Omnipur)
and KCl to make 200 mM in the case of stopped flow experiments with ammonium
formate buffer. The mixture was gently heated until all the solid crystals had dissolved.
The solution was allowed to cool and was then pH adjusted to the desired pH of 5, 6, 7,
7.4, 7.5, and 8 using HCl and NH4OH. CdOAc2 solutions at concentrations of 5, 10, 12.5,
15, 20, and 25 μM for use in stopped flow reactions were prepared by diluting the stock
10 mM Cd(OAc)2 solution with the appropriate amount of ammonium formate buffer and
GdmCl at the desired pH of 5, 6, 7, 7.4, 7.5, or 8 for a final denaturant concentration of 4
M.
Preparation of apo-MT with pH adjustment
A 1-2 mL solution of Cd7MT was thawed under a vacuum and demetallated by buffer
exchange using a pH 2.80 ammonium formate buffer, and then raised using ammonium
formate buffer of the desired sample pH of 5, 6, 7, 7.4, 7.5, or 8.
Mass spectrometric (MS) studies of the apo-MT structure were carried out using samples
prepared with a Millipore centrifuge filter tube with a cut-off of 3kDa. The MT and low
pH buffer were centrifuged at 4000 rpm for 30 minutes twice. The 10 mM ammonium
formate buffer at pH 7.4 was then added along with a drop of concentrated ammonium
hydroxide. The buffer exchange was performed under the same conditions as the
demetallation 3-4 times. The pH of the flow-through was tested after each spin. For MS
studies of the partial metallation of MT, the protein was demetallated using a PD-10 (GE
Healthcare) size exclusion column with pH 2.80 ammonium formate buffer. The protein
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was centrifuged once at 4000 rpm for 30 minutes and then run down another column at
pH 5 or 8 to raise the pH. The MT was then centrifuged again for 30 minutes at the same
speed as before. For stopped-flow studies, the MT was demetallated using the PD-10
column with the pH 2.80 ammonium formate buffer. It was then put down another PD-10
column with the buffer of pH 5, 6, 7, 7.5, or 8. The pH of the resulting protein solution
was tested.
The concentration of the apo-MT was determined by metallating a small portion of the
sample with excess Cd(OAc)2 and measuring the absorbance of the S → Cd(II) LMCT
band at 250 nm. Beer’s law was used to calculate the concentration using the molar
extinction coefficient of fully metallated βαMT of ε = 89000 cm-1.
For MS studies of the apo protein, the apo-MT sample was split into 2 vials. One of the
vials was denatured by adding 8 M GdmCl to make a final concentration of 3 M. The
other was left in its native state. The appropriate amount of 10 mM NEM solution was
added to both samples to equal 10 molar equivalents compared to the MT concentration.
The denatured solution was buffer exchanged by dialysis in 10 mM ammonium formate
buffer at pH 7.4 for 2 hours to remove the GdmCl, as its signal would dominate the mass
spectrum. Since the NEM was now covalently bound to the cysteine residues, the buffer
exchange does not affect the distribution of the modifications.
For the MS studies of the stepwise metallation of MT, the protein samples at pH 5 and pH
8 were metallated with the appropriate amount of Cd(OAc)2 to give approximately 0.5,
1.5, 4, 5, and 6 molar equivalents of Cd(II) per protein for the solutions at pH 5, and 1,
2.5, and 5 molar equivalents for the pH 8 samples. The exact equivalents of Cd(II) added
were calculated using the average of all the species present in the spectra.
For stopped-flow kinetics studies, the protein samples were diluted with 10 mM
ammonium formate buffer adjusted to pH 5, 6, 7, 7.5, or 8 and 8 M GdmCl to result in a
final solution of 5 μM MT with either 0, 1, 2, or 4 M of GdmCl. KCl was added to give a
final concentration of 200 mM KCl to keep the ionic strength of the solution constant. It
is important to note that the rate of metallation of native apo-MT was compared to the
rate in the presence of 5 M chloride ions and in the presence of sucrose matching the
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viscosity of 5 M GdmCl. This was to confirm that the presence of the chloride ions in
GdmCl did not interfere with the cadmium and the viscosity of the GdmCl did not affect
the rate of metallation.

2.2.2

Mass Spectral Studies

Mass spectra were collected on a MicroTOF ESI mass spectrometer (Bruker, Toronto).
The parameters were as follows: Capillary: 4200 V, end plate offset: 500 V, dry gas: 8.0
L/min, dry temperature: 100˚C, capillary exit: 180.0 V, Skimmer 1: 22.0 V, hexapole 1:
22.5 V, hexapole RF: 600.0 V, skimmer 2: 22.0 V, lens 1 transfer: 88.0 μs, lens 1 prepulse storage: 23.0 μs, mass range: 500-4000 m/z, flow rate: 10 μL/min. The spectra were
averaged over 2 minutes.

2.2.3

Stopped Flow Studies

An SFM-300 instrument (BioLogic, France), Figure 2-2, was used to rapidly mix and
transfer the reagents to a cuvette with a 10 mm path length and 1 mm aperture. The
reaction was observed with a MOS 250 spectrophotometer and the resulting kinetic traces
were recorded using BioKine software. This reaction was performed at 10 ˚C.
Apo-MT, ammonium formate buffer of the desired pH, and Cd(OAc)2 were loaded into
syringes 1, 2, and 3, respectively. First, 500 μL of buffer was shot at a flow rate of 5 mL/s
to clean the cuvette and to confirm the baseline level. Then, 160 μL each of apo-MT and
Cd(OAc)2 were shot at a flow rate of 8 mL/s. These were mixed and reached the cuvette
with a dead time of 1.9 ms. After 20 ms mixing time, the hard stop was closed and the
reagents were allowed to react in the cuvette. The reaction was monitored through the
LMCT band at 250 nm and recorded every 500 μs for a total of 2 s. This process was
repeated at least three times to give an average of multiple traces. The standard deviation
over multiple kinetic traces for each set of experimental conditions was 10 %.
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Figure 2-2 A schematic of the SFM apparatus.
The three syringes are shown with their respective reagents along with their path to the
mixing chamber and then the cuvette. The lowest achievable dead time from the mixer to
the cuvette is approximately 2 ms. Image from N. C. Korkola, reproduced with permission
from the Royal Society of Chemistry. 26

2.2.4

Fitting of the Kinetic Traces

The data were not transformed from absorbance to concentration units due to the multiproduct nature of the final solution. The partially metallated MT form a distribution of
species, each of which would have its own specific molar extinction coefficient. These
coefficient values have not been determined for the individual species, and is further
clouded by the averaging of the absorption signal. Therefore, Beer’s Law could not be
used to determine the concentration of the product. It should be noted that the rate
constants reported by this method are only relative, as the concentration must be known
to find the absolute values.
The fitting program GEPASI version 3.3034 was used to fit the experimental kinetic traces
and find the relative rate constants. The metallation reaction was treated as a single
bimolecular step as shown below. Although the acquired traces in reality consisted of
multiple overlapping bimolecular reactions, it was not possible to resolve these as the
overall reaction was close to the dead time of the instrument. The simplified single
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bimolecular reaction that encompasses all the metallation steps resulted in an appropriate
fit for this complicated kinetic mechanism.
Apo-MT + (1-5) Cd2+ → Cd1-5MT
Two different methods were used in combination to fit the traces. The Nelder and Mead
(Simplex) method was used until the sum of squares reached a constant value and then
the Levenberg-Marquardt was used until the final solution was found.

2.2.5

Molecular Modelling

The clustered, beaded, and fully metallated MT structures were modelled using Scigress
6.0 (Fujitsu, Poland).35 The sequence shown in Figure 2-1 (B) was input into the software.
The geometry of the MT was optimized to the lowest energy level using the MM3
procedure. The lowest energy conformation was then found by running the MD (MM3)
procedure to create multiple random conformations over a time of 5000 ps. The procedure
was run under low temperature conditions of 5 K to simulate the hydrogen-bonded native
protein and high temperature conditions of 1000 K to mimic the denatured conformation.
The dielectric was set at 78, the van der Waals cut-off distance at 9 Å, and the van der
Waals interaction update rate at 50. The output frequency was 200 steps and the refresh
rate was 100 steps.

2.3
2.3.1

Results
Denaturation of MT with Guanidinium Hydrochloride

The extent of unfolding of the apo-MT in the presence of the 3 M reversible denaturant
GdmCl was probed by adding N-ethyl maleimide (NEM) to covalently and irreversibly
modify solvent exposed cysteine residues. The denaturant was then removed, and the
resulting modified protein was examined using ESI-MS at pH 7.4. Figure 2-3, A shows
that the speciation profile of NEM binding to the apo-MT displays preferred modification
under physiological pH in the absence of denaturant. This spectral profile drastically
changes in the presence of 3 M GdmCl, Figure 2-3, B, where the alkylated species has a
Normal distribution profile.
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Figure 2-3 Native and denatured MT modified by NEM
Deconvoluted ESI mass spectra of (A) native apo-MT at pH 7.4 and (B) apo-MT
denatured with 3 M GdmCl at pH 7.4, both modified with 10 molar equivalents of NEM.
MT in the native environment (A) shows a cooperative modification pattern, while the
denatured protein (B) shows a modification distribution resembling a Normal curve. Data
and image from N. C. Korkola, reproduced with permission from the Royal Society of
Chemistry. 26
The series of stopped flow kinetic absorbance traces number Figure S1-5 are used to
create the plots of Figure 2-4.
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Figure S1. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT at pH 5 in the
presence of increasing amounts of GdmCl at concentrations of A) 0 M, B) 1 M, C) 2 M,
and D) 4 M. Data and image from N. C. Korkola, reproduced with permission from the
Royal Society of Chemistry. 26

Figure S2. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT in the presence of
4 M GdmCl at pH A) 5, B) 6, C) 7, D) 7.5, and E) 8. Data and image from N. C. Korkola,
reproduced with permission from the Royal Society of Chemistry. 26
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Figure S3. The kinetics traces of the binding of apo-MT to A) 1, B) 2.5, and C) 5
equivalents of cadmium at pH 5 and in the presence of (i) 0 M and (ii) 4 M of GdmCl.
Data and image from N. C. Korkola, reproduced with permission from the Royal Society
of Chemistry. 26
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Figure S4. The kinetics traces of the binding of apo-MT to A) 1, B) 2, C) 2.5, D) 3, E) 4,
and F) 5 equivalents of cadmium at pH 8 and in the presence of (i) 0 M and (ii) 4 M of
GdmCl. Data and image from N. C. Korkola in reference, 26 reproduced with permission
from the Royal Society of Chemistry.
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Figure S5. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT at pH 5 and with
no denaturant at temperatures of A) 10.1 ˚C, B) 15.3 ˚C, and C) 18.1 ˚C. Data and image
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26

2.3.2

Relative kobs Decreases with Increasing Denaturant at pH 5
and Fixed Metal Status

Figure S1 shows the change in absorbance at 250 nm for the reaction of apo-MT with a
fixed 2.5 mol. eq. of Cd(OAc)2 and increasing concentrations of GdmCl, at pH 5. The
relative kobs values are shown in Figure 2-4. The rate of metallation decreases as a
function of increasing denaturant concentration.
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Figure 2-4 Plot of the observed rate constant as a function of GdmCl concentration.
Apo-MT was reacted with 2.5 mol. eq. of Cd(OAc)2with increasing concentration of
denaturant, at pH 5. At this pH, the resulting product would be the [Cd4S11] 3- cluster. The
rate of metallation slows down as MT unfolds. Data and image from N. C. Korkola,
reproduced with permission from the Royal Society of Chemistry. 26

2.3.3

The Cd(II) Metallation Rate is pH Dependent

The pH dependence of metallation was determined using stopped flow kinetic methods
for the reaction of the apo-MT with 2.5 mol. eq. of Cd(OAc)2, with no denaturant present.
The choice of 2.5 mol. eq. was because the dominating metallation pathway (beads or
clusters) is readily apparent in the mass spectral data with this level of partial metallation.
The metallation of apo-MT by Cd(II) is rapid at physiological pH (3633 x106 mol-1 s-1),
but the rate decreases sharply as the pH is lowered (354 x106 mol-1 s-1), as seen in Figure
2-5.
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Figure 2-5 Relationship between observed rate constant k of the reaction of native apoMT
Apo-MT was reacted with 2.5 mol. eq. Cd(II) at pH 5, 6, 7, 7.5, and 8, in the presence of
4 M GdmCl. The product at each pH can be determined from Figure 2-6 and Figure 2-7.
At pH 5 the resulting product would be the [Cd4S11] 3- cluster. At pH 8 the resulting
product would be a series of [Cd1S4] 2- beads. Data and image from N. C. Korkola,
reproduced with permission from the Royal Society of Chemistry. 26
The mass spectral data shown in Figure 2-6 and Figure 2-7detail the speciation profiles at
the extremes of the pH range used in Figure 2-5 above. The two metallation pathways
manifest in different patterns of species abundance. The spectra taken at both pH 5 and 8,
with 1, 2.5, and 5 mol. eq. of Cd(II) added show differing speciation at the 2.5 and 5 mol.
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Figure 2-6 ESI mass spectra for the Cd(II) titration of apo-MT at pH 5
Deconvoluted ESI mass spectra at pH 5 of the partially metallated MT species using (A)
0, (B) 0.74, (C) 1.77, (D) 4.11, (E) 5.10, and (F) 5.84 mol. eq. of cadmium. The Cd4
cluster is favoured at low equivalence and the fully metallated Cd7 species is favoured
upon adding higher amounts of cadmium. Data and image from N. C. Korkola,
reproduced with permission from the Royal Society of Chemistry. 26.
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Figure 2-7 ESI mass spectra for the Cd(II) titration of apo-MT at pH 8
Deconvoluted ESI mass spectra at pH 8 of the partially metallated MT species using (A)
0, (B) 0.89, (C) 2.42, and (D) 4.86 mol. eq. of cadmium. The species display a Normal
distribution pattern centered around the molar equivalents of cadmium added. Data and
image from N. C. Korkola, reproduced with permission from the Royal Society of
Chemistry. 26.
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eq. point, where at pH 5, a strong preference for the clustered Cd4MT species is observed,
Figure 2-6. In the case of the pH 8 (Figure 2-7) metallation pathway, a Normal
distribution is observed, indicating the statistical formation of beaded products.
To test if the presence of denaturant affected either the cluster pathway (pH 5) or the
beaded pathway (pH 8), or both, the metallation rates were measured for apo-MT binding
to 2.5 mol. eq. Cd(OAc)2 under 0 M (no denaturant) and 4 M GdmCl conditions. Figure
2-8 shows the results for four unique conditions: A) pH 5 and no denaturant, B) pH 5 with
4 M GdmCl, C) pH 8 with no denaturant, and D) pH 8 with 4 M GdmCl. The rate
constants kobs for A-D are: 354, 325, 3633, and 2150 (106 M-1 s-1) respectively, which are
shown comparatively in Figure 2-9.

Figure 2-8 Kinetic absorption traces of MT metallation
Kinetic traces of the metallation of 2.5 mol. eq. of cadmium to apo-MT under conditions
of (A) pH 5 and no denaturant, (B) pH 5 and 4 M of GdmCl, (C) pH 8 and no denaturant,
and (D) pH 8 and 4 M of GdmCl. The traces show that the beaded pathway at pH 8
proceeds much faster than the clustered pathway at pH 5 and that denaturant slows down
both pathways Data and image from N. C. Korkola, reproduced with permission from the
Royal Society of Chemistry. 26

54

Figure 2-9 Comparison of rate constants
Bar graph representation showing the observed rate constants of the metallation with
2.5mol. equivalents of cadmium (A) pH 5 and no denaturant, (B) pH 5 and 4 M of
GdmCl, (C) pH 8 and no denaturant, and (D) pH 8 and 4 M of GdmCl. The effect of the
denaturant is much less pronounced than that of the pH environment. Data and image
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26

2.3.4

Relative kobs Decreases with Increasing Metallation

Figure 2-10 shows the relative kobs values of the reaction of a fixed concentration of apoMT with increasing Cd(II) mol. eq. at pH 5 (Figure 2-10A) and pH 8 (Figure 2-10B). In
both cases, in the absence of denaturant (black dashed line), the relative kobs rate
decreases as a function of the increase in the number of Cd(II) bound. In the presence of
denaturant (4 M GdmCl, red dotted line), the overall rates at both pHs are reduced. At pH
5, there is an approximately 50% reduction in the rate, but continues to follow a
decreasing trend with metallation. At pH 8 on the other hand, the denaturant dramatically
reduces the metallation rate.
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Figure 2-10 Cadmium equivalence vs. observed metallation rate k
Plots showing the relationship between the observed rate constant and mol. equiv. of
cadmium added at (A) pH 5 and (B) pH 8, both with denaturant (red dotted line) and
without denaturant (black dashed line). The observed rate slows down as MT binds
increasing numbers of cadmium ions. Data and image from N. C. Korkola, reproduced
with permission from the Royal Society of Chemistry. 26
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Figure 2-11 Arrhenius plot for Cd(II) metallation of MT
Arrhenius plot displaying the dependence of the observed rate constant on temperature.
The natural logarithm of the observed rate constant has a linear relationship to the
inverse temperature: y=-2791.4x+15.71, R2=0.9375. Data and image from N. C.
Korkola, reproduced with permission from the Royal Society of Chemistry. 26

2.3.5

Metallation is Temperature Dependent

The relative kobs for the metallation of apo-MT with 2.5 mol. eq. of Cd(OAc)2 at pH 5
were determined at 10.1, 15.3, and 18.1 °C, with the resulting Arrhenius plot shown in
Figure 2-11. The reaction rate slows as the temperature decreases, with a calculated
activation energy EA of 232 kJ/mol with an Arrhenius constant of 16. The rate of reaction
at 25 ˚C and above was too fast for the instrumentation.
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2.4
2.4.1

Discussion
Does Native Apo-MT have a Folded Structure?

Defining the structure of apo-MT is difficult. It is clear that metallation results in metalinduced folding, such that the metal-saturated product (M(II)) exists with two, welldefined binding domains.36 However, these domains do not exist in the absence of the
metal, unlike most metalloproteins. Circular dichroism spectroscopy can typically be used
to assess the degree or extent of 2° structure in a protein, from the characteristic CD
spectral profiles between 190 and 230 nm. However, no such spectral properties exist in
apo-MTs because of the absence of any defined folding. Mass spectrometry offers an
alternative and to some extent, a more precise measure of the degree of denaturation
associated with unfolding from the charge state manifold. Generally, when employing
mass spectrometry to probe changes in the protein structure as a function of an external
event, one examines the charge state envelope, its central number, and its spread to assess
the change in protein-solvent accessibility. With metallothioneins, their limited size
reduces the magnitude of changes in the charge state distribution, making this a less
precise method of tracking protein structure, compared to, for example, myoglobin
(~17000 Da). For greater sensitivity, cysteine alkylating agents, for example NEM or
pBQ as described in Chapter 1, provide detailed evidence of solvent accessible cysteines
as a function of increasing denaturant concentrations.6, 23 The use of GdmCl as a
denaturant allows protein denaturation without affecting the pH of the solution.
The data in Figure 2-3 showed that the apo-MT structure is dramatically and significantly
affected by the presence of denaturant. The two profiles have been described previously
in terms of the structural origins that would result in cysteine modification profiles with
such differences. The explanation that fits the experimental environment was described
first by Irvine et al. in 2014 for the structures of apo-α-MT fragment.7 Considering the
reaction as having simply run out of the NEM, the spectrum obtained is a snapshot of the
reaction, frozen by the lack of sufficient modifier. NEM covalently alkylates with the free
cysteinyl thiols in the MT protein to form a mass change readily discernible in the mass
spectrum. Irvine et al. have demonstrated that the more unfolded or solvent accessible the
protein is, the more Normal the distribution of the resulting modified species.24, 37 If the
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protein were folded with only a certain set of cysteines being solvent accessible, this
would be visualized in the ESI mass spectrum as a strong preference for a certain number
of alkylations. For the experimental conditions required in the rest of this Chapter, the
data show that 3 M GdmCl effectively unfolds apo-MT without altering the pH of the
solution, allowing elucidation of pH dependent metallation pathways, as is described
below.

2.4.2

Metallation Slows in the Presence of Denaturant

Both heat and acidity have been shown to be effective denaturants of MT.7, 8, 22, 23

Scheme 2-1 Guanidinium chloride CH6ClN3
However, due to the pH dependence of MT’s chelation properties, GdmCl (Scheme 2-1)
was chosen so that the pH would not be affected by addition of denaturant. GdmCl is a
chaotropic agent that denatures by disrupting hydrogen bonding.38 The MT sequence
contains few hydrophobic residues, suggesting that hydrogen bonds and electrostatic
interactions are solely responsible for the overall stabilization of the protein in the metal
free state.18 Previously reported molecular dynamics results showed that the hydrogen
bond network in metal-saturated MT is largely retained upon complete demetallation, but
increases upon stepwise, sequential, demetallation because the structure becomes more
folded. 15, 18
Figure 2-4 shows that even with the cluster structure, that the unfolded peptide metallates
more slowly. This result is coincident with previous results reported for just the apo α-MT
metallated with excess Cd(II) in 2015 by Irvine et al.7 pH 5 was chosen specifically for
the series of experiments described in Figure 2-4 as it ensures the dominance of the
Cd4S11 cluster.
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2.4.3

pH Changes the Dominant Metal Binding Pathway: Cluster
Formation at pH 5 is Slower than Bead Formation at pH 8

Irvine et al. have demonstrated the pH dependence for Zn(II) and Cd(II) metallation, and
that the pathway adopted at different pHs can be confirmed by observing the metallated
species in the ESI-mass spectrum.16 Acidic conditions promote the cluster pathway for
both metals, as shown in the low pH MS data for Cd(II), Figure 2-6. At physiological pH,
both Cd(II)and Zn(II) bind in a beaded fashion up to 5 M(II) ions bound, as shown in the
MS data for Cd(II) metallation, Figure 2-7. Figure 2-7 clearly shows the expected
stepwise progression of the speciation as a function of Cd(II) mol. eq. There is no
preference at this pH for the Cd4S11 clusters. The rate of metallation was obtained as
function of pH. However, Cd(II) switches to the cluster pathway at a much higher pH
compared to Zn(II). Zn(II) generally follows the tetrahedral terminal bead pathway over
this pH range, with the cluster pathway only playing a role at a pH <5.1.16 In the case of
Cd(II), cluster pathways can begin to dominate at a pH <7, which indicates the major
influence a small change in pH can have on metal binding structures. This is pertinent to
the discussion of metal anticancer therapeutics in the acidic condition of the tumor cell,
which would promote MT to form stable metal-thiolate clusters, impeding drug delivery
and efficacy.39
In Figure 2-5, the pH range 5-8 encompasses a change in metallation product for the 2.5
mol. eq. of Cd(II) of clusters at pH 5 and beads at pH 8. Because the trend in rate constant
follows almost exactly the trend in % terminal binding as a function of pH reported by
Irvine et al.,16 cluster formation (pH 5) is dramatically slower than bead formation (pH 8).
The mass spectral data shown in Figure 2-6 and Figure 2-7, indicate that for the solutions
used in the stopped-flow in Figure 2-8A and B, the metallation products are dominated by
Cd4S11 cluster formation in the α domain. For Figure 2-8C and D The increase from pH 5
to pH 8 increased the observed metallation rate tenfold in both cases, with the pH 8,
native apo-MT, beaded metallation pathway, remaining the most rapid of the four
conditions, Figure 2-9. It should be noted that in Figure 2-8, the plateaus of the kinetic
traces do not all end at the same y-value. This is due to instrument variability, caused by
measuring at 250 nm which is close to the detection limit. Normalizing the curves to end
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at the appropriate y-values according to Beer’s Law results in the same trends presented
here.

2.4.4

Why is Terminal Cysteine Coordination Faster than Cluster
Formation?

The formation of terminally bound metal beads is shown to be fast in Figure 2-5. This
could be because although there is no defined structure for the cysteines: (i) the ESI mass
spectral modification data, Figure 2-3, (ii) the modification data provided by Irvine et
al.,6, 23 and (iii) the previous molecular dynamics results, together support a structure for
the apo-MT that involves non-specific folding optimized for metallation. Beaded
metallation requires the concerted binding of 4 cysteine thiols at a time to M(II). The
folded apo-MT structure orients the cysteines in close proximity such that the beads are
formed rapidly. The cysteines that are most solvent exposed and have the most reduced
energy upon metallation may well be metallated first.12, 18, 19, 40, 41
In the case of cluster formation, this is a highly organized process with very specific
cysteines involved in bridging arrangements resulting in the most energy minimized
structure. The kinetic data show that this large-scale organization occurs at a slower rate
than that of the beaded pathway, presumably due to the requirement of such precise
cysteine coordination.

2.4.5

Rate as a Function of Metal Loading

kobs decreases with sequential metallation, with the initial metals having the highest
values. The last binding sites to be occupied are the slowest, as a reflection of a decrease
in available sites. This is reflected widely across all metal species, as previously shown
with time-dependent ESI-mass spectral data with Cd(II),16 As(III),42 and Cu(I).43 A
sequential increase in Kf is generally associated with the formation of a stable cluster, if
M>1, as has been shown in the titration of Cu(I)1-20MT,43 As1-6MT,11, 12, 36 and notably
with Cd4S11 and Co4S11 clusters in the α domain.
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2.4.6

Temperature Dependence of Metallation

Petering et al.41 and Stillman et al.30 have reported the temperature dependence of the
metal lability in metallothioneins. The interprotein exchange of Zn(II) between carbonic
anhydrase is much more rapid at 37 ° C than at 25 °C.41 The intraprotein exchange of
Cd(II)and Zn(II) between domains can be followed readily with circular dichroism
spectroscopy at temperature extremes.30 The initial metallation reactions studied in this
paper are also temperature dependent, as shown in Figure 2-11. There is an upper limit, as
shown by Irvine et al, who used heat assisted denaturation at 94°C to demonstrate
temperature dependent denaturation.22

2.4.7

Metallation of Unfolded Apo-MT is Slower than Native Folded
MT

The results of Figure 2-4, Figure 2-5, Figure 2-8, and Figure 2-9 show that the disruption
of the apo-MT structure affects the rate of both the bead and cluster formation. pH
influences the dominant pathway, but each pathway does have an optimal structure
required for efficient metallation. Other structure impeding agents present in the cellular
environment may cause similar disruption to the metallation process. Being particularly
sensitive to sulphur oxidation, oxidized MT manifests in the formation of disulphide
bridges, which will greatly disrupt the delicate and highly specific metal-thiolate
organization of the native MT.
Does the apparent lack of formal structure for the native apo-MT have an impact on
metallation rates? The use of a well-studied denaturant together with well understood
structural metal-thiolate products (beads up to 5 Cd(II) at neutral pH and up, cluster
formation below pH 6) meant that the single variable being tested was the extent of
folding of the apo-MT. The data in Figure 2-8 and Figure 2-9 clearly answer this
question. The metallation rate for Cd(II) is always faster in the absence of a denaturant.
At physiological pH (choosing pH 8 to eliminate cluster formation) the folded apo-MT
(absent denaturant), metallated over 50% faster than the unfolded (with denaturant). This
same trend is the case at pH 5.
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On a similar vein, these results demonstrate the effect of misfolding on the efficient
function of a native protein. A common source of protein damage occurs as a result of
oxidation. MT plays a role in both the protection and repair of oxidative damage.44-46
Oxidation and protein misfolding are thought to be one of the causes of cellular ageing,
with a build-up of misfolded proteins and metal ions aggregating in the lysosome.47 There
is increasing evidence that MT plays a protective role in metal aggregation limitation,
such as in the reduction of amyloid plaques in neurodegenerative diseases.48-50 With its
multitude of reduced cysteine residues, MT can repair oxidative damage through the
formation of disulphide bonds. This oxidation would greatly reduce MTs metal binding
efficacy and place the cell at risk for dysfunctional regulation. A build-up of these
misfolded products could result in differentiating cell conditions, such as decrease in pH,
thus altering the activity of MT metallation to promote stable cluster formation.
MTs are well known for their stable metal-thiolate clusters, that protect the MT from
oxidation and protease digestion.51, 52 From an evolutionary standpoint, MTs adaptive role
in metallation and oxidative protection makes it a key player against ageing. Its ubiquity
across all phyla cements this idea. Species specific amino acids may also impart finetuned structural influences to optimize efficiency in particular organisms, for which the
reader is courteously directed to selected references comparing plant and mammalian
MTs.53-55

2.5

Conclusions

The metallation of MT is a post-translational modification that is dependent on the
cellular environment, particularly pH and metal loading status. In lower pH environments,
such as hypoxic or tumorous cells, clustering pathways would predominate, especially in
the presence of toxic Cd(II). This is relevant towards developed metallodrug resistance
that some cancer types exhibit: MT of these cancerous cells is capable under these
conditions of binding soft metals in a stable metal-thiolate cluster, minimizing cellular
damage. At physiological pH, the evidence from the experiments reported in this Chapter,
suggest that apo-MT adopts a compact folded structure, with cysteines oriented for facile
metallation, indicated by the higher metallation rate. Folded apo-MT forms these very
specific structures during the stepwise metallation process. Further studies are needed to
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investigate how these structures change when the protein has been damaged as a result of
misfolding or binding to a foreign or xenobiotic metal.
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Chapter 3
Capturing Platinum in Cisplatin: Kinetic Reactions with
Recombinant Human apo-Metallothionein 1a*

3

3.1

Introduction

The prolonged use of cis-diamminedichloroplatinum(II) (cisplatin), a powerful
chemotherapeutic, can incur chemoresistance in cancers during treatment, reducing the
chance of therapeutic success. Metallothioneins (MTs) are suspected of metallodrug
interference via ligand removal and metal sequestration. The mechanistic details and
reactions rates kobs for the systematic deconstruction of cisplatin by apo-human MT are
reported and analyzed from mass spectral data.
In order to understand pre-target resistance in metallo-chemotherapeutics it is necessary
to investigate the mechanisms responsible for metal-protein binding reactions. Cisplatin, a
popular and extremely effective anti-cancer drug, is the focus of worldwide
interdisciplinary investigations into emerging chemoresistance and metabolic toxicology
in cancers. This present paper focuses on monitoring the abrupt and disruptive reaction
involving a major cellular thiol source, metallothionein, with cisplatin. MT is implicated
as a metal sink that may be also involved in nephrotoxicity. Time–dependent, solutionphase, ESI-MS was used to monitor the destruction of the cisplatin molecule. Kinetic
analysis provided the reaction rates for the individual steps from the initial binding of the
complete molecule, through extrusion of the ligands, and final accumulation of isolated
Pt(II) bound to metallothionein.

3.1.1

Cisplatin: A Standard Treatment for Cancer

Since its discovery by Rosenberg in 1978, cis-diamminedichloroplatinum(II) (more
commonly known as cisplatin) has been used as a potent anti-cancer agent for the
treatment of testicular, ovarian, head and neck, bladder, colorectal, and lung cancers.1-4
As a metallodrug, cisplatin can act upon several biochemical pathways to trigger cell
death. For instance, with its soft, transition metal core, cisplatin is capable of readily
binding the free thiols of glutathione and metallothioneins, reducing the cell’s facility to
*A version of this chapter has been published:
Metallomics,10(5), 713-721 (2018). Copyright 2018 Royal Society of Chemistry
Reproduced with permission from: D. L. Wong, and M. J. Stillman.
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respond to oxidative stress.1, 2, 5-9 Binding to glutathione (GSH) can instigate efflux from
the cell via MRP1 and MRP2, removing this thiol source from the cell.10-12 Similarly, by
binding to free thiols near the active site of enzymes, cisplatin can disrupt cell function.13,
14

However, its most well-known method of action is through the creation of DNA

adducts triggering mitochondrial apoptosis and cell death.

Scheme 3-1 Cisplatin and the aquation reaction involved in its initial entrance to the
body. Reproduced from D. L. Wong and M. J. Stillman with permission from the Royal
Society of Chemistry. 15
Upon administration in the body, cisplatin becomes an active form through aquation
reactions where the chloride ligands are spontaneously exchanged with water, as
described in Scheme 3-1, above.16, 17 This results in a complex that reacts readily with
endogenous nucleophilic groups, like the free thiols mentioned above, or, in particular,
the guanine N7 site on purines in DNA.2, 18 Multiple reactions can occur for each Pt(II)
core of the cisplatin, resulting in inter- and intra- strand crosslinking of DNA, disrupting
transcription and translation. It should be noted that in fact, very little (1%) of the
intracellular cisplatin binds to nuclear DNA.19 Clearly, DNA damage is not the only
cytotoxic pathway at play, as cisplatin also exerts toxic effects on enucleated cells.20
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3.1.2

Metallothionein and Drug Resistance

While initially effective in many cancer types, chemoresistance to cisplatin can develop
with prolonged treatment.21, 22 Increased expression of cellular thiols GSH and MT have
both been implicated in these resistance mechanisms but they are believed to be
independently induced.23 Kelley et al. remarked that there was a noticeable increase in
cellular MT levels in several cancer lines treated with cisplatin and antineoplastic agents
melphalan, and chlorambucil.24 It has also been suggested that MT is an obstacle in the
treatment of the ovarian cancer A2780CR cell lines that are cisplatin resistant. Work from
Surowiak et al. suggests that nuclear MT expression levels increase with cisplatin
treatment, which may be correlated with the diminished overall clinical response.22 The
direct correlation between cellular MT and chemoresistance is not clear cut for all cancer
types, as shown by Woo et al, nuclear and cellular MT levels vary greatly across cancer
types, and this subcellular compartmentalization of MT plays a role in its metal
response.23 While the relationship between MT expression and developed cisplatin
resistance is unclear, the correlation between the two has been suggested as a possible
biomarker for resistance. As such, the connection between the two has been the focus of
gene expression and metallomics studies.25
As described extensively in Chapters 1 and 2, MTs are a family of ubiquitous, low
molecular weight (6-8 kDa), cysteine-rich, metal binding proteins that most notably play
a role in Zn(II) and Cu(I) homeostasis, heavy metal detoxification, and response to
oxidative stress.7, 26-30 MTs are capable of creating a variety of metal-thiolate cluster
structures using 20 cysteine thiolates.29-33 The involvement of MTs in cisplatin resistance
is suggested to be due to their property of binding a wide array of soft, d-block,
xenobiotic metals, such as Cd(II), Hg(II), As(III), and Pb(II), as well as those of
therapeutic interest, like Bi(III), Au(I), Ag(I), and Pt(II), among others.27, 28, 34-37, MTs act
to sequester toxic metals for excretion, which in the case of cisplatin, can lead to renal
side effects associated with treatment.38
MT binding with cisplatin has been studied intensely due to its association with
developed cisplatin resistance. Reactions showing remetallation of Zn-MT and Cd-MT by
Pt(II) demonstrate the strong affinity of the cysteine thiol for the Pt(II).6, 39-47 MT 1 and
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MT 2 are capable of binding up to 7 Pt(II), mimicking the stoichiometry of the twodomain binding structure of native Zn7-MT and Cd7-MT.48 The Stillman group has
previously demonstrated low temperature (77 K) emissive properties of Pt-bound MT,35 a
property of metal-thiolate cluster formation.
Extensive kinetic analysis of the metallation of metallothionein by cisplatin has been
performed by Hagrman et al. involving spectroscopic methods.6 Mimicking chemical
conditions of the cell, their study involved monitoring in vitro the loss of cisplatin over
the course of full metallation of metallothionein. As expected, the Pt-MT product has
none of the ancillary ligands of the original cisplatin molecule. Hagrman et al. note that
there is a delay in the observed signal, indicating that initial reactions may be occurring
that are not detectable under the conditions used.6 A limitation of optical techniques is the
averaging of all the signals, which masks the individual mechanistic details in these early
stages of the reaction.

3.1.3

Biological Significance

Many of the in vitro methods described above utilize widely available rabbit liver or rat
liver metallothioneins, which often come in mixtures of isoforms, metallated with Zn(II)
or Cd(II), or as a mixed metal species. Using recombinant human metallothionein
expressed in Escherichia coli provides isoform-pure recombinant human MT 1a. MT
regulation is influenced by the presence of xenobiotic metals, like Bi(III), Au(I) and
Pt(II), and as such, apo-MT will be synthesized by the cell in response to the presence of
these metals.33, 36, 49 Indeed, several reports now confirm the presence of apo-MT in vivo
in large quantities.50-53 This perspective indicates that the metallation of MTs is a posttranslational modification. Therefore, the properties of the reaction between apo-MT1a
and cisplatin are investigated using the high species resolution of ESI-MS. The timedependence of this early reaction involving the deconstruction of the cisplatin complex
can be monitored at this resolution. This provides insight on the interactions between MT
and complex chemotherapeutic complexes, as opposed to the free ion metallation studies
of MT performed previously. The benefit of applying ESI-MS is the availability of highresolution snapshots of solution-phase intermediates throughout the course of the
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reaction. With this, the initial reaction that Hagrman et al. and Pattanaik et al. suggest
exist but have not yet characterized the speciation involved can be identified.6, 46
The following Chapters involving the aggressive reaction of human MT with
dirhodium(II) tetraacetate raised the question whether MTs might react similarly with the
most important and effective metal-based anticancer drug, cisplatin. In the reaction with
the dirhodium(II) tetraacetate, the MT bound the complete molecule and in a stepwise
fashion competed for the possible binding sites with its numerous cysteinyl thiols until
only the [Rh-Rh]4+ core remained encapsulated by the protein. The high resolution
capabilities of ESI-mass spectral data displayed each of the stepwise species formed
during the reaction, showing the systematic destruction of the dirhodium(II)
tetraacetate.54A similar destructive effect was demonstrated by MT upon antimetastatic
Ru(II)-arene complexes.55
The experiments reported in this Chapter leverage the exquisite power of the ESI-MS
technique to interrogate the products formed initially between MT and cisplatin. In this
manner, the early mechanistic details will become clear, allowing the determination of the
structural aspects of cisplatin that lead to MT deactivation. The goal of this work is to
determine the identity of the initial Pt-based species that bind to the MT, and then to
elucidate the subsequent reaction pathways of the Pt-based species while debilitatingly
immobilized in the MT. Unlike previous reports, the mechanism explored in this work
involves the metallation by each individual cisplatin molecule to form the Pt-MT product.
To avoid the complexity of a distribution of metallated species in partially-metallated
MTs, 31, 56, 57 The apo-MT with its 20 uncoordinated cysteines was chosen as a model for
the uncoordinated cysteines in partially metallated MT. The results may be used to guide
design of metallodrug structures that are resistant to this MT-thiolate destructive
chemistry.

3.2

Experimental Methods

Recombinant human metallothionein 1a were produced and purified according to
previously described methods with the sequence
GSMGKAAAACSCATGGSCTCTGSCKCKECKCNSCKKSCCSCCPMSCAKCAQGC
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VCKGASEKCSCCKKAAAA.56, 58, 59 This recombinant sequence has mutations (T27N
and I51V) compared with the native human MT1a for purposes of overexpression in E.
coli. The metallation properties of this recombinant isoform (MT1a) has been shown in
spectroscopic studies from the Stillman Group to behave similarly to mammalian MTs,
for example, rabbit liver MT2A.60, 61 The purified Cd-bound MT1a was demetallated by
acidification (pH<2) and the resulting free Cd(II) in solution were removed by centrifugal
filtration (Amicon Ultra-4 3000 Da MWCO). Protein concentration was calculated by
remetallating a measured aliquot with CdSO4 and determining the Amax at the 250 nm
shoulder characteristic of the LMCT of Cd-S bonds (ε = 89,000 L mol-1 cm-1).
Solutions of cisplatin (Sigma) were prepared in DI water well ahead of time to allow for
aquation. Aliquots containing cisplatin equivalent to ~ 3 mol. eq. of the apo-MT were
added to the apo-MT solution (20 mM ammonium formate buffer, Fluka, pH 7.0)
immediately prior to mass spectral data acquisition using a MicroTOF II (Bruker
Daltonics, Toronto). All solutions were at room temperature and thoroughly deaerated
using vacuum evacuation followed by Ar saturation. NaI was used as the calibrant.
Spectra were collected in positive ion mode, as a function of time following mixing. The
settings used are described in Chapter 1.
The averaged spectra and data analysis were carried out using the Bruker Data Analysis
4.2 program. The resulting spectral data were normalized, and the dominant species
identified by mass. The identified species and their abundance data were grouped and
input into GEPASI,62, 63 a biochemical kinetics simulator, as the reactions defined in
Scheme 2 in the Results and Discussion section. The four reaction rate constants, k1-4,
were defined as irreversible mass action, and the k’s and concentrations were limited by
user-defined parameters.

3.3

Results and Discussion

The time-dependent deconvoluted mass spectral data recorded during the reaction of
cisplatin with apo-metallothionein 1a experimental data are shown in Figure 3-1, and in
block form Figure 3-2. In the Apo panel of Figure 3-2, the black bar represents the ApoMT abundance at the beginning of the reaction. By one minute (A) each of the species
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found at the end of the reaction can be discerned. The speciation is grouped in terms of
MT involved in Pt1 complexes (red, “Pt1 Group”), Pt2 complexes (blue, “Pt2 Group”), Pt3
complex (green), and Pt4 complex (pink). The mass spectral data are rich in detail about
the many species involved in the initial binding of cisplatin to the MT. There are two
ways of describing the data shown in Figure 3-2: (i) Either by the time-dependence of the
individual groups, based on the number of Pt(II) bound to the protein (x = 1-4), (ii) or
based on the appearance of species at each time point (A – F). The kinetic analysis, to be
described below, is based on the 4 groups, but not the individual speciation within the
groups. At this point, the focus is directed to describing the change in speciation for each
individual platinum bound (Figure 3-1 A-F).

Figure 3-1 ESI mass spectra following the reaction of cisplatin with apo-MT1a.
The apo-MT peak is highlighted by the red dashed line. Platinated species are coloured
according to the number of Pt(II) atoms contained, with its associated partially ligated
(PtxL-MT) or fully ligated ((CDDP)x-MT) species sharing the same colour. MT bound to
Pt1 represented with green dashed lines. MT bound to Pt2 represented with blue dashed
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lines. MT bound to Pt3 represented with yellow dashed lines. MT bound to Pt4
represented with pink dashed lines. Reproduced from D. L. Wong and M. J. Stillman with
permission from the Royal Society of Chemistry. 15

Figure 3-2 ESI mass spectra following the reaction of cisplatin with apo-MT1a in bar
graph representation.
The apo-MT peak is highlighted by the black bar. Platinated species are coloured
according to the number of Pt(II) atoms contained, with its associated partially ligated
(L-Pt-MT) or fully ligated (CDDP-MT) species sharing the same colour. MT bound to Pt1
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represented with red. MT bound to Pt2 represented with blue. MT bound to Pt3
represented with green. MT bound to Pt4 represented with pink. Reproduced from D. L.
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15

Figure 3-3 Detailed ESI mass spectral data of CDDP1MT and CDDP2MT
Detailed comparison of mass spectral data for the “Pt1 Group” (Red, left) and “Pt2
Group” (Blue, Right). The selected panels are from the frames shown in Figure 3-1A-F.
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The overall cisplatin molecule deconstruction is observed from the overall decrease of the
“CDDP” species and the overall increase of the “Pt” species. Reproduced from D. L.
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15.
In Figure 3-2A, within the red Pt1 group, the whole CDDP is bound to the MT, and over
time to F, it loses its ligands, forming Pt1, which is seen in greater detail in Figure 3-3A.
The intermediate in this pathway reaction can be seen as the peak labelled LPt1-MT,
where the ligand (L) can be either (2 NH3) or Cl1-, but this cannot be distinguished
because of the overlap in the masses of these species. However, due to the nature of the
ESI-MS experiment, L is most likely to be NH3 from the ammonium formate buffer, and
due to the favourable loss of the Cl1- as shown in Scheme 3-1. Returning to Figure 3-2A,
the Pt2 species (blue) can be formed from both CDDP1Pt1-MT and CDDP2 species.
However, by F, the Pt2MT dominates, again illustrated more clearly in Figure 3-3.
Returning once more to Figure 3-2A, under the concentration conditions at this stage of
the initial reaction, only the Pt3Mt and Pt4MT species are observed, but these species
grow in abundance as the reaction proceeds, to F. To summarize the time-dependence of
the data, there is clear evidence that two complete CDDP molecules bind to MT, and that
these two molecules degrade to the sequestered metal core. In F, the dominant species are
Pt1MT, Pt2MT, Pt3MT, and Pt4MT. The Ptx-MT species without any ligands are the final
products of each metallation event. The coexistence of Pt1-4MT is not an unusual
observation for mechanisms that are not cooperatively driven. 31, 57, 58, 64, 65
Each of the individual species can be seen at the 3-4 minute point, Figure 3-2D. i) β,
Pt1MT, appearing as expected at 7062.7 Da, α, Apo-MT at 6868.8 Da. This mass
difference corresponds to the mass of cisplatin molecule. ii) γ, L-Pt1MT at 7096.8 Da, iii)
δ, CDDP1-MT 7167.8 Da, iv) ε, Pt2MT at 7258.7 Da, v) ζ, L-Pt(Pt)MT 7290.8 vi) η,
CDDP1Pt1MT at 7363.7, vii) θ, Pt3MT 7453.7, viii) ι, CDDP2MT at 7470.7, and ix) κ,
Pt4MT 7648.5 Da. MT species of Pt > 4 could not be distinguished from noise. The M4S11
stoichiometry is a well-known structure involving metal-thiolate cluster formation that
occurs in other divalent metals.27, 57, 66-68
Figure 3-3 show the time-dependent change in the Pt1 group (A, red) and Pt2 group (B,
blue) taken from panels A-F in Figure 3-2. In Figure 3-3A, the initially bound CDDP
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degrades to L-Pt1MT and then to Pt1MT. In the Pt2 group there are two reactants that can
form the Pt2MT species: CDDP1Pt1MT and CDDP2MT. Both of these are seen at 7363.7
and 7470.7 Da, respectively. The time-dependence data again show that the encapsulated
core, Pt2MT, is the product.

Figure 3-4 Experimental speciation abundance over time
Abundance speciation data over time taken from the experimental mass spectral data.
Apo-MT species are represented with black. The holoMT species (red) represents the sum
of PtxMT species (blue), ligated Pt species LPtxMT (green), and MT species with a whole
cisplatin molecule bound, CDDPxMT (cyan). Reproduced from D. L. Wong and M. J.
Stillman with permission from the Royal Society of Chemistry. 15
The time-dependence of the mass-spectral data is used to quantify the reaction
mechanism shown in Equation 3-1. The resolving power of ESI-mass spectrometer allows
monitoring this reaction in higher detail than has been possible previously. In particular,
the time-resolved spectra shows the emergence and subsequent loss of the intermediate
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species, as well as the composition of the intermediates that reach a steady state.
However, the 9 species present make the kinetic analysis extremely challenging. In Figure
3-4, the metal-free species, Apo-MT (Black), decreases over the course of the reaction, as
it begins to sequester the cisplatin in solution. All the resulting metallated species are
summed and reported in Figure 3-4 as Holo-MT (Red). Holo-MT represents the sum of
all the many sub-species that form as cisplatin is deconstructed while bound within the
MT. The specific components are i) the majority final products Ptx-MT where x=1-4,
contains the sequestered and deactivated platinum core that is no longer a functional
chemotherapeutic (Figure 3-4: Blue); and ii) the ligated species, LPtxMT (Figure 3-4:
Green) and CDDPxMT (Figure 3-4: Cyan) are intermediate species in much lower
abundance than those of Ptx-MT, and achieve a steady state over the course of the
reaction.

Equation 3-1 Bimolecular reaction equations for the metallation of MT by CDDP
Simplified reaction pathway. Products grouped according to its Pt stoichiometry, with the
reaction rates k representing the summation of the overall observed rate of the individual
species. Reproduced from D. L. Wong and M. J. Stillman with permission from the Royal
Society of Chemistry. 15
An unusual observation during the metallation reaction of MT with cisplatin (Figure 3-2)
was that the observed mass corresponds to the dichlorinated cisplatin. This was
unexpected given the time allowed for aquation to occur. However, the observation of the
chloride ion in the cisplatin molecule that is bound within the MT clearly delineates the
starting point of the subsequent deconstruction of the cisplatin. For instance,
distinguishing between the amine groups and water ligands in the aquated cisplatin would
be difficult by MS due to protein band broadening, but the loss of the chloride ligands is
clearly observed with the resulting significant mass difference. While this chlorinated
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speciation is not likely the physiologically observed form of cisplatin, its appearance in
these mass spectra provides information that can be used in the development of the
deconstruction reaction pathway.

Figure 3-5 Experimental and simulated relative speciation abundance
Experimental data (markers, labelled (E) in legend) and the fitted time dependent
reaction (smooth lines, labelled (S) in the legend) of speciation abundance. The top
spectra show the Apo-MT and HoloMT speciation, where HoloMT represents the sum of
the respective metallated species shown in the bottom spectra. Reproduced from D. L.
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15
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The presence of so many individual intermediate species can make kinetic analysis
difficult by standard fitting methods. Using GEPASI, a biochemical pathway simulator,
the observed kinetic rates can be simulated by fitting each of the metallation rate laws for
cisplatin binding to MT to the experimental data.62, 63 For the experimental data, we use
the time dependence of the abundance of each species in the ESI mass spectral data. To
simplify the overall process, reactions involving the CDDP-MT, CDDP-Pt-MT, and L-PtMT intermediate species were grouped based on their total Pt:MT stoichiometry (eg:
Pt1MT, Pt2MT, Pt3MT, Pt4MT) (Equation 3-1), as described for Figure 3-2. The observed
rate constants were then derived from the experimental data for each group (Table 3-1).
The four consecutive rate law equations modelled the experimental data using the initial
concentrations. Taking into account the errors in experimental MS abundancies, the fitted
k values are quite reasonable, with % standard deviations below 22%. The errors for the
formation for Pt4MT are large because the abundancies are low as it is the final step in the
mechanism. The analysis also shows that the reaction is still in progress at the 600 s time
point.
Figure 3-5, top, summarizes the fitting results. Apo-MT reacts rapidly with cisplatin to
form HoloMT, with more than 50% of the metallation occurring in the first 100 s. Figure
3-5, bottom, shows the individual components of the HoloMT that were fitted with the k
values shown in Table 3-1. These four k values are the rate constants for the steps by
which individual PtxMT (x = 1-4) form. They encompass ligand substitution by the MT
cysteine thiolates until only the Pt(II) core is left.
Table 3-1 Fitted reaction rate k values from experimental mass spectral data. Reproduced
from D. L. Wong and M. J. Stillman with permission from the Royal Society of Chemistry.
15

Parameter

Value (/10-6)

Std. Deviation

k1

34

6%

k2

23

6%

k3

14

11%

k4

28

21%
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The kinetic analysis provides details of the initial pathways by which metallothionein
interacts with the incoming cisplatin. The complexity of the reaction, indicated by the
similarity in the rate constants, arises from multiple overlapping consecutive pathways, as
noted in previous studies.6, 46 However, the ESI-MS data provides the time-dependent
concentration of each of these initial species. The kinetic analysis provides the
quantitative data to support the speciation sequence in the binding of cisplatin to MT to
form eventually the PtMT product. The first example of a complete analysis of the
metallation mechanism of MT was reported for As(III) binding using time- and
temperature-dependent MS data.34 The results of presented in this Thesis allows the
concentration of any of the 10 cisplatin-MT intermediate species to be calculated at any
time following mixing, starting with only the initial concentrations of Apo-MT and
cisplatin. It is interesting to note that Hagrman et al. reported a similar magnitude k value
for their overall reaction of apo-metallothionein with cisplatin.6
These ESI-mass spectral methods can be employed in the investigation of
pharmacodynamics of drug metabolism in other biological or clinical applications. With
respect to the interaction of MT with cisplatin as discussed above, it is important to
comment on the toxic effects of the metabolism and excretion of cisplatin through the
proximal renal tubules. It is now commonplace to induce metallothionein in the kidneys
using Bi(III) to reduce the tubular damage from the excretion of cisplatin metabolites.69
For instance, with relevance to Pt-based chemotherapeutics, platinum analogues including
carboplatin and oxaliplatin, employ alternative ligand structures to deter chemoresistance
mechanisms and toxic metabolite formation to reduce these symptoms.

3.4

Conclusion

This destructive property of MT towards transition metal complexes reported here with
cisplatin emphasize the role of MT as a major player in pre-target resistance. The role of
MT in metal metabolism and excretion coupled with the strength of binding to Pt(II),
demonstrates the route in which renal damage occurs is likely similar to that of Cd-MT
described in Chapter 1. Evidence of long term platinum persistence in individuals treated
with platinum anticancer treatments,70 indicates that the metabolism of Pt(II) is a long
process and chronic exposure would exacerbate this effect. When considering that the
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heightened reactivity of MT and related thiols with trans-diamminedichloroplatinate(II)
(transplatin) makes it unable to exact cytotoxic effects, it is clear that the character of the
ligand on the metal greatly influences treatment success. The importance of the design of
a thiol-resistant drug necessary to negate this resistance pathway. High resolution ESI-MS
is a means to quantify metabolic products following metallodrug administration, and
provides a sophisticated approach for identifying specific metabolic pathways.

3.5

References

1.

L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo
and G. Kroemer, Molecular mechanisms of cisplatin resistance, Oncogene, 2012,
31, 1869-1883.

2.

Z. H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of
resistance, Oncogene, 2003, 22, 7265-7279.

3.

S. Dasari and P. B. Tchounwou, Cisplatin in cancer therapy: molecular
mechanisms of action, Eur. J. Pharmacol., 2014, 740, 364-378.

4.

K. Mellish, L. Kelland and K. Harrap, In vitro platinum drug chemosensitivity of
human cervical squamous cell carcinoma cell lines with intrinsic and acquired
resistance to cisplatin, Br. J. Cancer, 1993, 68, 240.

5.

J. C. Dabrowiak, J. Goodisman and A.-K. Souid, Kinetic study of the reaction of
cisplatin with thiols, Drug Metab. Dispos., 2002, 30, 1378-1384.

6.

D. Hagrman, J. Goodisman, J. C. Dabrowiak and A.-K. Souid, Kinetic study on
the reaction of cisplatin with metallothionein, Drug Metab. Dispos., 2003, 31,
916-923.

7.

P. J. Thornalley and M. Vašák, Possible role for metallothionein in protection
against radiation-induced oxidative stress. Kinetics and mechanism of its reaction
with superoxide and hydroxyl radicals, BBA - Protein Struct. M., 1985, 827, 3644.

8.

P. D. Sadowitz, B. A. Hubbard, J. C. Dabrowiak, J. Goodisman, K. A. Tacka, M.
K. Aktas, M. J. Cunningham, R. L. Dubowy and A.-K. Souid, Kinetics of cisplatin
binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs,
Drug Metab. Dispos., 2002, 30, 183-190.

9.

L. Cubo, M. Groessl, P. J. Dyson, A. G. Quiroga, C. Navarro‐Ranninger and A.
Casini, Proteins as Possible Targets for Cytotoxic trans‐Platinum (II) Complexes
with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm,
ChemMedChem, 2010, 5, 1335-1343.

84

10.

A. Boumendjel, A. Florin and J. Boutonnat, Reversal agents of multidrug
resistance mediated by multidrug resistance-associated proteins (MRPs), ABC
Transporters and Multidrug Resistance, 2009, 261-288.

11.

G. D. Kruh and M. G. Belinsky, The MRP family of drug efflux pumps,
Oncogene, 2003, 22, 7537.

12.

E. M. Leslie, R. G. Deeley and S. P. Cole, Multidrug resistance proteins: role of
P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol.
Appl. Pharmacol., 2005, 204, 216-237.

13.

L. Messori and A. Merlino, Cisplatin binding to proteins: a structural perspective,
Coord. Chem. Rev., 2016, 315, 67-89.

14.

L. Messori and A. Merlino, Cisplatin binding to proteins: molecular structure of
the ribonuclease A adduct, Inorg. Chem., 2014, 53, 3929-3931.

15.

D. L. Wong and M. J. Stillman, Capturing platinum in cisplatin: kinetic reactions
with recombinant human apo-metallothionein 1a, Metallomics, 2018, 10, 713-721.

16.

B. Lippert, Cisplatin: chemistry and biochemistry of a leading anticancer drug,
John Wiley & Sons, 1999.

17.

M. Sooriyaarachchi, G. N. George, I. J. Pickering, A. Narendran and J. Gailer,
Tuning the metabolism of the anticancer drug cisplatin with chemoprotective
agents to improve its safety and efficacy, Metallomics, 2016, 8, 1170-1176.

18.

P. M. Takahara, A. C. Rosenzweig, C. A. Frederick and S. J. Lippard, Crystal
structure of double-stranded DNA containing the major adduct of the anticancer
drug cisplatin, Nature, 1995, 377, 649.

19.

V. M. Gonzalez, M. A. Fuertes, C. Alonso and J. M. Perez, Is cisplatin-induced
cell death always produced by apoptosis?, Mol. Pharmacol., 2001, 59, 657-663.

20.

A. Mandic, J. Hansson, S. Linder and M. C. Shoshan, Cisplatin induces
endoplasmic reticulum stress and nucleus-independent apoptotic signaling, J. Biol.
Chem., 2003, 278, 9100-9106.

21.

R. Schilder, L. Hall, A. Monks, L. Handel, A. Fornace, R. Ozols, A. Fojo and T.
Hamilton, Metallothionein gene expression and resistance to cisplatin in human
ovarian cancer, Int. J. Cancer, 1990, 45, 416-422.

22.

P. Surowiak, V. Materna, A. Maciejczyk, M. Pudełko, E. Markwitz, M.
Spaczyński, M. Dietel, M. Zabel and H. Lage, Nuclear metallothionein expression
correlates with cisplatin resistance of ovarian cancer cells and poor clinical
outcome, Virchows Arch., 2007, 450, 279-285.

85

23.

E. S. Woo, A. Monks, S. C. Watkins, A. S. Wang and J. S. Lazo, Diversity of
metallothionein content and subcellular localization in the National Cancer
Institute tumor panel, Cancer Chemother. Pharmacol., 1997, 41, 61-68.

24.

S. L. Kelley, A. Basu, B. A. Teicher, M. P. Hacker, D. H. Hamer and J. S. Lazo,
Overexpression of metallothionein confers resistance to anticancer drugs, Science,
1988, 241, 1813-1815.

25.

T. Gansukh, P. Donizy, A. Halon, H. Lage and P. Surowiak, In vitro analysis of
the relationships between metallothionein expression and cisplatin sensitivity of
non-small cellular lung cancer cells, Anticancer Res., 2013, 33, 5255-5260.

26.

E. Atrián-Blasco, A. Santoro, D. L. Pountney, G. Meloni, C. Hureau and P. Faller,
Chemistry of mammalian metallothioneins and their interaction with
amyloidogenic peptides and proteins, Chem. Soc. Rev., 2017, 46, 7683-7693.

27.

D. E. Sutherland and M. J. Stillman, The “magic numbers” of metallothionein,
Metallomics, 2011, 3, 444-463.

28.

T. T. Ngu and M. J. Stillman, Metal-binding mechanisms in metallothioneins,
Dalton Trans., 2009, 5425-5433.

29.

C. A. Blindauer, in Binding, Transport and Storage of Metal Ions in Biological
Cells, 2014, pp. 606-665.

30.

E. Freisinger, Structural features specific to plant metallothioneins, J. Biol. Inorg.
Chem., 2011, 16, 1035-1045.

31.

J. S. Scheller, G. W. Irvine, D. L. Wong, A. Hartwig and M. J. Stillman, Stepwise
copper (I) binding to metallothionein: a mixed cooperative and non-cooperative
mechanism for all 20 copper ions, Metallomics, 2017, 9, 447-462.

32.

C. A. Blindauer, Advances in the molecular understanding of biological zinc
transport, Chem. Commun., 2015, 51, 4544-4563.

33.

J. D. Otvos, D. H. Petering and C. F. Shaw, Structure—Reactivity Relationships
of Metallothionein, a Unique Metal-Binding Protein, Comment Inorg. Chem.,
1989, 9, 1-35.

34.

T. T. Ngu, A. Easton and M. J. Stillman, Kinetic analysis of arsenic− metalation
of human metallothionein: significance of the two-domain structure, J. Am. Chem.
Soc., 2008, 130, 17016-17028.

35.

M. J. Stillman, A. S. Zelazowski, J. Szymanska and Z. Gasyna, Luminescent
metallothioneins: Emission properties of copper, silver, gold and platinum
complexes of MT, Inorganica Chim. Acta, 1989, 161, 275-279.

86

36.

W. Bernhard, M. Good, M. Vašák and J. H. Kägi, Spectroscopic studies and
characterization of metallothioneins containing mercury, lead and bismuth,
Inorganica Chim. Acta, 1983, 79, 154-155.

37.

I. Bertini, C. Luchinat, L. Messori and M. Vasak, Proton NMR studies of the
cobalt (II)-metallothionein system, J. Am. Chem. Soc., 1989, 111, 7296-7300.

38.

D. M. Townsend, M. Deng, L. Zhang, M. G. Lapus and M. H. Hanigan,
Metabolism of cisplatin to a nephrotoxin in proximal tubule cells, J. Am. Soc.
Nephrol., 2003, 14, 1-10.

39.

A. J. Żelazowski, J. S. Garvey and J. D. Hoeschele, In vivo and in vitro binding of
platinum to metallothionein, Arch. Biochem. Biophys., 1984, 229, 246-252.

40.

B. Zhang and W. Tang, Kinetics of the reaction of platinum (II) complexes with
metallothionein, J. Inorg. Biochem., 1994, 56, 143-153.

41.

M. Knipp, Metallothioneins and platinum (II) anti-tumor compounds, Curr. Med.
Chem., 2009, 16, 522-537.

42.

B. Zhang, W. Tang, S. Gao and Y. Zhou, Platinum binding to metallothionein.
Analysis of circular dichroism spectra of complexes formed between
metallothionein and platinum from cis-and trans-diamminedichloroplatinum, J.
Inorg. Biochem., 1995, 58, 9-19.

43.

A. V. Karotki and M. Vašák, Reaction of human metallothionein-3 with cisplatin
and transplatin, J. Biol. Inorg. Chem., 2009, 14, 1129-1138.

44.

M. Knipp, A. V. Karotki, S. Chesnov, G. Natile, P. J. Sadler, V. Brabec and M.
Vašák, Reaction of Zn7Metallothionein with cis-and trans-[Pt (N-donor) 2Cl2]
anticancer complexes: trans-PtII complexes retain their N-donor ligands, J. Med.
Chem., 2007, 50, 4075-4086.

45.

R. Mandal, R. Kalke and X. F. Li, Mass spectrometric studies of cisplatin‐induced
changes of hemoglobin, Rapid. Commun. Mass. Spectrom., 2003, 17, 2748-2754.

46.

A. Pattanaik, G. Bachowski, J. Laib, D. Lemkuil, C. Shaw, D. Petering, A.
Hitchcock and L. Saryan, Properties of the reaction of cisdichlorodiammineplatinum (II) with metallothionein, J. Biol. Chem., 1992, 267,
16121-16128.

47.

A. Kraker, J. Schmidt, S. Krezoski and D. Petering, Binding of cisdichlorodiammine platinum (II) to metallothionein in Ehrlich cells, Biochem.
Biophys. Res. Commun., 1985, 130, 786-792.

48.

D. C. Lemkuil, D. Nettesheim, C. F. Shaw and D. H. Petering, Reaction of Cd7metallothionein with cis-dichlorodiammine platinum (II), J. Biol. Chem., 1994,
269, 24792-24797.

87

49.

T. T. Ngu, S. Krecisz and M. J. Stillman, Bismuth binding studies to the human
metallothionein using electrospray mass spectrometry, Biochem. Biophys. Res.
Commun., 2010, 396, 206-212.

50.

A. Pattanaik, C. F. Shaw III, D. H. Petering, J. Garvey and A. J. Kraker, Basal
metallothionein in tumors: widespread presence of apoprotein, J. Inorg. Biochem.,
1994, 54, 91-105.

51.

M. Apostolova, P. Bontchev, C. Nachev and I. Sirakova, Apometallothionein in
rat liver, J. Chromatogr. B Biomed. Sci. Appl., 1993, 620, 191-197.

52.

D. H. Petering, J. Zhu, S. Krezoski, J. Meeusen, C. Kiekenbush, S. Krull, T.
Specher and M. Dughish, Apo-metallothionein emerging as a major player in the
cellular activities of metallothionein, Exp. Biol. Med., 2006, 231, 1528-1534.

53.

Y. Yang, W. Maret and B. L. Vallee, Differential fluorescence labeling of
cysteinyl clusters uncovers high tissue levels of thionein, Proc. Natl. Acad. Sci.
U.S.A., 2001, 98, 5556-5559.

54.

D. L. Wong and M. J. Stillman, Destructive interactions of dirhodium (II)
tetraacetate with β metallothionein rh1a, Chem. Commun., 2016, 52, 5698-5701.

55.

A. Casini, A. Karotki, C. Gabbiani, F. Rugi, M. Vašák, L. Messori and P. J.
Dyson, Reactivity of an antimetastatic organometallic ruthenium compound with
metallothionein-2: relevance to the mechanism of action, Metallomics, 2009, 1,
434-441.

56.

G. W. Irvine, T. B. Pinter and M. J. Stillman, Defining the metal binding
pathways of human metallothionein 1a: balancing zinc availability and cadmium
seclusion, Metallomics, 2016, 8, 71-81.

57.

G. W. Irvine and M. J. Stillman, Cadmium binding mechanisms of isolated
domains of human MT isoform 1a: Non-cooperative terminal sites and
cooperative cluster sites, J. Inorg. Biochem., 2016, 158, 115-121.

58.

D. P. Jayawardena, I. U. Heinemann and M. J. Stillman, Zinc binds noncooperatively to human liver metallothionein 2a at physiological pH, Biochem.
Biophys. Res. Commun., 2017, 493, 650-653.

59.

J. Chan, Z. Huang, I. Watt, P. Kille and M. J. Stillman, Characterization of the
conformational changes in recombinant human metallothioneins using ESI-MS
and molecular modeling, Can. J. Chem., 2007, 85, 898-912.

60.

W. Lu and M. J. Stillman, Mercury-thiolate clusters in metallothionein. Analysis
of circular dichroism spectra of complexes formed between. alpha.metallothionein, apometallothionein, zinc metallothionein, and cadmium
metallothionein and mercury (2+), J. Am. Chem. Soc., 1993, 115, 3291-3299.

88

61.

M. J. Stillman, D. Thomas, C. Trevithick, X. Guo and M. Siu, Circular dichroism,
kinetic and mass spectrometric studies of copper (I) and mercury (II) binding to
metallothionein, J. Inorg. Biochem., 2000, 79, 11-19.

62.

P. Mendes, Biochemistry by numbers: simulation of biochemical pathways with
Gepasi 3, Trends Biochem. Sci., 1997, 22, 361-363.

63.

P. Mendes, GEPASI: a software package for modelling the dynamics, steady
states and control of biochemical and other systems, Bioinformatics, 1993, 9, 563571.

64.

D. E. Sutherland and M. J. Stillman, Noncooperative cadmium (II) binding to
human metallothionein 1a, Biochem. Biophys. Res. Commun., 2008, 372, 840-844.

65.

D. E. Sutherland, K. L. Summers and M. J. Stillman, Noncooperative metalation
of metallothionein 1A and its isolated domains with zinc, Biochemistry, 2012, 51,
6690-6700.

66.

D. E. Sutherland, K. L. Summers and M. J. Stillman, Modeling the Zn 2+ and Cd
2+ metalation mechanism in mammalian metallothionein 1a, Biochem. Biophys.
Res. Commun., 2012, 426, 601-607.

67.

T. B. Pinter and M. J. Stillman, Putting the pieces into place: Properties of intact
zinc metallothionein 1A determined from interaction of its isolated domains with
carbonic anhydrase, Biochem. J., 2015, 471, 347-356.

68.

I. Bertini, C. Luchinat, L. Messori and M. Vasak, Proton NMR spectra of the
Co4S11 cluster in metallothioneins: a theoretical model, J. Am. Chem. Soc., 1989,
111, 7300-7303.

69.

E. R. Tiekink, Antimony and bismuth compounds in oncology, Crit. Rev. Oncol.
Hematol., 2002, 42, 217-224.

70.

G. Rentschler, I. Rodushkin, M. Cerna, C. Chen, F. Harari, R. Harari, M. Horvat,
F. Hruba, L. Kasparova and K. Koppova, Platinum, palladium, rhodium,
molybdenum and strontium in blood of urban women in nine countries, Int. J.
Hyg. Environ. Health, 2018, 221, 223-230.

89

Chapter 4

4

Destructive Interactions of Dirhodium(II) Tetraacetate
with  Metallothionein rh1a*
4.1

Introduction

Metallodrugs have a long and successful history in curing many different classes of
disease; for example, cisplatin for testicular cancer, sodium aurothiomalate for
rheumatoid arthritis, Li salts for psychological disorders, and Bi salts for gastrointestinal
distress.1, 2 Challenges in the development of new metallopharmaceuticals include
overcoming the cellular metal defences protecting the target. Metal-chelating gate-keeper
proteins can result in dramatically decreased drug efficacy. The experiments in this
Chapter report that one such gate-keeping protein, metallothionein, both binds dirhodium
acetate, a potential anticancer metallodrug, and sequentially strips off the acetate ligands
reducing the complex to just a thiolate-coordinated dirhodium core. This reaction may
indicate a possible mechanism for a cellular metallodrug resistance pathway.
Metallothioneins (MTs) are sulfur rich proteins that bind a variety of metals including
toxic metals and those of medicinal interest. Current metallodrug designs aim to
overcome these defences, for example using non-platinum compounds, like the robust
series of half-sandwich arene Ru(II) anti-cancer compounds.3-5 While the over-expression
of the cysteine-rich MT has been correlated to drug resistance,6, 7 there is very little direct,
quantitative evidence of the mechanism that may be involved in the proposed
interactions. In addition, there have been no reports of the subsequent fate of the
metallodrug following its interaction with MT. Studies with cisplatin have provided some
insight into the rates of metal ion isolation as seen in the previous Chapter,8, 9 but much
more detailed information on the mechanism of destruction of the metal complex by the
MT through ligand exchange is needed. Using dirhodium(II) tetraacetate as a model
complex this ligand exchange can be observed with four identical ligands, while featuring
a central metal-metal bond.

*A version of this chapter has been published
Chemical Communications,52(33), 5698-5701. (2016). Copyright 2016 Royal Society of Chemistry.
Reproduced with permission from: D. L. Wong, and M. J. Stillman.
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4.1.1

Dirhodium(II) Tetraacetate as a Model Chemotherapeutic
Complex

Metal-metal bonded dirhodium carboxylate complexes have gained interest as an
alternative to classical platinum anti-cancer compounds.10 Dirhodium complexes are 18
electron systems when the two axial positions are capped by solvent, with octahedral
coordination of the rhodium metals. Ground work studies have shown high in vivo
antitumor activity of Rh2(O2CR)4 (R = Me, Et, Pr) against L1210 tumors, Ehrlich ascites,
and the sarcoma 180 and P388 tumor lines,11 as well as the ability to bind DNA and
inhibit protein synthesis in a manner akin to cisplatin.12 Current research has extended the
applications of rhodium compounds to medical imaging and protein labelling, but the
significant antitumor characteristics of these rhodium complexes remain of great
interest.13-16 However, the dirhodium carboxylates are particularly sensitive to sulfur
coordination from cysteines in biomolecular targets.17, 18 This is significant because MT
may stand in the way as a formidable defence for cancerous cells due to the tendency of
cysteine coordination of any incoming metal. Herein, preliminary studies involving the
remarkable and systematic deconstruction of dirhodium(II) tetraacetate (Rh2(OAc)4), a
compound with anti-tumor activity, by the β-domain fragment of human metallothionein
1a, are reported and discussed.

4.1.2

Electrospray Ionization Mass Spectrometry (ESI-MS)

ESI-MS is a powerful technique that allows for the quantitative visualization of a reaction
as it progresses. In particular, mass spectrometry is especially effective in monitoring
drug-protein binding reactions, as it is able to provide information regarding intermediate
species as they develop in real time. 19, 20 ESI mass spectral data can be used in the
characterization of species formed in a reaction by providing kinetic and stoichiometric
details. When combined with UV-visible absorption and circular dichroism spectroscopic
information, binding sites and changes of protein structure as a result of metal binding
can be determined. These techniques provide a simple, yet information-rich method for
assessing the viability of a preliminary study. While in vivo studies may be suited for
determining mobility and target binding site information in a cell, the high detail of the in
vitro studies shown here provide the mechanistic insight required to understand the
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protective function that MT may perform in such drug resistant cancer forms. In this
study, ESI-MS, UV-visible absorption and circular dichroism spectroscopy, together with
molecular dynamics calculations were employed to monitor the binding reaction of
Rh2(OAc)4 with apo-β-MT.

4.2

Experimental Methods

Preparation of recombinant human Metallothionein1a
Preparation of isolated MT domain fragments followed previously reported methods. 21
The amino acid sequence for the isolated domain used in this study was based on the
recombinant human MT1a 38-residue β-MT domain fragment sequence
(MGKAAAACSC ATGGSCTCTG SCKCKECKCN SCKKAAAA). Each of the
corresponding DNA sequences was inserted as an N-terminal S-tag fusion protein into
pET29a plasmids and individually expressed in E. coli BL21(DE3) with cadmiumsupplemented growth medium, as described in Chapter 1. The protein was expressed and
purified as the cadmium saturated form for stability. All purified protein solutions were
evacuated and saturated with argon to impede cysteine oxidation.
Preparation of apo-β-Metallothionein
Cadmium was removed from the purified, isolated MT domains by acidifying the protein
solutions to pH 2.7. The protein was desalted and buffer exchanged with argon-saturated
deionized water, returned to neutral pH, and concentrated using Millipore Amicon Ultra-4
centrifuge filter units (3 kDa MWCO). Protein concentrations of the final, pH-adjusted
apo-β-MT solutions were determined by cadmium remetallation of small fractions of each
protein monitored using UV-visible absorption (Cary 50, Varian Canada): ε250 values of
Cd3-β-MT is 36000 M-1 cm-1.22 Protein solutions were diluted to a final concentration of
10 µM.
Preparation of Rh2(OAc)4 solutions
Stock solutions of 500 µM dirhodium(II) tetraacetate (Sigma-Aldrich) were freshly
prepared in deionized water, evacuated and argon saturated. The MT cysteine
concentration was determined and two-fold excess of Rh2(OAc)4 was added to the MT
solution and mixed immediately prior to MS acquisition. The room-temperature UV-
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visible and circular dichroism (CD) spectra of the solutions were also measured following
Rh2(OAc)4 saturation.
Electrospray Ionization Mass Spectrometry, UV- Visible and Circular Dichroism
Absorption
A Bruker Micro-TOF II instrument (Bruker Daltonics, Toronto, ON) operated in positive
ion mode was used to collect the data. NaI was used as an external calibrant. The settings
are the same as those described in Chapter 1. The spectra were collected continuously
over 1 hr and time slices were deconvoluted using the Maximum Entropy algorithm of the
Bruker Compass DataAnalysis software package.
A Cary 50 (Varian, Canada) was used to collect UV-visible absorption data from the
visible region. A Jasco J810 spectropolarimeter was used to collect CD spectral data. The
following scan parameters were used: step scan; range, 800-200 nm; data pitch, 1 nm;
bandwidth, 0.5 nm; response, 1 s.
Molecular Dynamics Calculations
A minimized structure of the 38-residue Cd3-β-MT1a domain fragment was used
(Scigress 6.0.0 MM3/MD method with augmented force field; Fujitsu Poland) to test if
the Rh24+ core could be reasonably coordinated by 8 of the 9 cys of the β-MT1a. The
three Cd2+ ions were deleted from the original structure and the Rh24+ core inserted using
cysteine thiolate connections that were in close proximity to the 8 x/y ligand positions on
the Rh24+ core. The alignment of the core was locked to stop rotation about the Rh-Rh
bond. The molecular dynamics calculation was carried out for 200 ps at an average
temperature of 355 K with 2 fs steps using a dielectric of 78.5. The initial structure
relaxed immediately then was stable.

4.3

Results

ESI mass spectra were recorded continuously over 60 min following the mixing of
(Rh2(OAc)4) with apo-β-MT in water. Six representative mass spectra extracted at
different times from the 60 minute collection are shown in Figure 4-1. The spectral data
were averaged over 15 seconds meaning that the average data point time is 7.5 s from the
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start of the averaging in each spectrum resulting in data at 7.5, 37.5, 52.5, 67.5, 95.0 and
127.5 s.
Apo-β-MT is recognizable at a mass of ~3751 Da (track A), with the metallated species
resulting in a series of higher mass species (tracks D-H). The metallated Rh2-β-MT has a
mass of ~3952 Da (track D), with each Rh replacing four of the cysteine thiol protons,
which, we propose, results in an octahedral geometry for each Rh(II) in the dirhodium
core, retaining its Rh-Rh bond. The remarkable feature of this binding reaction is that the
data show, in sequence, the systematic removal of each of the four acetate groups, whose
mass initially starts at ~4193 Da (track H) and with each acetate removal being noted at
peaks M = ~4136 (track G), 4081 (track F), and 4016 Da (track E), respectively. The
released acetates in solution likely form surface adducts to positively charged amino acids
(such as lysine) in the remaining MT, with these adducted species identified by a mass
difference of 59 Da, and in proportional amount to the formation of Rh2-β-MT. There was
no other source of acetate in the solution. The time-dependent data indicate that loss of
the acetates is faster than the initial interaction because the partially-ligated Rh-MT
complexes with 2, 3 or 4 acetates are in very low proportional concentration (tracks F-H)
compared with the mono-acetate and Rh24+ core (track D). The overall binding rate can be
seen from the decline in apo-β-MT abundance. As the Rh24+ core binds to the MT, the
remaining apo-β-MT diminishes so that by 127.5 s almost none remains (tracks A-C).
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Figure 4-1 Deconvoluted time-dependent ESI-mass spectra recorded following the
mixing of apo-β-MT with excess Rh2(OAc)4 at pH 7.3.
The vertical axis shows the normalized intensity; the horizontal axis shows the mass in
Da. Data were averaged for 15 seconds starting at 0, 30, 45, 60, 90 and 120 s from a
data set collected over 60 minutes. The apo-β-MT is marked in track A, the final product
with the Rh24+ bound is marked by track D. Track identifiers: A) Apo-β-MT; mass 3751.
B) Apo(OAc)1-β-MT; 3811. C) Apo(OAc)2-β-MT; 3875. D) Rh2-β-MT; 3951. E)
Rh2(OAc)1-β-MT; 4013. F) Rh2(OAc)2-β-MT; 4075. G) Rh2(OAc)3-β-MT; 4136. H)
Rh2(OAc)4-β-MT; 4192. Reproduced from D. L. Wong and M. J. Stillman, with
permission from the Royal Society of Chemistry. 23
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Figure 4-2 Absorption and CD spectra of the reaction of Rh2(OAc)4 and β-MT
UV-visible absorption spectra (A) and circular dichroism spectra (B) of a 55 µM
Rh2(OAc)4 solution in water with 0.5 and 1.0 mol. eq. of apo-β-MT added. Figure 4-2A.
Spectral assignments: λA = 350 nm; σ (H2O) → σ*(Rh2). λB = 455 nm; π* (Rh2) → σ*(RhO). λC = 580 nm; π* (Rh2) → σ*(Rh2). λD = 350 nm; σ (S) → σ*(Rh2). Figure 4-2B.
Spectral assignments: λ1 = 255 nm, a new band appearing upon Rh2(OAc)4 binding.

96

Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society
of Chemistry.23
The UV-visible absorption spectra recorded with 0.5 and 1 mol. eq. of Rh2(OAc)4 added
to the apo-β-MT showed appearance of bands near 3250 nm associated with a change in
color from blue to yellow (Figure 4-2A). The Rh-Rh metal-metal bond was indicated by
the band near 580 nm that only slightly blue shifted, as reported by others regarding
rhodium axial coordination by solvents.18
The circular dichroism spectra show a new band forming near 255 nm that only appears
as a result of the protein binding to the Rh2(OAc)4 (Figure 4-2B).
The ESI-mass spectral data together with the absorption spectral data, support our
proposal that the Rh2(OAc)4 complex is bound as the Rh24+ core after each of the acetate
bridging ligands is released and replaced by pairs of cysteinyl thiolates from the MT. In
this mechanism, the thiolates displace the acetates stepwise, allowing the Rh-Rh bond to
survive. However, the proposal does require a test of whether the Rh24+ core could exist
within the peptide using a reasonable folding motif achievable from the 9 cysteines of the
apo-β-MT fragment. To test this, an energy minimized structure of Cd3β-MT1a was used
to establish a typical host volume.24 Using the Rh2(OAc)4 complex structure as a starting
point, the deleted 3 Cd2+ ions in the protein binding site and inserted the Rh24+ core
aligned by the acetates. The alignment was locked as the MM3 system has no information
about the electronic structure of the Rh24+ metal-metal bond requirement. The 8
coordination points for the 8 x/y aligned thiolate ligands are defined in the electronic
structure as being eclipsed. There are two further z-axis coordination points frequently
used by solvents.18 The cysteinyl thiolate alignments following deletion of the three Cd2+
ions were used to guide bond formation to the Rh24+ core. The MD calculation trajectory
showed that the peptide backbone realigned within 10 ps, indicating that the Rh24+ core
required very little rearrangement to use the volume previously occupied by the 3 Cd2+
ions. Figure 4-3 shows the space filling representation and the ribbon alignment of the
orientation at 200 ps. No significant change in the energy was observed for over 170 ps.
The ribbon (Figure 4-3, right) shows that the peptide encapsulates the Rh24+ core.
Emission data from Cu+ binding studies to metallothioneins support the proposal that
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when the MT peptide binds using all the cysteines in a cluster that there is little access to
the solvent,25 so water was not included in the binding region. The ribbon depiction of the
peptide orientation in Cd3-β-MT was virtually the same as shown in Figure 4-3,
confirming that replacement of the three Cd2+ ions by the Rh24+ core did not require major
reorientation of the cysteines. The structure in Figure 4-3 is a hypothetical model
designed to indicate the possible conformational changes necessary for the 38-amino acid,
9 cysteine apo-β-MT to bind the Rh24+ core.

Figure 4-3 Molecular Dynamics structure for Rh2-bound β-MT.
Results of a molecular dynamics calculation where the Rh24+ core was inserted into the
apo-β-MT1a binding site. The calculation was carried out for 200 ps at an average
temperature of 355 K with a dielectric constant set to the 78.5 of water. The yellow
spheres are cysteinyl thiolates while the white spheres (right) are the two Rh2+ ions. The
intention of this calculation was to examine if the Rh24+ core could bind using 8 cys S
without major change to the normal conformation. Reproduced from D. L. Wong and M.
J. Stillman, with permission from the Royal Society of Chemistry. 23

4.4

Conclusion

This Chapter introduces investigations of the simplest dirhodium carboxylate,
dirhodium(II) tetraacetate (Rh2(OAc)4), and its deconstruction in vitro by the human
MT1a β-domain fragment of the metal-defence protein, MT. Metallothioneins have a
well-documented chemistry of scavenging toxic metals that enter the cell. Our group and
others have suggested that this property can contribute to greatly reduced efficacies for
metal-based drugs. In the reaction described in this Chapter, the four metal-coordinated
acetates are replaced stepwise by the more aggressive cysteinyl thiolates of the
metallothionein. The protein wraps around the rhodium complex, maintaining the Rh-Rh
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bond, bringing the cysteinyl thiolates closer to the interior core. To further investigate this
metallation mechanism, studies continue with the full length, two-domain MT, in the
following Chapter.
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Chapter 5

5

Metallothionein: an Aggressive Scavenger– The
Metabolism of Rhodium(II) Tetraacetate (Rh2(OAc)4)*
5.1

Heavy Metal Pollution from Anthropogenic Sources

With the turn of the millennium, sales of consumer products produced with xenobiotic
metallic elements have increased globally. Examples of these metals are: Ti, Pb, Ni, and
Sn in cosmetics,1-6 Sn, Ni, and rare earth elements in electronic cigarettes,7-9 Cd in
batteries, Hg in lamps, As in older microchips, and Platinum Group Metals (PGM’s, Pd,
Pt, Rh, Ru, Os, Ir) in jewelry , and widely in the automotive industry.10-13 In addition,
occupational exposure and environmental pollution can occur as a direct result of metal
mining and refining.14, 15 These metals have no known physiological role, and with
multiple routes of exposure, pose an unknown and largely unavoidable risk to human
health. In the case of metallotherapeutics incorporating a range of rare metals (e.g. Au,
Ag, Pt, Pd, Rh, and others), humans are directly exposed to acute concentrations. This
increase in mobilization of these rare metals results in widespread human exposure,
spreading from concentrated points and diffusing across the globe.
The physiological response to these rare metals relies on the body’s own protective
response mechanisms to metals. Because of their nucleophilicity and metal scavenging
ability, biological thiols like metallothioneins (MTs) and glutathione are involved in toxic
metal resistance, whether directly or due to a downstream response triggered by metal
exposure. Reports of these platinum group metals in urban environments and prevalence
and accumulation in marine life near industrial runoff indicates the impending
omnipresence and perturbance to daily life.16, 17 This may be reflected in the increased
expression of MTs and the documented accumulation of PGMs initiated in a wide variety
of marine, shellfish, seaweed and plant MTs, to changes in mineral environment. This
metal accumulation in organisms can be used as a natural marker for environmental
toxicity.18-22 Regardless, while the introduction of such foreign metals trigger an apparent
defensive response, renal toxicity can still occur (e.g. Cd in MT, Itai-Itai disease). The
long-term storage of Cd by MT in the kidneys raises the question about whether these
*A version of this chapter has been published:
ACS Omega,3(11), 16314-16327. (2018) Available with open access from the American Chemical
Society, 2018.
Reproduced with permission from: D. L. Wong, and M. J. Stillman.
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xenobiotic metals will follow this pathway and bioaccumulate. For instance, platinum
levels persist in the blood of women many years after their anticancer treatment.23
As a consequence of this growing threat, it is important to understand the reaction of MTs
with metals that humans and the natural world are now becoming increasingly exposed to.

5.2

Exposure to Xenobiotic Metals from Therapeutics

Since the discovery of platinum based anti-cancer drugs, developed chemoresistance in
certain cancer types has been associated with increased expression of MT.24-27 MTs can
interfere with a chemotherapeutic agent before it can reach its desired target, or act in
converse to its desired cytotoxic effect. Cellular thiols like glutathione and MT are
correlated to expression in resistant cancers, although their direct causation to resistance
is unclear. MT expression levels are affected by a variety of stress inducers18, 25, 27-37
including metal therapeutics, e.g. Au and Ag nanoparticles,38-40 and Pd, Pt, and Rh
particles airborne through mining and industrial exposure.15 Cisplatin resistance and its
relationship with MT’s aggressive metal binding behavior is the focus of much
research.41-46 MTs are rich in highly reactive cysteine thiolates, which are suspected of
being involved in the interference of platinum drugs. The many stress inducers of MT
may easily cause upregulation of the protein following a dosage of platinum drugs. This
trend has been identified by looking at MT mRNA expression and cellular MT levels in a
variety of cisplatin resistant cell lines compared to their parent lines.24, 38, 45, 46 In
medicine, new metallocomplexes show promising results in clinical trials, many of them
consisting of PGMs and related metals.47 This present study focuses on this new realm of
“non-traditional metallation” to draw attention to the mechanism behind the metallation
of xenobiotic metals to mammalian metallothioneins.
In this study, the global issue is the specific exposure of humans to a xenobiotic metal
complex, where the clearest examples come from well-defined cytotoxic agents. The antitumor agent and common chemical catalyst dirhodium(II) tetraacetate (Rh2(OAc)4) and
its binding reactions to MT is the focus of the study described here.
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5.3
Cytotoxic Dirhodium(II) Tetraacetate as a Model
Metal Complex
The discovery of cisplatin in 1978 opened exploration of the cytotoxicity of metal-based
complexes for cancer treatment.48-50As described in Chapter 4, dirhodium(II) carboxylates
are one of the classes of complexes of interest for their therapeutic and cytotoxic
activity.51-53 Similar to cisplatin, these dimeric compounds also cause disruption of DNA
replication and transcription, as well as creating DNA adducts and crosslinking.54-58 Most
notably, these anti-tumor dirhodium complexes irreversibly bind free cysteinyl thiols,
inhibiting thiol-dependent enzymes.51, 53, 59 Unlike other amino acids, the reaction of
cysteines with these rhodium complexes results in a breakdown of the carboxylate cage
structure by thiolate replacement of the O donor ligands.52, 58 Their sensitivity to sulfur
coordination from cysteines in biomolecular targets means rhodium(II) carboxylates can
also act as radiosensitizers by depleting cellular thiol sources, lowering the cell’s ability
to respond to oxidative stress.59, 60 Current research has extended the applications of
rhodium compounds to medical imaging, radioactive isotope therapy, photodynamic
therapy, and protein labelling, but the significant antitumor characteristics of these
rhodium complexes remain of great interest. 59, 60

Figure 5-1 Ball-and-stick representation of (Rh2(OAc)4).
Teal represents Rh, red represents O, grey represents C, white represents H. Reproduced
from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61
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Dirhodium(II) tetraacetate (Rh2(OAc)4), Figure 5-1, is the simplest of the dirhodium(II)
carboxylates. Rh2(OAc)4 is used widely as a synthetic catalyst in many organic reactions,
a unique form of occupational exposure. It is used in many chemical synthesis reactions,
such as catalysis of C-H, X-H insertion, and aromatic cycloaddition, with a relatively high
solubility in aqueous solutions compared to Cu(II) acetate. Rh2(OAc)4 and related
dirhodium complexes have demonstrated significant anti-tumor activity; Rh2(OAc)4
administered to mice dramatically decreased the size of tumors.51-53 Tumor growth was
inhibited by the interruption of DNA replication and protein transcription. Exhaled 14CO2
from 14C labelled Rh2(OAc)4 indicated that the complex was decomposed within the
organism. Urine analysis showed ~1% of the Rh was excreted, indicating that the
remaining rhodium irreversibly bound to its target and accumulated. However, the exact
target of Rh2(OAc)4 activity is unknown, and toxic renal side effects were high.51-53
Because these dirhodium(II) carboxylates are uniquely sensitive to cysteine binding, MT
is a likely binding target. Another major cellular thiol, glutathione, was found to rapidly
form adducts with Rh2(OAc)4 both aerobically and anaearobically.62, 63 If cytotoxicity by
Rh2(OAc)4 involves DNA adduct formation, or inhibition of specific enzymes, then MT
would be acting as a pre-target interference source. Alternatively, if the cytotoxicity
involves the depletion of cellular thiols, then MT would be the desired target. This can
provide beneficial information for the design of future chemotherapeutics.

5.4

Scope and Application of Results

To prepare for the inevitable increased exposure of humans to xenobiotic metal
complexes from many sources, it is of vital importance to understand their physiological
chemistry. For the success of metal-based chemotherapeutics, it is imperative to
understand drug metabolism and resistance mechanisms. The strong correlation between
cellular thiol induction and chemoresistance requires the study of the metal binding
pathways to the key thiol molecules, especially ubiquitous metallothioneins. In this
Chapter, the work from Chapter 4 is extended. The systematic and rapid deconstruction of
the tetraacetate ligands in Rh2(OAc)4, and the robust Rh2 binding by the 20 cysteines in
apo-βαMT is reported. The metallation speciation was modelled using semi-quantitative
electrospray ionization mass spectrometry (ESI-MS) data to obtain relative Kf values. The
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results and their impact on the cytotoxic and environmental effects of the bioconjugation
of MT and dirhodium complexes are discussed.

5.5 Experimental Methods
Preparation of Apo-MT
Recombinant human metallothionein 1a (rh-βαMT 1a, referred when used in this study as
“MT” unless specified otherwise) was overexpressed with an S-tag in Escherichia coli.
The S-tag was removed and the MT purified according to previously described
methods.64, 65 The cleaved construct has the sequence GSMGKAAAACSCATGGSCT
CTGSCKCKECKCNSCKKSCCSCCPMSCAKCAQGCVCKGASEKCSCCAKKAAAA.
This construct contains two mutations when compared with the human MT 1A sequence
archived on UniProt protein database, T27N and I51V. These mutations are commonly
found in other mammalian MTs including other human isoforms (as seen in Chapter 1,
Figure 1-5), and are not involved in metallation reactions of the cysteinyl thiolates.66 The
purified Cd-bound MT1a was demetallated by acidification (pH<2) and the resulting free
Cd(II) in solution were removed by centrifugal filtration (Amicon Ultra-4 3000 Da
MWCO). Protein concentration was calculated by remetallating a measured aliquot with
CdSO4 and determining the Amax at the 250 nm shoulder characteristic of the LMCT band
of Cd-S bonds (ε = 89,000 L mol-1 cm-1).67
UV-visible absorption and circular dichroism spectroscopy
UV-visible absorption and circular dichroism (CD) spectral data were acquired on a Cary
UV Bio50 and JASCO J-810 Spectropolarimeter, respectively. Solutions were evacuated
and backfilled with Ar gas prior to data collection, and measured in a sealed, 1 cm x 1 cm
quartz cuvette.
ESI-MS Studies
Solutions of Rh2(OAc)4 (Sigma Aldrich) were prepared in deoxygenated, argon aerated,
DI water. Aliquots containing known molar equivalents were added to the apo-MT
solution immediately prior to mass spectral data acquisition using a MicroTOF II (Bruker
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Daltonics, Toronto). All solutions were at room temperature and thoroughly deaerated
using vacuum evacuation followed by Ar saturation. NaI was used as the calibrant.
Spectra were collected in positive ion mode, as a function of time following mixing. The
settings used are described in Chapter 1. The averaged spectra and data analysis were
carried out using the Maximum Entropy application in Bruker Data Analysis 4.2 program.
The resulting spectral data were normalized and the dominant species identified by mass.
Cysteine Modification by p-benzoquinone and n-ethyl maleimide
10 mM stock solutions of p-benzoquinone (pBQ) and N-ethyl maleimide (NEM) were
dissolved in 10% v/v methanol in water and the solution vials wrapped in aluminum foil
to protect from photochemical degradation. Aliquots of the modifiers were added to
protein samples containing Rh2, Rh4, and Rh6MT, and mass spectral data of the resulting
products were obtained to identify the species present. The modifier was titrated to
excess, until the mass spectra no longer changed between additions.
Molecular Dynamics Models of Rh2MT, Rh4MT, and Rh6MT Structures
Molecular modelling calculations were carried out using Scigress Version 6.0.0 (Fujitsu
Poland Ltd.). Structures, modelling parameters and sequence information were adapted
from previously reported Cd7MT and As6MT models to build the Rh2MT models.64, 68, 69
In brief, the Cd(II) ions were deleted and replaced with Rh(II) prior to Molecular
Mechanics calculations (MM3). Molecular Dynamics calculations were carried out at 300
K for 500 ps using the dielectric constant for water of 78.5. Metal thiolate structures in
the alpha domain were based on bridging thiol arrangements in Cd7MT.
Methodology
Spectroscopic and mass spectral studies provide the identity of the binding moiety and
detailed speciation data. The mass spectral data were simulated computationally to
determine the stepwise equilibrium constants. Cysteine modification was used initially to
determine the metallation stoichiometry by quantifying the number of cysteines not
involved in binding the Rh2(OAc)4. However, these results directed the research focus
towards understanding the protein structural changes in metallation, using molecular
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dynamics modelling and mass spectral titrations under unfolded conditions. Altogether,
these experiments fully document the metallation process by which xenobiotic
dirhodium(II) tetraacetate is accumulated by MT.

5.6 Results
5.6.1

Metallation Reactions of MT with Rh2(OAc)4: Optical
Spectroscopic Properties

Figure 5-2, top, shows the UV-visible absorption spectral data for the titration of apo-MT
with increasing mole equivalents of Rh2(OAc)4 added. Significantly, the UV-visible
absorption data show an increased absorption at ~ 300 nm, corresponding to the wellknown cysteine S→Rh LMCT band. Similar absorption is also observed with glutathione,
cysteine, methionine, and other biological thiols.62, 63, 70-74 This LMCT band is very strong
and the transition from the blue of the metal solution to the yellow of the protein-bound
product can be followed readily with the naked eye.
The CD spectra in Figure 5-2, bottom, shows the titration of increasing mol. eq. of
Rh2(OAc)4. The apo-MT spectra is shown in blue. Unlike the UV-visible absorption
spectra, there is no significant change in the spectra with increasing Rh2(OAc)4.
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Figure 5-2 Spectroscopic results of the Rh2(OAc)4 into MT titration
UV-visible absorption (top) and circular dichroism (bottom) spectra for a titration with
increasing molar equivalents of Rh2(OAc)4. The arrow indicates the direction of
increased [Rh2(OAc)4]. The S→Rh LMCT band increases in absorbance at ca. 300 nm.
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical
Society.61
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Figure 5-3 Initial deconstruction of Rh2(OAc)4 by apo-MT observed with ESI – MS.
Stepwise addition of 0.0 to 1.0 mol. eq. of Rh2(OAc)4 to apo-MT. Major species are
indicated by dashed lines: black for apo-MT, red for Rh2MT, blue for Rh4MT and green
for species bound to at least one complete Rh2(OAc)4 molecule. Carboxymethylated MT
species are mass shifted by ~ 60Da and are represented with a triangle. Reproduced from
D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61

5.6.2

Initial Deconstruction of Rh2(OAc)4 by Apo-MT: Rapid
Displacement of the Tetraacetate Ligands

Figure 5-3 shows a series of ESI-mass spectra as a function of increasing molar ratio of
Rh2(OAc)4:MT (from 0 to 1 mol. eq.). The data shown in Figure 5-3 provide a snapshot
of speciation at very low molar ratios during the early stages of apo-MT (6875 Da)
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metallation. As previously demonstrated with cisplatin,75 the apo-MT rapidly (within the
dead time of the instrument) engulfs the incoming Rh2(OAc)4 molecule (441.99 Da), then
systematically shreds the ligands from the metal complex until only the Rh-Rh core is
sequestered within its thiolate binding site. The mass spectral data show the presence of
the incoming complete complex, and the final isolated Rh2 core bound to the MT. The
protein species with masses of 7316, 7517, and 7758 Da are representative of Rh2(OAc)4MT, Rh2(Rh2(OAc)4)-MT, and (Rh2(OAc)4)2-MT, respectively. These dominant masses
gradually diminish as the reaction inside the MT proceeds, until the masses of the final
products of Rh2MT and Rh4MT, at 7074 and 7273 Da, respectively, dominate. The
change in mass coincides with the mass differences between the lost acetate moieties
from the Rh2(OAc)4 bound protein species, where each acetate group has a mass of 59.04
Da.

5.6.3

Accumulation of Rh2: Formation of Rh2MT, Rh4MT, and
Rh6MT

The formation of Rh2-metallated MT products can be described by three stepwise
bimolecular reactions, as shown in Scheme 5-1. Each metallation event begins with
encapsulation of the whole molecule, followed by rapid deconstruction of the ligand
structure to the dirhodium core. The metallation continues with formation of the ligandstripped Rh4MT (7273 Da) and Rh6MT (7473 Da). Figure 5-4 shows a series of stepwise
metallation reactions as from 0.0 - 2.0 mol. eq. of Rh2(OAc)4 were added to apo-MT
under equilibrium binding conditions. The major product of the reaction is Rh4MT, which
forms rapidly, with a small amount of Rh6MT.

Scheme 5-1 Proposed bimolecular, stepwise metallation reactions for Rh2(OAc)4 binding
to apo-MT.
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Figure 5-4 ESI mass spectral data recorded during the titration of apo-MT with aliquots
0.0 to 2.0 mol. eq. Rh2(OAc)4.
The major species are indicated by dashed lines: black for apo-MT; red for Rh2MT; blue
for Rh4MT; and green for Rh6MT. The inset bar graphs on the right of each spectra
shows simulated mass spectral data based on the model described in Figure 5-5, using Kf
values in Table 5-1. Carboxymethylated MT species are mass shifted by ~ 60 Da and are
represented with a triangle and are not included in the simulation. Reproduced from D.
L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61
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Figure 5-5 Experimental and simulated speciation abundance
Experimental mass spectral speciation abundance data (A, left) and simulated data (B,
right) calculated from the fitted relative Kf values (Table 1). Reproduced from D. L. Wong
and M. J. Stillman. Copyright 2018 American Chemical Society.61

5.6.4

Modeling the Reaction: Determination of Relative Binding
Constants (Kf)

Using the Hyperquad Simulation Speciation (HYSS)75 software, the mass spectral
abundances associated with these reactions were modelled based on the concentrations
and mole equivalences of the Rh2(OAc)4 added, using the equations in Scheme 5-1. The
three relative K values (shown in Table 5-1) were calculated so that the simulated model
matched the experimental data, Figure 5-4. The calculated abundances were used to
simulate the mass spectra as seen in the red bar graph Figure 5-4 insets. The simulated
mass spectra closely match the experimental MS data over the course of the titration.
Figure 5-5A shows the experimental speciation data extracted from Figure 5-4. The
sequence of speciation clearly follows a typical non-cooperative metallation mechanism76
in which Rh2MT forms, followed by Rh4MT, followed by Rh6MT. The fitted results, in
Figure 5-5B, match the experimental data closely, and provide the relative binding
constants as shown in Table 5-1.
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Table 5-1 Relative equilibrium binding constants for the reaction of Rh2(OAc)4 with ApoMT
MT(Rh2)n
1
2
3

Log β
4.22
7.22
8.89

Log Kf
4.22
3.00
1.67

Figure 5-6 ESI -mass spectral data of modified and unmodified mixed Rh2 metallated
species
(A): non-modified Rh2-, Rh4-, and Rh6-MT, represented by a triangle. (B): solution in (A)
following addition of p-BQ. (C): non-modified Rh2-, Rh4-, and Rh6-MT, represented by a
triangle. (D): solution in C following addition of NEM. The experimental data are shown
in bar graph representation Persistent titrations to excess and long incubation times did
not affect the resulting spectra indicating completed reaction. Rh2MT species shown in
red, Rh4MT species in blue, and Rh6MT species in green. Reproduced from D. L. Wong
and M. J. Stillman. Copyright 2018 American Chemical Society.61
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The data in Figure 5-6 show modification of MT containing Rh2MT, Rh4MT, and Rh6MT
by both pBQ (Figure 5-6, A, B, left half) and NEM (Figure 5-6, right half). The Rh2MT,
Rh4MT, and Rh6MT spectra measured prior to modification are shown in Figure 5-6, top
(A and C). In B and D, these same species are present (identified by triangles) even
though excess modifier was added. Both sets of modified species (Figure 5-6, lower)
display a variety of Normal distributed species, as shown in Figure 5-6 in bar graph
format. The experimental mass spectral data is shown below in Figure 5-7, but is
represented in bar graph format in Figure 5-6 for clarity.

Figure 5-7 Mass spectral data of the alkylation of Rh2-bound MT
ESI Mass spectral data collected for a mixture containing Rh2MT, Rh4MT, and Rh6MT
(top left and top right) and their subsequence modification by pBQ (bottom left) and NEM
(bottom right). Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018
American Chemical Society.61
As described by Irvine et al, cysteine accessibility can be understood by the distribution
of cysteine modified species.77 A Normal distribution represents statistically equal
accessibility of the modifier to all available free cysteines. This means that the unbound
cysteines are exposed. Therefore, the breadth or spread of the distribution tells us the
number of available cysteines, and the shape of the distribution tells us if there is
conformation specificity or equal accessibility of the free thiols. Figure 5-6B shows the
distribution of the modified Rh2(BQ)xMT species (red bars). The data indicate the
presence of two species, one with x = 0-8 free cysteines, and another with x = 10-15 free
cysteines. This means that there are two distinct Rh2MT products: one coordinating the
Rh2 with 12 cysteines, and the other coordinating the Rh2 with 5 cysteines. This is harder
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to distinguish at increased concentrations as the abundancies of the two distributions
overlap each other, Figure 5-6D. The steep rise of the modified Rh4(BQ)yMT (blue) also
displays a Normal distribution with y = 0-7 free cysteines. The formation of a modified
Rh6(BQ)zMT species with z = 0-4 free cysteines also can be observed (green).
There is a small discrepancy between the number of modified cysteines observed using
pBQ and NEM. This is likely due to the reaction occurring at physiological pH, at which
pBQ is not as effective as NEM.78 Therefore, our conclusions about the number of free
cysteines for the metallated MT is based on the greatest number of NEM-modified
cysteines for each Rh-bound complex.

5.6.5

Accumulation of Rh2(OAc)4 in αMT: Evidence for StructureDependent Metallation

Figure 5-8 shows the time-dependent metallation of the single domain apo-αMT fragment
at low pH (<2) with Rh2(OAc)4. Over the time course of the reaction (44 minutes),
species ranging from [Rh2(OAc)4]1-MT to [Rh2(OAc)4]6-MT are observed. This is
completely different when compared with the results from the titration carried out at pH
7.4 with the two-domain protein (Figure 5-4).
These data show that the unfolded, loose structure caused by the high [H+] greatly
increases cysteine accessibility to the incoming Rh2(OAc)4 in this single domain
fragment. In the presence of excess Rh2(OAc)4, this manifests as two distinct reaction
pathways: i) ligand replacement by thiolates following Rh2(OAc)4 binding, as described
for the whole protein above, and ii) proposed axial coordination of Rh2(OAc)4 by
cysteine. These two reaction pathways are outlined in Figure 5-8, right. The acidic
conditions minimize the nucleophilicity of the cysteinyl thiols, and allow for the lower
Cys:metal ratios to bind with metal ratios of up to 6 x Rh2(OAc)4. Despite the observation
of this “supermetallation,” the cysteine replacement of the tetraacetates still occurs albeit
slower than at physiological pH.
In Figure 5-8, the key species identified are: apo-αMT, [Rh2(OAc)4]1-αMT,
[Rh2(OAc)4]2-αMT, [Rh2(OAc)4]3-αMT, [Rh2(OAc)4]4-αMT, [Rh2(OAc)4]5-αMT,
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[Rh2(OAc)4]6-αMT, Rh2[Rh2(OAc)4]1-αMT, Rh2[Rh2(OAc)4]2-αMT, Rh2[Rh2(OAc)4]3αMT, Rh2[Rh2(OAc4]4-αMT, Rh2[Rh2(OAc)4]5-αMT, Rh2MT, and Rh4MT.

Figure 5-8 ESI mass spectral data of the low pH titration of Rh2(OAc)4 into αMT
(Left) Time-dependent mass spectral data of apo-αMT at low pH (<2), recorded over 44
minutes following addition excess Rh2(OAc) 4. Red arrows indicate mass shift resulting
from the loss of (OAc)4. (Right) Labels for identifiable species in the mass spectral data
and proposed formation pathways Reproduced from D. L. Wong and M. J. Stillman.
Copyright 2018 American Chemical Society.61
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5.6.6

3D Models: Cysteine Accessibility throughout Metallation

Representative structures of apo-MT, Rh2MT, Rh4MT, and Rh6MT are shown in Figure
5-9. Energy minimized geometries using MD for apo-MT, Rh2MT, Rh4MT, and Rh6MT
were constructed in Scigress 6.0.0 and geometry optimized using Molecular Mechanics
(MM3) prior to Molecular Dynamics (MD) calculations at 300 K for 500 ps. These
structures are shown in ball and stick format in Figure 5-9 and in full page format along
with H-bond mapping in Appendix C.
The apo-MT model, Figure 5-9A, shows the structure of the non-metallated cysteines,
and how MT orients itself with respect to metallation. The energy minimization of apoMT results in a compact globular structure, in accordance with mass spectral studies at
physiological pH.79 The cysteine residues (-SH shown with yellow spheres in Figure 5-9)
are oriented to the exterior when metal-free, but coalesce toward the interior of the
protein when metal-bound. In the apo-MT structure, the backbone and cysteines arrange
themselves in a similar fashion to a helix, with cysteines facing outward. This agrees with
results from Irvine et al. and Rigby et al. that the cysteine solvent accessibility in the apo
form facilitates metal binding.80-82 The driving force for organized structural formation in
mammalian metallothioneins is the metal-induced folding with each sequential M-SCYS
chelation event.80 Once bound to a metal, these cysteines become buried within the
protein interior, shielding them from the cellular environment. The fully bound Rh6MT
(Figure 5-9H, “Rh2β4αMT”) shows this clearly. The configuration of the peptide back
bone shows that MT wraps around the metal core upon binding. This effect is observed in
the partially metallated Rh2MT and Rh4MT structures as well, in Figure 5-9. When the
Rh2 is bound to cysteines that nominally form a single domain (Figure 5-9, Rh2βMT,
Rh2αMTI, Rh2αMTII, Rh4αMT), the metal-bound cysteines are buried, while the remaining
metal-free cysteine maintain their external orientation. This reflects the globular protein
structure seen in the apo-MT model, Figure 5-9A. However, these one-domain-bound
MTs are fluxional and capable of further subsequent metallation. In contrast, for twodomain metal binding, like in the Rh2β2αMTI, Rh2β2αMTII, and Rh6MT, a dumb-bell-like
structure typical of M(II) ion metallation is obtained.83 When both domains are bound, the
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cysteine accessibility is greatly diminished. This accounts for the lower abundance of the
Rh6MT species in the mass spectral data.

Figure 5-9 Energy minimized molecular dynamics models of apo-MT, Rh2MT, Rh4MT,
and Rh6MT.
Rh shown enlarged in teal, cysteines shown enlarged in yellow, C in gray, O in red, N in
blue, H in white. Structures were constructed based on Cd7MT structures from previously
reports,10, 64, 68 using Scigress 6.0.0.84 Details of the minimization are given in the text.
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical
Society.61
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5.7 Discussion
5.7.1

Chronic Presence of Anthropogenic Pt, Pd, Rh (PGM’s)

Platinum group metals have no biological role, and little is known about their long-term
toxicity. Pd and Rh are naturally found alongside metallic Pt, therefore, their
contamination is often mobilized by the same routes. With the use of these metals in catalytic converters in automobiles (to reduce volatile organic components), airborne
PGM particulate is becoming a widespread route of exposure. Higher concentrations of
these PGM’s are related to higher traffic density.10, 13, 23, 85 Spreading from urban areas
and carried by the winds, fine metal particulate (< 10 nm) enter the soil, water, and food
chain, often being converted into inorganic complexes through ingestion, inhalation, or
absorption through damaged skin.11, 13, 16, 86-90 Bacterial, organismal, and environmental
transformations can convert inert metal species into reactive ones. With the number of
automotive vehicles ever increasing, the biofixation of these metals makes them more
bioavailable than ever before. The accumulation and biological effects of subclinical
levels of these PGM’s (in public areas like playgrounds, tramways, narrow streets)
particularly in cities with dense populations and heavy traffic are of a concern for the
future.10, 12, 13
There are already several examples of anthropogenic PGMs affecting waterways and
corresponding ecosystems near urban regions, detectable in Arctic ice cores, with
documented metal levels increasing over several decades.88-92 Varying soil and water
conditions, such as pH, N and S availability, and temperature and precipitation levels can
affect metal solubility, thereby accelerating permeation through the food chain.93
Bacterial resistance and introduction of metals into the food chain results by
biomethylation.94 The Hg cycle, for example, causes bioaccumulation in fish and shellfish
species, which magnifies through larger predators.95
The cytotoxicity of these metals has been demonstrated in current and potential cancer
metallodrugs, showing the danger of exposure in the form of their side effects. Although
the long-term effects of sub-clinical levels of exposure are relatively unknown, it is
concerning especially for vulnerable populations, like children.96 These soft, heavy metals
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are more likely to be accumulated by coordination with biological thiols and exhibit long
biological half times, increasing the risk of nephrotoxicity. While other lighter or
physiologically essential metals are recycled or excreted through the urine rapidly, heavy
metals like Pt, and Cd can remain in the body for decades.

5.7.2

Binding Reactions of MT with Rh2(OAc)4: Explaining the
Spectroscopic Results

As expected, the replacement of the acetate groups with cysteine thiols resulted in a
strong absorbance at ~ 300 nm (Figure 5-2, top). This agrees with other spectroscopic
studies involving biological thiols (cys, GSH for e.g.62, 63, 72-74, 97, 98) and confirms the
cysteine thiol as the binding moiety involved in the Rh2 complexation.
In the case of the CD spectral data (Figure 5-2, bottom), it is surprising that no significant
spectral intensities are observed during the titration of the full apo-MT. However, the lack
of a distinct CD spectral intensity is likely due to the overlap from the presence of several
structurally different species because the mass spectral and structural cysteine
modification data indicate that the Rh2(OAc)4 has bound to the apo-MT. This contrast the
results previously reported for Rh2(OAc)4 binding to the β-domain fragment, in which a
single product is formed in a 1:1 fashion, producing a strong CD signal, as seen in
Chapter 4.70

5.7.3

Metallothionein: Non-Traditional Metallation and Metal
Complex Deconstruction is Evident from the Mass Spectra

Mass spectrometry is especially helpful in identifying biological targets.99 ESI-MS is a
soft ionizing, high resolution, solution-phase technique that is ideally suited for tracking
the metallation status of MT. The advantage of using ESI-MS is that it allows for
confirmation of the presence of intermediate states in real time. These versatile properties
have been widely exploited in Native ESI-MS,100 allowing detailed kinetic and
equilibrium studies of the metallation of MTs.65, 70, 76, 83, 100-109 The stoichiometric and
structural information provided by the ESI method is particularly important for MT
because the lack of typical protein features and its high sensitivity to oxidation makes
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MT’s protein structure difficult to observe with crystallography, NMR, or other structure
elucidating methods.
The conditions for cooperative and non-cooperative bimolecular metallation of Zn(II),
Cd(II), and Cu(I) to MT have been studied with consistent stoichiometric ratios identified
primarily using ESI-MS, including traditional metallation to form stable cluster states
M(I)6S9, M(II)3S9 M(II)4S11.65, 76, 83, 102-104, 110, 111 Binding coefficients can be accurately
extracted from these data. The observed kinetic binding of Pt(II)1-7 from cisplatin was
first determined by chromatographic methods,112 which were then enhanced by our ESIMS modelling methods,41 a similar methodology to that applied to this current dirhodium
study.
The metallation of Rh2(OAc)4 to apo-MT can be categorized as non-traditional
metallation, because the binding of MT involves chelating Rh2(OAc)4 followed by
disassembly of the initial metal complex by displacement of the original coordinated
ligands. ESI-MS has been used to observe this destructive effect MT has with cisplatin,
and Ru-based arene complexes41 This step-wise, sequential deconstruction of Rh2(OAc)4
has been reported previously with the single apo-β-domain fragment of MT1a. Under
those conditions, one discernible product (Rh2MT) is formed in a linear fashion.70 In this
present ESI-MS study, the full, two-domain protein has a higher sulfur availability (20
cysteines), which greatly increases the rate of reaction and the number of possible
conformers (Rh2MT, Rh4MT, Rh6MT) that can form. The ligand loss of the coordinating
acetates and accumulation of the sequestered metal species shows that Rh2(OAc)4 does
not survive intact when bound to MT. This emphasizes the destructive effect MTs can
have on both chemotherapeutically related complexes and xenobiotic metals from
environmental sources.
The presence of metal-thiolate (Zn(II), Cd(II), Cu(I)) clusters that form in higher ratios of
these metals make MTs resistant to trypsin digestion.105 However, it should be noted that
As(III) binding is not considered to involve cluster formation. The As(III) bound to the
isolated MT fragments form M(III)3S9 (α-domain), and M(III)3S9 (β-domain), and to the
full protein forms M(III)6S18,111 which means that the MT peptide flexibly accommodates
a completely different style of binding than reported for the Group 12 M(II) ions. The
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results of this Chapter show Rh2 binding also does not follow traditional cluster formation
of Zn(II), Cd(II), and Cu(I), instead binding to MT in a rigid manner. MT is unable to
perform its usual metal relocation, as described in Chart 5-1. Therefore, a novel MT
binding mode is now reported for Rh2 in this study, which enforces the difference
between the metallation of complexes and metal ions by the protein.

Chart 5-1 Proposed pathway for metallation of βαMT 1a by Rh2(OAc)4 at physiological
pH.
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The two pathways shown apply to different configurations. Pathway A: Rh2MT binds an
additional Rh2(OAc)4 which is deconstructed, forming Rh4MT of configuration I. No
further metallation occurs at this point. Pathway B: Rh2MT binds an additional
Rh2(OAc)4 which is deconstructed, forming Rh4MT involving a proposed alternate
configuration II. This form can proceed to bind a further Rh2(OAc)4, producing Rh6MT.
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical
Society.61

5.7.4

Structure-Dependent Metallation of Metallothioneins: Rigid
Rh2 Binding and Comparison of Binding Constants

The 2° and 3° structure of MT is only defined by metallation,80 as it exhibits no 2°
structural elements or aromatic residues. A broad distribution of metallated and metal-free
MT species exist in the cell.65, 83, 103, 104, 113-115 Despite the sensitivity of the free cysteines
to oxidation, fluorescence labelling has demonstrated the presence of metal free apo-MT
in roughly equal quantities to holo-Zn-MT, both in the oxidized and reduced form.116 This
confirms that metallation of MT is a post-translational modification that can only occur
once the protein is fully synthesized, due to the cross-linking nature of metal-cysteine
coordination that forms the metal-thiolate clusters. To better understand the metallation
reaction, the fully demetallated apo-MT is used as the model for the partially metallated
MTs expected in vivo.
Metal binding to MT is generally fluxional such that the metal ions can move from site to
site in search of the lowest thermodynamic product (for example, the well-known change
in Cu(I)-MT emission signal when Cu(I) is titrated into Zn-MT 1A or Zn-MT 2A).117 In
the case of the dimeric rhodium binding, the bound cysteines form multiple metallated
species (Chart 1). The orientation of the initial metal binding in relation to the MT
cysteines defines how the metallation proceeds. Due to the decreased abundance of
Rh4MT and Rh6MT, the domain location and formation of Rh2MT determines whether
the metallation continue to Rh6MT. The two distributions for the Rh2(BQ)xMT modified
speciation data reflect these products. The decrease in relative log Kf’s demonstrates its
rigidity as metallation progresses (Table 5-1). Previous work with the single β domain
fragment shows that the β-domain accommodates 1 Rh2 moeity.70 The 11 cysteines of the
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alpha domain can accommodate the remaining 2Rh2 if metallated efficiently (Chart 5-1,
right pathway B). If not, the cysteines become too tangled to accommodate further metals
(Chart 5-1, left pathway A).
It is evident that the magnitude of log Kf’s cannot be directly compared between
chemically different metals because of both different binding geometries, and the
presence of competitive coordinating ligands. A comparison can only be made
meaningfully between isomorphous metals. Due to the fluxional nature of the 20 cysteine
thiols in MTs, metals with different oxidation states can form vastly different binding
geometries. Just as Zn metallation of MT differs from Cd metallation, free metal ion
accumulation in MT cannot be compared to the deconstructive process that MTs exert on
ligated metal complexes. Complex deconstruction cannot be included in these values, as
these are the final, observed, relative binding constants. This is important in comparing
values, because this emphasizes the versatile nature of MT, in that there is no consistent
metal binding site across metal families.

5.7.5

Solvent-Cysteine Accessibility and Protein Flexibility
throughout Metallation

Typically, protein structural information can be obtained by analyzing the charge state
distribution patterns in the mass spectral data. Due to the small size of MTs, this method
is not as effective, especially to probe the apo-protein or partially metallated states. More
recently, however, structural information about MT has been obtained through the
reaction profiles of cysteine modifiers that take advantage of MT’s cysteine rich structure.
p-Benzoquinone (pBQ) and N-ethyl maleimide (NEM) are organic agents capable of
binding covalently with free thiols, as shown in Scheme 5-2. Similarly to Ellman’s
Reagent (5,5′-dithiobis(2-nitrobenzoic acid), DTNB), this irreversible binding permits
quantification of free thiols.77, 78, 103, 111, 118 This is observed as a predictable mass change,
but in addition with respect to MT and its 20 cysteines, the modified speciation
distribution can also provide information about the solvent accessibility of the cysteines.78
This technique has been used to understand metallation of apo-MT through partially
metallated and fully metallated Cu6MT, Cu13MT, Cu20MT, and As6MT.65, 103
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Scheme 5-2 Structure and reaction mechanism involved in the formation of covalent
bonds between cysteine and modifiers pBQ (A, top) and NEM (B, bottom). Reproduced
from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61
In this present study, both pBQ and NEM are used in conjunction with mass spectrometry
to quantify the number of free cysteines and to probe the surface structure and the solvent
accessibility of the partially metallated states of Rh2MT, Rh4MT, and Rh6MT. Structural
characteristics can be inferred from the reaction profile of modification observed in the
mass spectral data.77 As expected, the higher metallated Rh4 and Rh6 bound MT shows
less solvent accessibility because of the lower spread of the p(BQ)-modified species. The
most solvent accessible species, Rh2MT, shows two distinct distributions, indicating that
two metallated states are created. From the change in intensity for the higher metallated
states, we can infer that only one of the observed Rh2MT species is capable of further
metallation, as described pictorially in Chart 5-1. This rigidity is reflected again with the
lowered abundance of Rh4MT and Rh6MT, and in the decrease of the relative log Kf
values showing that progressive metallation is less favorable.
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3D structures constructed using MM/MD modelling techniques from previously reported
AsMT119, 120 and Cd-MT64, 68 metallated forms were adapted to examine the possible
metal thiolate constructs MT may adopt when bound to dirhodium cores. The absence of
aromatic and hydrophobic residues, and the absence of mean that the driving force for
protein folding is the cross-linking that results from the metallation of the cysteines,
stabilized by hydrogen bond formation. As the cysteine modification results and the MD
structures indicate, metal-free cysteine thiolates are found to be solvent accessible,79
while holo cysteines are buried within the protein structure. MD calculations on the holoRh6MT shows no change in the conformational geometry, demonstrating the holo-MT’s
rigid status.
The low pH experiment shows that while the unfolded, 9 cysteine apo-αMT can bind to
the Rh2(OAc)4, it is unable to effectively displace the coordinating ligands of the
complex. Instead, the unfolded peptide quickly binds to 1-6 Rh2(OAc)4 species Figure
5-8), which occupies and locks the cysteine thiolates from other reactivity. Significantly,
the MS data recorded at pH<2 demonstrates that Rh2(OAc)4 has a strong binding affinity,
surpassing that of Cd, which is completely demetallated from MT at this pH. These low
physiological pH, in which the more folded MT structure can orient its cysteines to
displace the coordinated ligands more effectively than the unfolded protein.
The unusual malleability of MT, first reported for As(III) binding,111 is clearly an
additional characteristic property of MT. The many species seen in the Rh2-binding mass
spectral data imply multiple coordination possibilities for metal binding. This suggests
that the “magic numbers” concept83 prevalent in the literature does not apply to transition
metal complexes.
The data reported here support the findings in Chapter 2 that the initial, intrinsically
disordered, native MT structure at physiological pH can flexibly entrap metal complexes
and is a necessary conformation to further react, deconstruct, and isolate the metal for
storage.
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5.8 Conclusions
This Chapter reports the reaction of a xenobiotic complex with MT as a test of the
possible chelation properties of MTs with transition metal complexes. Rh2(OAc)4, a
robust synthetic catalyst, binds intact to the metal-free apo-MT. The tetraacetate ligands
are rapidly removed upon binding by the folded MT at physiological pH, in a manner
reported previously for cisplatin. The initial reaction of the apo-MT involves the
displacement of tetraacetate groups by the cysteinyl thiolates. Where the first Rh2 binds in
the protein, which domain, governs the remaining space in which metallation can
continue. This intermediate state can then proceed towards two structures, one of which
allows the metallation of a third dirhodium moiety, forming Rh6MT, the other pathway
stops at Rh4MT. These branching pathways were determined using complementary
techniques of cysteine modification and mass spectrometry, together providing speciation
data for equilibrium reaction modelling.
The increase in global exposure to anthropogenic xenobiotic metals demands updated
understanding of the metabolic effects caused. Rh and PGMs are known to exert
cytotoxic and nephrotoxic activity, through metabolic process that can increase the
bioavailability. The experiments in this Thesis demonstrate the ease with which biological
structures can greatly change the chemical activity of rhodium. A metal’s persistence in
ever changing chemical forms emphasizes the need for long-term study and caution for
the continued utilization of these elements for human health.
Finally, of concern, the long term accumulation and storage of PGM’s can provoke
chronic toxic effects. Cd-bound MT has a reported half-life in the kidneys exceeding
twenty years.121 Due to the firm and rigid binding of Rh2(OAc)4 to MT, Rh would be
expected to accumulate in a similarly dangerous manner. The heavy and widespread use
of PGM’s pose a risk that cannot be ignored, as history would remind us with the use of
lead in gasoline and paints causing widespread toxic effects. This long-term storage is
also applicable for these xenobiotic metals. The bioaccumulation of these metals can pose
a significant health risk in the future.
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Chapter 6

6

Glutathione Binding to Dirhodium(II) Tetraacetate: a
Spectroscopic, Mass Spectral and Computational Study
of an Anti-Tumor Compound Bound to a Model Thiol*

6.1 Introduction
Intracellular thiols play an important role in metabolism.1 Non-protein, sulfhydryl
compounds aid in protection against oxidation, as well as in the safe detoxification of
harmful or foreign agents through thioether formation.1-4 This latter property may
substantially reduce the efficacy of drug delivery pathways and, subsequently, the success
of a drug, which can lead to drug resistance.5-11 In particular, thiol-based resistance can be
deleterious for metal-based chemotherapeutics, as the electron-rich thiolate favours
binding to the soft, d-block metals commonly used in such pharmaceuticals, for example,
Pt(II), and Au(I).10-12
Glutathione (GSH) is a tripeptide that is required in many metabolic cycles and is vital in
cellular defence because of its cysteine thiol (Figure 6-1A).1, 2, 6, 9, 13 Intracellular
concentrations of GSH can reach up to 10 mM, with its regulation and synthesis tightly
controlled.2, 3 This cysteinyl thiol provides the main ordnance through which glutathionebased protective chemistry acts in guarding the cell against oxidative damage and
conjugating metabolites for efflux.2, 3, 14 GSH is a common coenzyme and is also heavily
involved in metabolic pathways such as glutathione peroxidases, reductases, and
glutathione S-transferases.2, 6, 7, 15
GSH S-transferases catalyse the combination of GSH with xenobiotic compounds for
metabolism and excretion using the highly nucleophilic cysteinyl thiolate (GS-).2 The
predominance of GSH in the cell, coupled with its conjugation abilities, means that GSH
is a major player in the destructive metabolism of therapeutic compounds, acting through
conjugation as a means of drug resistance. 3, 9, 11 Metal-based therapeutic compounds that
are vulnerable to thiol chemistry can be structurally altered, and even deactivated,
following reaction with intracellular GSH.8, 16, 17
*A version of this chapter has been published:
Metallomics,9(5), 501-516.(2017) Copyright 2017 Royal Society of Chemistry.
Reproduced with permission from: D. L. Wong et al.
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Figure 6-1 Structures described in Chapter 6
Structures of (A) glutathione (GSH), (B) Rh2(OAc)4, (C) [Rh2(OAc)4(GS)], (D)
methionine (Met), (E) [Rh2(OAc)4(GS)2], (F) Rh2(OAc)4(H2O), (G) Rh2(OAc)4(H2O)2, (H)
[Rh2(OAc)5], (I) [Rh2(OAc)6], (J) Rh2(OAc)4(Met), (K) Rh2(OAc)4(Met)2, (L)
[Rh2(OAc)4(GS)(Met)]. Colour coding: rhodium-turquoise, oxygen-red, sulfur-yellow,
nitrogen-blue, carbon-grey, hydrogen-white. Calculations and image from A. Zhang in D.
L. Wong et al., reproduced with permission from the Royal Society of Chemistry. 18
Glutathione reacts with large, soft, metals such as the toxic metals Cd(II), Hg(II), Pb(II),
and As(III).19-23 This tendency to bind soft metals also extends to the wide range of metals
used in therapeutic complexes, for example, Ag(I), Bi(III), Pt(II) in cisplatin, and Au(I) in
Auranofin.10, 12, 24-27 A marked increase in glutathione synthesis is often correlated with
cisplatin resistance, such as the case in human ovarian cancers.10, 28, 29 This type of
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protective chemistry is the basis for the co-administration of glutathione as a defence
against renal toxicity in platinum-based chemotherapies.4, 14 There is evidence that the
inhibition of glutathione synthesis reverses cisplatin resistance in some cancer types.30-32
With an increase in the use of d-block metals as the key components of
metallotherapeutic agents, it is critical to understand how this prominent defensive
thiolate will interact with biologically-targeted metal complexes. Such interactions would
likely reduce the efficacy of these metallodrugs.
Dirhodium(II) carboxylates and their derivatives are an emerging class of anti-tumor
compounds that are described as exhibiting greater potency than cisplatin in vitro,33-39 as
described in Chapter 4 and 5. However, significantly, with respect to possible cellular
chemistry, rhodium(II) carboxylates bind strongly to sulfur containing compounds.33, 34, 36,
38, 40-42

Indeed, the propensity for these rhodium complexes to deplete intracellular thiols

makes them especially useful as radiosensitizers 43, 44. Other classes of dirhodium
carboxylates, such as the Rh2(O2CR)4 (R = Me, Et, Pr), display potent anti-tumor activity
that stems from their ability to inhibit enzymes with sulfylhydryl groups in their active
sites 34, 35, 45. Dirhodium(II) tetraacetate (tetrakis(μ-acetato)dirhodium(II), hereby referred
to as Rh2(OAc)4, Figure 6-1B) is a bimetallic complex with four bridging acetate ligands
bound in an octahedral geometry, with two empty axial sites usually coordinated by
solvent molecules. This complex is capable of inhibiting DNA polymerase I and RNA
polymerase, showing cytotoxic behaviour in vivo against L1210 tumors, Ehrlich ascites,
and the sarcoma 180 and P388 tumor lines, as well as exhibiting DNA-binding in a
manner similar to that of cisplatin 35, 36, 46, 47 and is a suitable model complex for these
therapeutic dirhodium carboxylates. However, because of the strong affinity for thiolate
binding to the dirhodium(II) carboxylates’ axial coordination sites, intracellular thiols like
glutathione may prevent these rhodium-based therapeutics from reaching their intended
target unchanged, especially with the Rh axial bioactive site remaining available. Axial
coordination by the strongly binding thiolates will then block the intended activity.
Spectroscopic studies of glutathione binding to dirhodium tetraacetate and related
compounds have been reported previously by Jakimowicz et al.48 In the case of
Jackimowicz et al., following the addition of molar equivalents of GSH to Rh2(OAc)4, the
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authors surmised that the stoichiometric ratio, GSH:Rh2(OAc)4, for the final conjugate
was 2:1. Unfortunately, optical spectra provide limited information, as the spectral data
results from an averaged signal of all the chromophores present. The determination of the
stoichiometric ratio as a function of GSH is of critical importance in the assessment of
dirhodium complexes with therapeutic properties, because chemistry that involves
coordination to both axial sites would effectively block the therapeutic drug. With the
resolving power of electrospray ionization mass spectrometry (ESI-MS), one is able to
accurately describe the products formed in reactions of Rh2(OAc)4 with thiolates and
determine whether this potentially therapeutic agent would likely survive attack by
biological thiols.
This Chapter reports on the products formed following reaction of GSH with Rh2(OAc)4,
as well as its competition with methionine-bound Rh2(OAc)4,to probe the fate of the
rhodium complex after attack by the thiol and thioether groups, respectively. The
reactions were studied in vitro using UV-visible and circular dichroism (CD) absorption
spectroscopy, and electrospray-ionization mass spectrometry (ESI-MS). ESI-MS, which
is now in this Thesis well established as an especially powerful as a technique for
monitoring all possible intermediates formed in a reaction. Computational analysis by
time-dependent density functional theory (TD-DFT) shows the extent of the overlap of
both the linking acetates with the dirhodium d orbitals, and the major influence of the
presence of water and thiolate axial ligands on all orbitals of the complex. The TD-DFT
results explained the unexpected stoichiometric ratio of the glutathione products. These
calculations show that the lowest energy absorption band blue-shifts with the addition of
strong electron donors. The results described below show that GSH does attack the
Rh2(OAc)4, but the stoichiometric ratio is 1:1 (Figure 6-1) unless there is large excess. If
the drug complex was protected with the thioether of methionine (Figure 6-1D), the ESImass spectra show that GSH would eventually displace that group. However, unlike
previously reported reactions with the cysteine-rich, human protein, metallothionein,49
GSH did not disassemble the complex, leaving it intact, but with one of its axial reaction
sites blocked. These results give detailed guidance for predicting the pharmacokinetics of
potential metallodrugs and provide a mechanism by which the strongly binding GSH may
be inhibited.
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6.2

Experimental Methods

Solutions of 500 μM Rh2(OAc)4 (Sigma Aldrich) and 10 mM glutathione (Fluka) in
deionized water were deoxygenated under vacuum and backfilled with argon gas. For the
UV-visible (Varian Cary 50 UV-visible Spectrophotometer) and circular dichroism (CD)
(Jasco 810 Spectropolarimeter (Jasco, New Jersey, USA)) spectroscopic measurements,
aliquots of 0, 0.5, 1.0, 1.5, 2.0, and 2.5, mol. eq. (and additionally, 3.0, and 4.0 mol. eq.
for the UV-visible absorption spectra) of GSH were added to an argon-backfilled quartz
cuvette sealed with a septum cap containing the dirhodium solution, with the data
recorded after each addition. For the first ESI-MS data collection (Figure 6-4), excess
reduced glutathione was added to a 500 µM Rh2(OAc)4 solution in water at pH 3.0, and
the mass spectral data were collected in positive ion mode; in the second series (Figure
6-4), solutions with 500 μM Rh2(OAc)4 were titrated with 1.0, 1.5, and 2.5 mol. eq. 500
μM GSH in 1 mM NH4OAc buffer at pH 7.4, recorded in both positive and negative ion
mode. A Bruker Micro-TOF II instrument (Bruker Daltonics, Toronto, ON) operated in
both positive and negative ion mode was used to collect the data. NaI was used as an
external calibrant. The following settings were used: scan, m/z 50−3000; rolling average,
2; nebulizer, 2 bar; dry gas, 80°C at a rate of 8.0 L/min; capillary, 4000 V; end plate
offset, −500 V; capillary exit, 175 V; skimmer 1, 30.0 V; skimmer 2, 23.5 V; hexapole
RF, 800 V.
For the reactions with methionine followed by competition with GSH, solutions of 500
μM Rh2(OAc)4, 10 mM DL-methionine (Sigma), and 10 mM glutathione in deionized
water were deoxygenated under vacuum and backfilled with argon gas. The changes in
the Rh2(OAc)4 solution were monitored following the addition of 2 mol. eq. of
methionine using UV-visible absorption spectroscopy, followed by a subsequent addition
of 2 mol. eq. of GSH. ESI-mass spectra were taken after each addition using the negative
ion mode. The settings were similar to those described previously.
Rh2(OAc)4, Rh2(OAc)4(H2O)2, [Rh2(OAc)4(GS)(H2O)]-, and [Rh2(OAc)4(GS)2]2-, models
were drawn using the Scigress Modelling Software.50 GS represents the deprotonated
glutathione moiety. Ground-state geometry optimization and TD-DFT calculations were
performed using the Gaussian G09 program,51 using the CAM-B3LYP functional. The 6-
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31G(d,p) basis set was used for all atoms except for Rh, and the LANL2DZ basis set was
used for Rh atoms. The TD-DFT calculations were carried out on the minimized
geometry in single point mode, with 100 excited states calculated using the CAM-B3LYP
functional, the 6-31G(d,p) basis set for all atoms except for Rh, and the LANL2DZ basis
set for the Rh atoms.

6.3 Results and Discussion
6.3.1

UV-Visible and Circular Dichroism Spectroscopy Following
the Colourful Reaction of Glutathione with Rh2(OAc)4

The reaction of GSH with Rh2(OAc)4 was followed with UV-visible absorption
spectroscopy (Figure 6-2) and CD spectroscopy (Figure 6-3). With the introduction of
glutathione, a new absorption shoulder appears at approximately 353 nm (Figure 6-2)
which has been assigned to a S(σ) →Rh(σ*) LMCT characteristic of sulfur coordination
to dirhodium carboxylates.45, 48 A similar band has been previously reported for the
spectrum of Rh2(OAc)4 coordinated to the cysteine-rich protein, metallothionein.49
discussed below, the assignment is better described as resulting from a mixture of
molecular orbitals (MO) involving both the Rh-Rh MOs and the thiolate orbitals. The
rapid change in spectral properties was observable with the naked eye, as the solution
changed from sky blue to golden yellow as the titration progressed. This was expected as
a result of the development of absorbance below 400 nm, which was much more intense
than the weaker 589 nm absorption characteristic of the metal-metal-bond. The band at
448 nm has been assigned to Rh2(π*) → Rh–O(σ*) transitions of the tetraacetate
ligands,45, 48 which will be expanded on in the computational results below. The band at
589 nm represents the Rh2(π*) → Rh2(σ*) transition of the metal-metal single bond,
which persists throughout the addition of the GSH and, therefore, shows that the Rh-Rh
single bond is still intact following thiolate coordination. Only water was used as the
solvent for these spectroscopic studies as others, like acetonitrile, involve coordinating
moieties that can drastically alter spectroscopic results.
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Figure 6-2 UV-visible absorption spectra of 500 μM Rh2(OAc)4 with aliquots of reduced
GSH added at pH 3.0 in deionized water.
λA: S(σ) →Rh(σ*) LMCT at 353 nm. λB: Rh2(π*) → Rh–O(σ*) at 448 nm. λC: Rh2(π*) →
Rh2(σ*) at 589 nm. The arrows show the direction of change in absorbance with an
increasing amount of GSH present. Reproduced from D. L. Wong et al., reproduced with
permission from the Royal Society of Chemistry. 18
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Figure 6-3 CD spectral results of glutathione reacting with Rh2(OAc)4
Circular dichroism spectra of 500 μM Rh2(OAc)4 following addition of 0, 0.5, 1.0, 1.5,
2.0, and 2.5 mol. eq. aliquots of 10 mM reduced GSH added. The arrows show the
direction of change in absorbance with increasing amount of GSH present. GSH does not
absorb in the region shown. Reproduced from D. L. Wong et al., reproduced with
permission from the Royal Society of Chemistry. 18.
The CD spectra shows that Rh2(OAc)4 is achiral, as expected (black line, Figure 6-3).
However, with the introduction of GSH, two new bands appear, a maximum at 298 nm
(marked as λ1) and a minimum at 339 nm (marked as λ2), with a crossover point between
325 and 330 nm. The development of the strong CD spectrum with the coordination of
GSH indicates that a chiral structure is formed upon binding GSH to the dirhodium
complex. The arrows show the change in chiral signal over the course of the titration.
Similar CD spectral changes have been reported previously for reactions of GSH with
Cu(I) and Cd(II).52 There was little to no CD intensity under the metal-metal-bond band
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at 589 nm. This was not unexpected, as the transition dipoles obtained from the
computational results below are located away from the chirality introduced by the GSH.

6.3.2

Analysis by Electrospray Ionization Mass Spectrometry

An inherent property of mass spectrometry is the creation of charged species for their
detection. All the masses in the spectra correspond to the charged species.
Spectra taken at pH 3.0 of Rh2(OAc)4 with excess reduced glutathione show the presence
of mono- and di-glutathione adducts (Figure 6-4). The ESI-mass spectral data shows that
the reaction creates a mixture of species: (i) glutathione polymers (at 615.1, 922.2 (A),
and 1229.3 (C) m/z, Figure 6-4); and (ii) deprotonated glutathione coordination of the
Rh2(OAc)4 forming [(GS)Rh2(OAc)4], [(GS)2Rh2(OAc)4], and [GS)3Rh2(OAc)4] at below
1% relative intensity (at 749.9 (star, Figure 6-4), 1056.0 (star, Figure 6-4), and 1364.1
m/z (D, Figure 6-4)). The two most prominent conjugates are those of a single
deprotonated glutathione-bound complex, [GS-Rh2(OAc)4] (Figure 6-1C), and that of a
double deprotonated di-glutathione-bound complex, [(GS)2-Rh2(OAc)4] (Figure 6-1E).
With the accuracy of the ESI-MS experiment, it is observed that the masses of these two
new complexes differ from the sum of the individual components by one and two protons,
respectively, indicating that a proton is lost to form the binding moiety. Coupled with the
optical spectroscopic data, we identify the cysteine sulfur as being the donor atom from
the GSH that is involved. The GS- binds to the vacant axial position of Rh2(OAc)4 that is
generally coordinated by solvent, as is confirmed by similar studies concerning dirhodium
complexes.38, 40
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Figure 6-4 Low pH reaction of Rh2(OAc)4 with GSH
ESI – mass spectra of 500 μM. Rh2(OAc)4 with excess reduced glutathione added, at pH
3.0 in deionized water. Taken in the positive ion mode. The circles identify GSH-related
complexes, where A = (GSH)3 at 922.2 m/z , C = (GSH)4 at 1229.3 m/z and the stars
indicate Rh2(OAc)4,-related complexes, where B = (GS)[Rh2(OAc)4] 2 at 1191.8 m/z, D =
(GS)3Rh2(OAc)4 at 1364.1 m/z and E = (GS)2-[Rh2(OAc)4] 2 at 1498.9 m/z. (Note that in
the positive ion mode the complexes will be oxidized in the ionization process so the
masses correspond to the complexes with correct charges, but are observed as the
monocation). Reproduced from D. L. Wong et al., reproduced with permission from the
Royal Society of Chemistry. 18.
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Figure 6-5 Reaction of Rh2(OAc)4 with GSH at physiological pH
ESI-Mass spectra of 500 μM Rh2(OAc)4 with 2.5 mol. eq. 500 μM GSH added, in 1 mM
NH4OAc buffer at pH 7.4, recorded in both positive (left) and negative (right) ion mode.
The insets show detail of the mono-adduct glutathione-rhodium complex region at near
750 m/z for both polarities. The individual peaks are assigned in the tables. (Note that in
the positive ion mode the complexes will be oxidized in the ionisation process so the
masses correspond to the complexes with correct charges, but are observed as the
monocation.) Reproduced from D. L. Wong et al., reproduced with permission from the
Royal Society of Chemistry. 18
To test the possibility of conjugation under a more physiologically relevant environment,
the reaction was carried out using 500 μM Rh2(OAc)4 with 2.5 mol. eq. GSH added in 1
mM NH4OAc at pH 7.4, Figure 6-5. Under these conditions, glutathione remains largely
unbound at 308.1 m/z in the positive ion mode (further denoted as “+ mode”), and 306.1
m/z in the negative ion mode (further denoted as “- mode”). The main Rh2(OAc)4 species
observed are the mono-aquated products (Figure 6-1F) at 459.8 m/z (+ mode), or 458.8
m/z in the negative ion mode, where the bis-aquated (Figure 6-1G), mono-acetate (Figure
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6-1H) and bis-acetate coordinated species (Figure 6-1I) are also observed at 476.8, 500.8,
and 559.5 m/z. At a relative intensity of under 10%, the glutathione mono-adduct product
is observable at 749.9 m/z (+ mode), and 747.9 m/z (- mode), corresponding to a complex
involving a deprotonated glutathione and the Rh2(OAc)4. Very little di-glutathione adduct
product was observed, at 1056.4 m/z (+ mode) and 1053.0 m/z (- mode), both at less than
1% relative abundance, with virtually none of the possible tri-adduct detected.
These quantitative results provide evidence for the exact products made in solution, and
their relative abundancies viewed in both positive and negative ion mode. It is clear that
the strong absorption band reported by Jakimowicz et al. should not be assigned to a 2:1
GSH: Rh2(OAc)4 stoichiometry, rather the product formed in that study was likely 1:1.
The computational results below provide an interpretation of the appearance of the strong
absorption below 400 nm following coordination with thiolates.
At this point, it has been established that GSH binds as a deprotonated peptide to the
Rh2(OAc)4 axial positions, forming the mono-adduct at 749.9 m/z (+ mode). The
combination of mass spectral data and the absorption and CD spectra suggest that the
tetraacetate linkers are intact and that the Rh-Rh single bond persists. To address the
structures of the proposed products, the structure of the singly-bound, and doubly-bound
glutathione-Rh2(OAc)4 complexes were constructed in the Scigress Modelling Software
and their geometries optimized prior to molecular orbital (MO) calculations using TDDFT methods, described below.

6.3.3

Competition by Glutathione for the Axially-Coordinated
Methionine in Rh2(OAc)4(Met)

In Chapter 4 and 5, the studies with metallothionein suggested axial coordination of the
dirhodium core by the cysteinyl thiolates was the initiating reaction prior to complex
deconstruction, because the additional cysteines in the protein bound in the place of the
O-donors of the tetraacetate ligands.49 As discussed above, cellular resistance can be
associated with thiol coordination of the active sites of metallodrugs. Blocking these axial
positions of the metallodrug with weak nucleophiles should introduce a defense against
cellular resistance due to steric effects impeding the attack by strong nucleophiles. The
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question arises how best to protect the complex against fast attack by such agents as
metallothionein and GSH. The use of a weaker binding ligand, such as the thioether of
methionine, may provide this protection. The reaction of methionine and related thioether
complexes with Rh2(OAc)4 has been reported by Pneumatikakis et al. and others 38, 42, 53.
This Chapter explores the reaction when glutathione is added after methionine is bound to
the Rh2(OAc)4. Scheme 6-1 summarizes the series of possible reactions that were used to
investigate the potential protection offered by methionine (Met) against competition by
GSH. First, when Met is added to the dirhodium complex. Using absorption spectra and
ESI-mass spectral data, the products formed can be determined: either a single Met binds
(Scheme 6-1, Equation 1, also Figure 6-1J) or two Met bind (Scheme 6-1, Equation 2a,
also Figure 6-1K). Next, GSH is added, and again, Scheme 6-1 shows the possible
outcomes: either displacement of one Met bound (Scheme 6-1, Equation 2b, also Figure
6-1L), addition to the 2nd axial position (Scheme 6-1, Equation 3), or complete
occupation of both axial positions (Scheme 6-1, Equation 4). The question then is, does
Met offer any protection against axial ligation and therefore deactivation by strongly
nucleophilic biological thiols, such as GSH and metallothionein, before the drug can
reach its eventual target?

Scheme 6-1 Reaction equations depicting possible outcomes of glutathione added to
methionine-bound Rh2(OAc)4.
The structures of each species described here in Scheme 6-1 Reaction equations depicting
possible outcomes of glutathione added to methionine-bound Rh2(OAc)4.are shown in
Figure 6-1. The reactions all depict axial ligation of the dirhodium core. The GSH
coordinated cores will be monoanions or dianions in solution but following the
ioniosation process the mass spectral data show only monocations and monoanions
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representing the redox nature of the ionisation process. Reproduced from reference 18
with permission from the Royal Society of Chemistry.

Figure 6-6 UV-visible absorption spectral changes following the reaction of an aqueous
solution of 500 μM Rh2(OAc)4 with 2 mol. eq. of methionine (Met) following 20 minutes
of mixing. 2 mol. eq. of glutathione was then added and the spectrum monitored.
The absorption spectra (left) can be separated into three sections: A) black line, the
initial blue solution; B) with 2 mol. eq. Met followed for 20 minutes, red, green, and blue
lines; the red and green lines are obscured by the 20 minute blue line as the reaction was
fast. C) after addition of 2 mol. eq. GSH, followed for 180 min, cyan, pink, yellow, green,
brown lines. ESI-mass spectra of the initial methionine bound solution (right, top) and
following glutathione addition (right, bottom) were recorded at 20 minutes and 60
minutes after mixing, respectively, in negative ion mode. Notable peaks: Met1(Rh2(OAc)4)
589.9 m/z; (Met)2(Rh2(OAc)4 738.9 m/z (GS)(Rh2(OAc)4) 747.8 m/z; (GS)2(Rh2(OAc)4)
1054.9 m/z. There was no evidence for (Met)(GSH)Rh2(OAc)4 in the expected region of
890-895 m/z. Reproduced from D. L. Wong et al., reproduced with permission from the
Royal Society of Chemistry. 18
Figure 6-6 shows the absorption and ESI-mass spectra recorded for the reactions outlined
in Scheme 6-1. The absorption spectrum follows the same trends as described above. The
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starting spectrum of the Rh2(OAc)4 in Figure 6-4(A) is the same as in Figure 6-1. The
addition of 2 mol. eq. of Met results in a slight, but distinct blue-shift in the wavelength
maximum of the Rh2(π*) → Rh2(σ*) metal-metal bond band from 589 to 570 nm,
indicating as before, that while Met has bound to the complex, the Rh-Rh bond is still
intact. The most significant change is the intensification of the band at 350 nm associated
with the thioether coordination 40 (Figure 6-6B). The reaction is fast and there is no
change after 20 minutes following mixing (B). Now the Met coordination is challenged
by addition of 2 mol. eq. of GSH, which results in a slow change in the optical spectrum,
with a significant increase in absorbance in the 353 nm region representing the
competition of glutathione for the axial position occupied by the methionine (Figure
6-6C). There is a slight red shift in the 580 nm region that confirms the Rh-Rh bond is
still present.
Negative ion mode ESI-mass spectra are very important in providing identification of the
species present at each step (Figure 6-6, inset, top). Following the addition of the Met, the
solution measured in the absorption as “B”, is primarily (Met)1(Rh2(OAc)4) at 589.9 m/z
as shown in Scheme 6-1, equation 1, with a very small fraction of (Met)2(Rh2(OAc)4 at
738.9 m/z formed in equation 2a. Following GSH addition (lines “C” in the absorption
spectra), the negative ion ESI-mass spectrum (Figure 6-6, inset, bottom) shows the
presence of [(GS)1(Rh2(OAc)4)] at 747.8 m/z formed in Scheme 6-1, equation 2b, and
also [(GS)2(Rh2(OAc)4)] at 1054.9 m/z formed in Scheme 6-1, equation 4. The reactions
with GSH were slow, as indicated in the absorption spectra measured over 3 hours, and
still possibly not at completion when the mass spectra were measured.
These results conclude that indeed Met does offer some protection because the
displacement reaction is slow, and the binding by the strongly nucleophilic GS- is
impeded. However, from a pharmacokinetic point-of-view, the exact rates in vivo would
need to be determined.
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6.3.4

DFT Calculations Provide Insight into the Stability of the
GSH Complexes

An accurate X-ray structure of the Rh2(OAc)4(H2O)2 was reported by Cotton et al. in
1971, showing specifically, for this paper, the location of the two water molecules on the
z-axis defined by the Rh-Rh bond.54 The Rh-Rh bond length calculated here for
Rh2(OAc)4(H2O)2 is 2.390 Å, which compares well with the reported value of 2.386 Å.54
For the results described above, we wanted to examine the electronic structure of the
complex in solution and when axially coordinated by GSH. There were three specific
question: (i) how extensive is the stabilizing role of the acetate linkers (ii) what is the
extent of the disturbance to the Rh-Rh 4d-based MO structure of the core caused by
coordination of the glutathione thiolate ligand, and (iii) can the dramatic colour change
from blue to yellow immediately after addition of the thiolates be explained from the
calculated absorption spectrum using time dependent-DFT (TD-DFT) methods? A charge
of -1 and -2 was entered in the Gaussian input file for [Rh(OAc)4(GS)(H2O)]- and
[Rh(OAc)4(GS)2]2-, respectively, because the GS thiolate brings in a negative charge
when it coordinates to the neutral dirhodium core.
i)

The electronic structure of Rh2(OAc)4 and Rh2(OAc)4(H2O)2 to determine the

effect of axial coordination by the water solvent
Axial coordination of the Rh2 core has been the subject of much study38, 40, 42, 44, 45, 48, 53, 5558

since the electronic structure for the metal-metal bonded species suggested a single

bond, that would leave 5pz or the 4dz2 as available, empty orbitals. The electronic
structure leading to the Rh-Rh bond and its bond order, are reflected in the absorption
spectrum. Polarized crystal spectra of Martin et al.59 (1979, revised slightly by Miskowski
et al. in 1984)60 provided key information in the assignment; first of the lowest energy,
visible region band to the π* to σ* transition, followed at higher energies to mixtures of
Rh-based MOs to the σ* orbital and also ligand to Rh-Rh core transitions. A more recent
report by Futera et al. in 2011,61 reported the electron occupancies based on DFT
calculations. For completeness in our discussion of the GSH to the axial Rh(II) bond
formation, we have included DFT results for the axial ligand-free core Figure 6-7, and the
H2O ligated core in Figure 6-8.
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Figure 6-7 MO energies and isoelectric density surfaces for the MOs that contribute to
the visible-near UV absorption spectra for [Rh2(OAc)4], from DFT geometry optimization
calculations.
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond.
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of
orbitals. An expanded version is available in Appendix D. Calculations and image from
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of
Chemistry. 18
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Figure 6-7 shows the DFT results for the dirhodium core with just the acetate linkages.
The MO order follows the expected sequence with the exception of the increased energy
of the δ* MO (79). The gas phase calculation shows that δ* lies just above the π* MOs
(77 and 78). We have labelled the well-known MOs with 4d origin (the occupied: σ (70),
π (74, 75), δ (76), π* (77, 78), and δ* (79) and the lowest unoccupied MO, σ* (80)). The
isoelectric surface images provide the spatial distribution of these orbitals, showing two
orientations. On the left, the view is looking down the Rh-Rh bond, so this is the x/y
direction. On the right, the viewing direction is perpendicular to the Rh-Rh bond, which is
aligned horizontally to show the axial ligands and acetate linker MOs. Expanded views of
all the MO surfaces are presented in Appendix D.
In aqueous solution the axial positions are coordinated by water (as in the X-ray
structures of Cotton et al. (1971)54) and this represents the species expected for optical
and ESI-MS measurements. The MO energies and surfaces are shown in Figure 6-8. The
coordination of the two water molecules increases the electron density of the two rhodium
atoms, raising the energy of all the MOs in this region. Particularly, the σ MO (86) now
lies above the δ (85) and π (83 & 84). In addition, the energy of the σ* MO (90) is raised
roughly 1 eV with respect to that orbital without the ligands (Figure 6-7, MO 80). As seen
below (Figure 6-12), the lowest energy absorption band is blue-shifted from the 800 nm
of the anhydrous Rh2(OAc)4 to 600 nm for the dihydrate, because the π* to σ* energy gap
increases. Except for the rise in σ (86), the ordering does not change, with the occupied δ
(85) and δ* (89) being located above the respective π and π* MOs (83, 84, and 87, 88).
The surfaces again provide interesting contrasts in the electron distribution for the linking
acetates, the two waters, and the two Rh atoms. Symmetry rules mean that the water MOs
are only involved in significant overlap with the z-axis σ and σ* MOs (86 & 90).
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Figure 6-8 MO energies and isoelectric density surfaces for the MOs that contribute to
the visible-near UV absorption spectra for [Rh2(OAc)4(H2O)2] from DFT geometry
optimization calculations.
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond.
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of
orbitals. An expanded version is available in Appendix D. Calculations and image from
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of
Chemistry. 18
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ii)

The electronic structure when thiol is coordinated: [Rh2(OAc)4(GS)(H2O)]-

and [Rh2(OAc)4(GS)2]2The ESI-MS data in Figure 6-5 show the presence of both the mono- and di-GS2complexes, although the di-GS2- product is in extremely low abundance. Figure 6-9 and
Figure 6-10 show the interaction between the GS- MOs and the dirhodium MOs. Figure
6-11 shows the expanded view of the σ*, σ, and π* MOs for [Rh2(OAc)4(GS)(H2O)]- and
[Rh2(OAc)4(GS)2]2-. The MO structure for the mono-adduct (Figure 6-9) shows a
significant rise in the energy of all the MOs compared to the bisaquated structure (Figure
6-10). This is due to the increased density on the Rh atoms from the axial coordination of
the thiolate ligand. This time, because of the lack of axial symmetry, the σ (164) and one
of the π* (165) MOs rise in energy, now above the π* (163) and δ* (162). The surfaces
show that the three residues of the tripeptide, GS-, interact strongly with many of the RhRh MOs, and not with the tetraacetate MOs. For example, of the highest lying occupied
MOs, only π* (163), δ* (162), and δ (155) do not have significant contribution from the
GS- MOs. MOs 159, 160, and 156 are located mainly on the GS-. The extensive overlap
of the GS- density with the Rh-Rh core MOs (Figure 6-11) accounts for the retention of
the GS- coordination of the Rh2(OAc)4 complex in the ESI-mass spectrometer under the
dehydrating conditions of the MS vacuum (Figure 6-5). Figure 6-10 shows the results of
the calculations for [Rh2(OAc)4(GS)2]2-. The large donation of density from the two
anionic glutathiones in [Rh2(OAc)4(GS)2]2- raises the energy of the Rh-Rh σ MO (241)
above π (240). With two GS- there is significant overlap of the MOs of the tripeptide with
all the Rh-Rh core MOs (Figure 6-11), shuffling the energy stack considerably. MOs 242232 are located on the two GS- ligands. Despite searching down to MO 220, an MO with
symmetry characteristics of the δ (like MO 155 in Figure 6-10) were not found. The
surfaces provide much more detail concerning the overlap of electron density than text
can do justice to, so we direct the reader to Appendix D. The H2O in
[Rh2(OAc)4(GS)(H2O)]- does not coordinate to the dirhodium, instead it hydrogen bonds
to the acetate linkers, seen in Figure 6-9.
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Figure 6-9 MO energies and isoelectric density surfaces for the MOs that contribute to
the visible-near UV absorption spectra for [Rh2(OAc)4(GS)(H2O)]- from DFT geometry
optimization calculations.
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond.
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of
orbitals. An expanded version is available in Appendix D. Calculations and image from
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of
Chemistry. 18
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Figure 6-10 MO energies and isoelectric density surfaces for the MOs that contribute to
the visible-near UV absorption spectra for [Rh2(OAc)4(GS)2]2- from DFT geometry
optimization calculations.
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond.
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of
orbitals. An expanded version is available in Appendix D Calculations and image from A.
Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of
Chemistry. 18
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Figure 6-11 Electron density surface representation of the highest occupied and lowest
unoccupied orbitals for [Rh2(OAc)4(GS)(H2O)]- and [Rh2(OAc)4(GS)2]2-.
These surfaces show the extensive overlap of the axially coordinated GS- with the σ and π
MOs of the Rh-Rh bond. An expanded version is available in Appendix D. Calculations
and image from A. Zhang in D. L. Wong et al., reproduced with permission from the
Royal Society of Chemistry. 18
iii)

Calculated absorption spectra for [Rh2(OAc)4], [Rh2(OAc)4(H2O)2],

[Rh2(OAc)4(GS)(H2O)]- , and [Rh2(OAc)4(GS)2]2Figure 6-12A shows the calculated absorption spectra, labelled with the Excited States
(ES) that show significant oscillator strength (a list of the excited states are available in
Appendix D). Figure 6-12B shows the molecular orbital contributions to each excited
state for [Rh2(OAc)4(H2O)2], [Rh2(OAc)4(GS)(H2O)]-.
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Figure 6-12 Calculated absorption and orbital contributions to the excited states from
TD-DFT calculations for Rh2(OAc)4 and the complex coordinated by water and GS1A) Calculated absorption spectra for [Rh2(OAc)4], [Rh2(OAc)4(H2O)2],
[Rh2(OAc)4(H2O)(GS)] -, and [Rh2(OAc)4(GS)2] 2-. The labels “ES1,” etc. identify the
Excited States for which the oscillator strength for the transition from ES0 is greater than
0.001. The excited states calculated from TD-DFT are tabulated in Appendix D. (B)
Orbital participation in the excited states above 230nm with oscillator strengths >0.001
for [Rh2(OAc)4(H2O)2] and [Rh2(OAc)4(H2O)(GS)] -. The red arrow represents the
transition with the highest contribution. The detailed contributions are shown in Table S1
in Appendix D. The MOs of the Rh2 core are shown in the two boxes. Calculations and
image from A. Zhang in D. L. Wong et al., reproduced with permission from the Royal
Society of Chemistry. 18
TD-DFT calculations were carried out for the four complexes described above, however,
as the only two that are described in the experimental optical data for are the bisaquated
and the mono-adducted GS-, only those results are described here. The full results for the
calculations between 900 and 200 nm are shown in Appendix D, with the resulting
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spectral data shown in Figure 6-12. The data in Figure 6-2 identify two visible region
bands for the bisaquated complex, at 589 and 448 nm before intense absorbance below
300 nm giving these solutions a sky blue colour. The calculations for the bisaquated
predict bands at 549 and 537 nm, and 397 and 389 nm, with a much more energetic and
intense band at 238 nm. The relative intensities and band energies are reproduced very
closely by the calculations. The calculation for the bisaquated complex (Figure 6-8)
shows that the visible region bands arise from pairs of transitions that add contributions
from each of the Rh 4d orbital set. Symmetry labels are added to allow the mixing to be
seen clearly. The δ*MO does not contribute significantly to any absorption. The predicted
absorption is essentially purely the Rh core offset by the electron density from the two
waters.

6.3.5

Origins of the Electronic Absorption Spectrum

[Rh2(OAc)4(H2O)2]
The bisaquated dirhodium tetraacetate is a sky blue colour in solution with the lowest
energy band at 589 nm, Figure 6-2. The TD-DFT results (Figure 6-12) assign this band to
a mixture of transitions from the π* and σ (86, 87, & 88) to the σ* (90) and MO 91, but
not from the δ* (89) because of application of selection rules. However, the major
contribution to the oscillator strength is from π* (88) to σ* (90). The theoretical
absorption spectrum (Figure 6-12A) shows the presence of three distinct absorption bands
(labelled ES1/2, ES3/4, ES5) that arise from pairs of transitions involving all the
dirhodium MOs as shown in Figure 6-12B. The predominant transition remain π* to σ*
for the visible region bands. The lack of strong absorption between 500 and 300 nm
accounts for the blue colour. The ES3/4 can be seen in the absorption spectrum at 448 nm
(Figure 6-2). These four transitions all involve a significant contribution from the acetateRh MOs. However, ES5 is strongly connected with a σ (86) to σ* (90) transition, which
involves the two coordinated waters and not the acetates.
[Rh2(OAc)4(GS-)(H2O)]Addition of thiols results in a yellow colouration (Figure 6-2) arising from the increase in
absorption at 353 nm. The calculated results for the mono-thiolate (Figure 6-12A and B)
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show the presence of new transitions in the visible and near-UV regions. The calculations
again place the lowest energy transition near 600 nm, as seen in the experimental
spectrum, but now introduce a series of bands, mostly very weak, but with the most
intense new band being at 326 nm (ES5). These bands result from charge transfer from
GS--dominated MOs to the σ* (166) Rh2 core MO. By plotting the theoretical spectrum
with realistic band widths, the origins of the shoulder in Figure 6-2 as the GSH is added
are seen. The CD spectrum Figure 6-3, indicates the asymmetry introduced by the chiral
GS- binding to the Rh2 core between 250 and 370 nm, a region associated in the
calculations with bands at 321 and 326 nm.
The theoretical electronic absorption spectrum of [Rh2(OAc)4(GS)2]2The calculation for the di-GS- shows an increase in the charge-transfer transition below
400 nm (Figure 6-12, ES3-8) and the blue-shift of the lowest energy transition near 530
nm (ES1) is associated with stronger contributions from both coordinated glutathiones.
Table 6-1 summarizes the computational results for the Rh-Rh bond length, the energies
of the σ, σ*, and π* MOs for the four complexes. As more electron donating groups are
added, these MOs increase in energy, and the Rh-Rh bond length increases. With the
increase of electron density on the rhodium, the Rh-Rh single bond is weakened. In
addition, the data show that as a result of the interaction between the axial ligands and the
Rh-Rh MOs, the axial ligands become more involved in the structure of the complex.
Table 6-1 Computational parameters derived from TD-DFT calculations. Calculations
from A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of
Chemistry. 18
Complex

Rh-Rh bond
length /Å

E(σ) /eV E(σ*) /eV

E(π*) /eV

Rh2(OAc)4

2.370

-10.104

-1.902

-8.126

[Rh2(OAc)4(H2O)2]

2.390

-8.349

-0.291

-7.411

[Rh2(OAc)4(GS)(H2O)]-

2.464

-4.006

2.013

-3.637

[Rh2(OAc)4(GS)2]2-

2.471

-0.895

4.691

-1.447
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6.4 Conclusions
Glutathione is well known as a strongly coordinating thiol that exists in high cellular
concentration. It is upregulated in homeostatic response to soft and potentially toxic
metals. In the results described above, glutathione binds to Rh2(OAc)4, forming primarily
the mono-adduct with retention of the single Rh-Rh bond. This means that glutathione
binds axially and does not disrupt the intended, therapeutically-important, structure, but
does block one of the axial sites. In the cellular milieu, this may mean that dirhodium
carboxylates can survive and retain their anti-cancer activity. The computational results
provide insight into the extensive overlap of the glutathione molecular orbitals with the
Rh2(OAc)4 core orbitals, leading to interpretation of the strength of the glutathione
cysteine thiolate-rhodium bond. The calculations also allow an understanding of the
optical spectral properties, showing how the introduction of axial ligands introduce new,
strong absorption in the 300-400 nm region, and blue-shifting the lowest energy band at
500-600 nm. The presence of the axial ligand results in significant charge transfer in each
of the optical transitions. The calculated MO energies for the four species studied show
that the presence of the axial ligand is to destabilize all orbitals as a result of the
introduction of electron density onto the rhodium core. Significantly, the relative energy
of the Rh σ is raised with respect to δ and π. Despite the extensive overlap of the
glutathione orbitals with the Rh MO, the acetate linker MOs remain largely unaffected,
which accounts for the observation that the acetates are retained following axial
coordination with GSH.
The results from the previous Chapters show that the cysteine-rich metallothionein
protein not only binds Rh2(OAc)4, but sequentially deconstructs the complex by replacing
the four carboxylate ligands with the metallothionein cysteine thiolates.49 In this case, the
Rh2(OAc)4 would be deactivated. Metallothionein has long been associated with a
detoxification role, and this reaction with Rh2(OAc)4 is just one example of this property.
However, glutathione is present in at least 100 times greater concentration in the
cytoplasm than metallothionein. This suggests, based on the results presented here, that a
major feature in the design for these therapeutic rhodium carboxylates should be the
incorporation of weakly coordinated sulfur at the axial position of the dirhodium core. If
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such groups were included in the overall design, the results presented above suggest that
the complex could remain intact longer in the cell and be somewhat protected against
rapid metabolic deconstruction.
Metallodrugs offer a future of tunable therapeutic complexes that will be applicable to a
large number of diseased states; well-known examples include Platinol (Pt), Ridaura
(Au), and Trisenox (As).62 For the drug to be effective, the delivered form of the metal
complex must be as designed. Pro-drugs are designed to change, following metabolism,
into the active therapeutic agent, in which case the metabolic pathways must be well
known. In other cases, it is assumed that the metallocomplex will be unchanged following
passage into the cell. The plasma and cellular cytoplasm contain coordinating
biomolecules that will bind tightly to these xenobiotic metals that form the therapeutic
complex, changing the complex's properties. If this change significantly alters their
therapeutic activity, then this drug has no value, and may result in higher toxicity.
Understanding the potential coordination chemistry that can take place in either the
plasma or the cytoplasm is important in the design and subsequent application of these
drugs. The data confirm the view that the dirhodium(II) tetraacetate could easily be
targeted by the intracellular thiols like glutathione, but could be protected by weak axial
ligands commonly present in the cellular milieu, and still be able to bind to their intended
biological targets.
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Chapter 7

7

Conclusions: Xenobiotic Metals in Therapeutic
Agents as Models for Toxicity*

As a result of the Internet and the technological age, decades worth of electronic metal
waste have been produced at a rate higher than can be sustainably dealt with. From this
waste, xenobiotic metals are being introduced into the ecosystem. Already, metallic
particulates of Pt, Pd, Os, Rh, and Ir are evident in the environment from their use in
catalytic converters in the automotive industry.1-4 With the new age of smart devices, a
host of exotic xenobiotic consumer waste will become a global concern.
Metallotherapeutics leverage the properties of xenobiotic metals in the treatment of
cancers and tumors, and, in addition, anti-inflammatory, or anti-microbial agents in other
medical treatments. However, metallotherapeutics directly expose humans to these
xenobiotic metals, and this risk must be considered when determining the
pharmacokinetics of these drugs. Often these treatments are intravenously administered,
and this means that the metallo-drug will encounter a host of adduct-forming proteins in
the blood plasma (e.g. albumin).
With its 20 cysteine thiols, metallothionein (MT) is a small protein with a powerful Lewis
basicity that makes it highly reactive towards metal ions. Additionally, isoforms with
single amino acid mutations may assist in the binding of metals using modes other than
homoleptic cysteine coordination. This type of flexible bonding could also be considered
as an example of non-traditional binding when discussing the metallation of MTs.
In the research described in this Thesis, I have postulated that these potentially toxic
metal complexes could be intercepted by MT. Because of its flexible structure, it is well
known that MT does not have specific, well-defined metal binding sites, unlike typical
metalloproteins. Thus, MT is able to accommodate the specific coordination demands of
many different metals, but the protein itself is not innocent in its coordination when these
metals bind as complexes. This is because the thiolate ligands are such strong sigma
donors, that they displace the original metal-bound ligands. In this way, one might say

*A version of this chapter is in preparation for publication
D. L. Wong and M. J. Stillman (2019)
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that MT “digests” the complex. The experimental data reported in this Thesis provide a
number of major novel findings. Clearly, the first is that metallocomplexes are not
immune to coordination by this ubiquitous protein, and their bound form may be
subsequently modified. Secondly, MT does not (as noted above) exert its coordination
through the traditional binding site model of metalloproteins, rather the structures formed
depend entirely on the conformation of the 20 cysteines and the incoming complex.
Thirdly, the apoprotein is a folded structure that is highly fluxional and dependent on the
surrounding solution environment. The flexibility of the backbone allows MT to
effectively ensnare incoming metal complexes, encapsulating them within the protein
core.

7.1

Exotic Metals as Medicines

This Thesis has introduced the reader to the double-edged sword that xenobiotic metals
represent to humans. Some of this class of metals can be used therapeutically and, in that
sense, they are beneficial. On the other hand, exposure from metal waste pollution is
toxic, and, therefore, detrimental. However, if metallothionein becomes involved in the
pharmacokinetic pathways of any of these routes of exposure, new metabolic pathways
may result that may be more or less beneficial or detrimental. This mechanistic dilemma
leaves many unanswered questions concerning the relative value of the beneficial use of
xenobiotic metals in consumer goods, which must be reflected in the challenge of safe
and sustainable heavy metal recovery. Before revisiting the conclusions drawn from the
specific experiments reported in this Thesis, I will first introduce brief examples of dblock metals currently in therapeutic and diagnostic use, to put into context the specific
studies I have reported on cisplatin and dirhodium(II) tetraacetate. The examples of the
exotic metals described below are: Technetium, Rhenium, Platinum, Ruthenium,
Rhodium, and Gold.
Technetium
Tc, with its emission of 140.5 keV γ-rays and biological half-life of 6 hours,5 makes

99m

this synthetic metal a versatile imaging agent.6 The groundbreaking research by Morelock
and Tolman on utilizing MT as a radiolabel drug delivery mechanism showed that the
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stable decay product, 99TcO3+ bound readily to MT. Significantly, coordination
determined using extended X-ray absorption fine structure (EXAFS) showed the Tc was
bound to both N/O ligand donors as well as the cysteine thiols.7 99mTc has been used to
effectively image many organs, the first being the liver.8 These types of diagnostic agents
used in medicine are likely encapsulated by MT for up take in all tissues.
Rhenium
With similar properties to 99Tc, 186Re and 188Re have also been utilized for the
radiopharmaceutical imaging of cancerous liver tissue.9
The binding reaction of Re to MT has been investigated by Palacios et al. in the form of
[facRe(CO)3] and these Re moiety-containing complexes were observed to bind
significantly slower compared to the analogous reaction with [facTc(CO)3].10 The same
study showed that of the four human isoforms of MT, the most Cu-philic, MT3, reacted
most readily with the Re complex. This was likely due to the presence of a histidine
residue in MT3, that is not present in the other isoforms.
Platinum
Platinum and its anti-cancerous effects introduced the world to metal based cancer
therapeutics. Its original anticancer activity was discovered by Rosenberg et al.,11 and it is
now a flourishing billion dollar industry with a variety of analogs of refined activity,
examples are shown in Figure 7-1.12 Since its discovery and subsequent use, it has been
found that many cancer types have developed resistance following prolonged treatment.13,
14

A number of these platinum resistant cancer types display an increased expression in

nuclear MT, correlated to platinum treatment.15-17
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Figure 7-1 Cisplatin and its subsequently developed analogs.
MT reacts readily with cisplatin,18-20 more so than its transplatin analog.21 With cisplatin,
the ammine ligands are removed by the cysteine thiolates of MT,22 but transplatin retains
its ammines.21 There are a variety of newly developed analogs of cisplatin designed to
increase selectivity by adopting ligand structures that are more stable at biological levels.
These are currently in use as effective treatments of a variety of cancer types.12 An
example of a novel therapeutic, is platinum(II) 9-aminoacridine, a structure resistant to
MT1a reactivity.23 The downside of these platinum based anti-cancer treatments are their
side effects (nephrotoxicity, neurotoxicity, nausea) and their limited selectivity. As a
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result, researchers are currently surveying non-platinum metal complexes for similar
anticancer therapeutic activity.
Ruthenium
Ruthenium complexes are studied for their low toxicity and antimetastatic behavior, with
many displaying strong anti-tumor activity. The most promising examples of these Ru
complexes are shown in Figure 7-2. Imidazolium transimidazoledimethylsulfoxidetetrachloro-ruthenate (NAMI-A) is a stable Ru(III) prodrug
that is converted to its active Ru(II) state upon entering the reducing environment of the
cancerous cell. Trans-tetrachlorobis(indazole)ruthenate(III) (KP1019) imparts its activity
by binding with the iron transport protein transferrin,24 interfering with iron uptake of the
nutritionally-starved cancer cells. RAPTA agents are Ru(II) arene piano stool compounds
that carry a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand. They are a family of potent
cytotoxics that significantly reduce metastatic activity.25 The organometallic, arene
structure proves to be a robust chemical architecture withstanding thiolate attack, and
continues to show promise with Rh and Os analogs in selective anti-tumor activity.26
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Figure 7-2 Structures of Ru(II) complexes NAMI-A (Left), KP1019 (Right), and
RAPTA-C (bottom).
Rhodium
Rhodium was considered as an alternative to Ruthenium because it is more inert
biologically. It is also promising as a radiosensitizer, for direct enzyme inhibition, and
photodynamic therapy. Rh3+ complexes exhibit therapeutic effects by inhibiting beta
amyloid aggregation, kinase inhibition, and DNA intercalation.27
Dirhodium carboxylate anti-tumor activity has been known since the 1970’s,28-31 but due
to the serious nephrotoxic side effects, they are not currently used. However, the
construction of these bimetallics can be finely tuned with their ligand decoration, and
these complexes has been the subject of much research.27, 32-40
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Gold
Au(I) salts have been used for decades to relieve the chronic side effects of rheumatoid
arthritis, in a multi-action approach known as chrysotherapy.41 Chrysotherapeutic effects
include anti-inflammatory and antimicrobial response, inhibition of T-cell proliferation
and enzyme inhibition.42 The Au(I) complexes are known to interact with MTs, and are
deactivated upon binding. This includes the well-known therapeutic agent,
aurothiomalate.43
Some Au(III) complexes show activity against cisplatin-resistant cells,44 demonstrating
promising alternatives for non-platinum therapeutics. These include the tetrapyrrole
Au(III) porphyrin,42 Au(III) corrole complexes,45 and multi-dentate N donor ligands,46
and as such, these new structural designs are focused on improving their durability as
cytotoxic agents.

7.2

MT Metabolism of Metal-based Drugs

After introducing examples of metal-based drugs above, and the known interactions of
these metals with MT, I now return to the conclusions drawn from the experiments
performed in this Thesis.
Chapter 3: Human MT Metallation with Cisplatin
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Figure 7-3 Graphical abstract for the breakdown of cisplatin by MT using ESI-MS.
Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society
of Chemistry. 22
In vitro reactions involving cisplatin and transplatin binding to mammalian MTs were
studied previously using HPLC and NMR spectroscopy. ESI-MS was used to provide
quantitative detail of the effects of transmetallation of Zn-MT by Pt(II), but there were no
details concerning the initial metal displacement reaction.21, 47 Chapter 3 describes the
initial binding and dissection of cisplatin when bound to MT1A utilizing ESI-MS to
quantify the mechanism for these primary ligand substitution reactions, Figure 7-3.
Hagrman et al. showed that there were multiple phases to the cisplatin-MT reaction, but
the first phase occurred far too rapidly to be observed using LC methods.48 With the high
resolution and time resolving power of the ESI TOF MS, it was possible to measure the
rates of the first 4 metallation reactions, k1-4, and to propose a detailed mechanism for the
interaction between cisplatin and MT.22
Chapters 4 and 5: Human MT Metallation with Dirhodium(II) Tetraacetate

Figure 7-4 Graphical abstract depicting the encapsulation of a Rh-Rh core by the β-MT
domain.
Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society
of Chemistry. 49
The biological uptake of Rh and its related platinum group metals has gained interest with
the reports of metal particles in soil and freshwater species near routes of heavy traffic.1,
50-52

This increase in the presence of such biologically exotic metals has been linked to the

advent of platinum-based catalytic converters in automobiles to reduce noxious
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emissions. However, these metal-based catalysts are not completely stable; thermal
decomposition and mechanical sintering results in these metal particulates being released
into the environment.
A way to study the possible physiological effects of toxic rhodium exposure from this
pollution is to examine the use of rhodium-based platinum alternatives in chemotherapy.
The work described in Chapter 4, and 5 proves that MT can play an active role in the
metabolic destruction of dirhodium metallocomplexes; a result that had not been reported
in the literature previously.49, 53 The sequestration of a dirhodium(II) tetraacetate by MT
results in the removal of the acetate ligands, leaving the Rh-Rh core intact. Chapter 4
described the reaction with the 9 cysteine, β-domain fragment, which easily
accommodates one and only one Rh2 core. In Chapter 5, the reaction with the full, 20
cysteine, two domain protein is more complex, with multiple metal binding
conformations possible due to the elegant flexibility of MT. Rh uptake by MT is fixed at
a Rhn:MT ratio, where n = multiples of 2. MT-to-MT metal-transfer equilibration would
result in odd-numbered stoichiometries, which were not observed. The resulting
encapsulated Rh-Rh core was visualized as being embedded in the MT structure using
molecular dynamics. Rh2(OAc)4 is easily taken up by MT and the resulting product in
vivo may exhibit nephrotoxic effects similar to Cd-MT54, 55 due to its comparable size.
Chapter 6: Strength of the Cysteine Thiolate Metal Coordination- Studies with
Glutathione

Figure 7-5 Graphical abstract emphasizing the harmony of the methods used to explain
the properties of the metal-thiolate bond.
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Calculations and image from A. Zhang in Wong et al., reproduced with permission from
the Royal Society of Chemistry. 56
Reactions with glutathione provide a model system from which we can understand the
reaction of the dirhodium complex with MT. Glutathione on its own does not dismantle
the tetraacetate cage under our anaerobic conditions. However, the GSH clearly did bind
to the dirhodium complex, based on the changes in the optical spectrum, and this
prompted a computational investigation into the strength of the resulting metal-thiolate
bond.
Strong electron donation from the thiolates of the cysteines raises the energy of the Rh-Rh
bond MO, weakening the Rh-Rh single bond. This was observed from the increase in the
calculated bond lengths with the coordination of the glutathione. The effect of acetate
replacement with multiple glutathione molecules would be of interest in order to
understand the hyperchelative effect of MT, and the change in energy that results from
the stepwise replacement of the acetate ligands.

7.3

A New Biological Role for MT

Active Disassembly and Binding Metals of Complexes
In the work described in Chapters 3, 4, 5, and 6, I have introduced the dilemma of
beneficial and detrimental pathways for which metallothionein may be implicated. In the
six decades of research since its discovery, the reactions of metallothioneins with metal
ions have been well documented and, in this Thesis, we have defined these as traditional
reactions (for e.g. Zn(II) and Cd(II),57 see Scheller et al. for a comprehensive list).58
However, in the context of these xenobiotic metals, I have described the metallation as
non-traditional. Reactions of coordination complexes with MT are far more complicated.
Metallothionein is a multidentate hyperchelator, which in its action, envelopes and
systematically exchanges its ligands in an irreversible fashion, deconstructing the
incoming metal complexes using its 20 electrophilic cysteine thiolates.
Historically, MT was considered to bind Zn(II) and Cd(II) into well-defined clustered
structures. The reactions reported at the time were analyzed based on the assumption that
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metallation always involved complete cluster formation and metal saturation, even with
mixed-metal products. However, Yang, Maret and Vallee, through the analysis of cellular
content, identified and confirmed the in vivo presence of partially-metallated
metallothionein (5 Zn(II) instead of 7) and postulated that there would be free thiols based
on the assumption that incomplete clusters formed.59 With recent data, particularly with
the advent of ESI-MS studies, including those shown in this Thesis, it is now clear that
the partially-metallated metallothioneins may not require cluster formation, instead the 5
Zn(II) referred to above have been shown to bind with terminal thiolates. We now
understand the metallation mechanism and chelating behavior of MT and its isoforms
better than before. This new recognition that partially metallated metallothioneins do not
require cluster formation leads to the description of the non-traditional binding of
xenobiotic metals that have been described here.
As we approach the future with computers and electronics becoming deeply integrated
into daily life, the possibility of chronic exposure to xenobiotic metal waste increases.
The issue is that the combined controlled and uncontrolled (legal and illegal) extraction,
purification, recycling and reclamation results in the incorporation of these metals into the
food chain. At this point, the studies described in this Thesis suggests that non-traditional
binding to metallothionein will occur. Metallothioneins in all Life will be required to
adapt as a result.
In cancer, the abhorrent growth and replication of diseased cells causes an overdrive in
protein expression, of which cellular thiols like MT are heavily implicated. The studies
described in this Thesis suggest that the exacerbation of this metal scavenging by the
increased amount of cellular MT will greatly hinder the efficacy of metal-based
anticancer drugs.
We have now completed the description of the aggressive attack of therapeutic
metallocomplexes by this cellular metal gatekeeper, metallothionein (MT). The
metallation of de novo MT would be the first response in the inherent cellular defense
against xenobiotic metals. Therefore, in closing, and as a final comment on the
chemistries described in this Thesis, I conclude that the epic method by which MT
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eviscerates metal complexes uniquely allows MT to adopt novel, and unprecedented
structural properties to defend the cell against these intruding xenobiotic complexes.

7.4
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Appendix A: Observed Rate Constants for Experiments
Performed in Chapter 2
Figure

Constant Conditions

Variable

Kobs (106s-1)

Conditions
pH Titration

Cd Titration

Standard
Deviation

4 M GdmCl

pH 5

215.48

3.127 (1.45%)

2.5 eq. Cd (II)

pH 6

317.95

2.842 (0.89%)

10 ˚C

pH 7

422.40

5.084 (1.20%)

pH 7.5

918.93

8.412 (0.92%)

pH 8

2150.00

41.75 (1.94%)

pH 5

1 eq

830.89

21.57 (2.60%)

0 M GdmCl

2.5 eq

353.97

3.797 (1.07%)

10 ˚C

5 eq

182.60

1.252 (0.69%)

pH 5

1 eq

404.28

7.262 (1.80%)

4 M GdmCl

2.5 eq

215.48

3.127 (1.45%)

10 ˚C

5 eq

147.17

1.313 (0.89%)

pH 8

1 eq

7198.20

265.4 (3.69%)

0 M GdmCl

2 eq

4690.10

72.29 (1.54%)

10 ˚C

2.5 eq

3633.30

78.59 (2.16%)

3 eq

1953.90

19.02 (0.97%)

4 eq

1459.70

10.27 (0.70%)

5 eq

2318.80

11.29 (0.49%)

pH 8

1 eq

1238.10

9.705 (0.78%)

4 M GdmCl

2.5 eq

2150.00

41.75 (1.94%)
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10 ˚C

5 eq

878.86

14.15 (1.61%)

GdmCl Titration pH 5

0M

353.97

3.797 (1.07%)

2.5 eq. Cd (II)

1M

265.67

1.827 (0.69%)

10 ˚C

2M

252.91

1.58 (0.62%)

4M

215.48

3.127 (1.45%)

Temperature

pH 5

10.1 ˚C

353.97

3.797 (1.07%)

Dependence

0 M GdmCl

15.3 ˚C

407.14

4.142 (1.02%)

2.5 eq. Cd (II)

18.1 ˚C

468.10

7.597 (1.62%)
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Appendix B: Known Kinetic and Equilibrium Binding
Constants for MTs
Table 2. Reports of kinetic data for the metallation of individual metallothioneins
Metal

Stoichiometry

Technique

MT1a

Fragment/
Protein
α

As3MT

ESI-MS

human20

MT1a

β

As3MT

ESI-MS

human20

MT1a

βα

As6MT

ESI-MS

Bi

rabbit

MT2

βα

Bi7MT

UV-visible
absorption, 1H
NMR

Cd

human20

MT1a

α

Cd4MT

Stopped flow
spectrophotometry

horse
kidney20

MT

βα

Cd7MT

Absorption
spectroscopy

rabbit20

MT2

βα

Cd7MT

Stopped flow
spectrophotometry

rabbit20

MT2

α

Cd4MT

Stopped flow
spectrophotometry

rabbit20

MT2

βα

Zn7MT

Stopped flow
spectrophotometry

As

Zn

Organism
**
human20

Isoform

Rate constants
k [M-1 s-1]
k1 5.5
k2 6.3
k3 3.9
k1 3.6
k2 2.0
k3 0.6
k1 25
k2 24
k3 19
k4 14
k5 8.7
k6 3.7
k1 5.8 × 10-3
(Cd
displacement)
k2 1.0 × 10−4
(Cd
displacement)
k1 7.2 × 10−3
(Zn
displacement)
k2 5.9 × 10−5
(Zn
displacement)
k1-4 60.4
(native)
k1-4 3.32
(denatured)
2.7 x 10-6
(Demetallatio
n by EDTA)
pH 4.1
60±10
pH 4.6
140±30
pH 5.1
280±50
pH 5.4
350±100
pH 4.6
170±60
pH 5.1
350±100
pH 5.4
460±200
pH 4.6
10±1
pH 5.2
15±1

Reference
1

1

2

3

4

5

6

6

6
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rabbit20

MT2

α

Zn4MT

Stopped flow
spectrophotometry

Pt

rabbit20

MT

βα

Pt7MT

Atomic absorption
spectroscopy, UV
absorption, HPLC

Zn

horse
kidney20

MT

βα

Zn7MT

Absorption

** superscript shows the number of cysteines in the peptide

pH 5.8
28±2
pH 6.3
43±7
pH 6.6
100±15
pH 7.2
300±100
pH 6.6
90±10
pH 7.2
230±100
pH 7.5
690±300
0.14 (to apoMT)
0.75 to
Cd/Zn-MT
0.53 to
Cd7MT
0.65 to
Zn7MT
Demetallation
by EDTA
k1 fast
k2 14.2x10-4
k3 2.0x10-4

6

7

5
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Table 3. Reports of binding constant data for the metallation of individual human metallothioneins
Metal
Isoform
Fragment/P Stoichiometry Technique***
Binding constant
rotein
value (logK)
Cu
MT2
βα
Cu10MT
ESI-MS, pH 7.5
K
14.6
MT1a
βα
Cu20MT
ESI-MS1
K1
15.5
pH 7.4
K2
15.0
K3
14.6
K4
19.3
K5
14.6
K6
18.9
K7
12.9
K8
13.1
K9
13.7
K10 15.5
K11 10.7
K12 11.2
K13 12.9
K14 9.5
K15 9.5
K16 8.6
K17 8.1
K18 7.0
K19 6.1
K20 5.0
Pb
MT3
βα
Pb7MT
ITC, pH 6.0
K1-2 11.7
K3-4 10.2
K4-7 8.7
Zn
MT2
βα
Zn7MT
K1-4 11.8
Fluoresence
K5
10.45
spectroscopy2
K6
9.95
pH 7.4
K7 7.7
MT3
βα
Zn7MT
ITC, pH 6.0
K1-4 10.8
K5 10.5
K6 9.9
K7 7.7
MT1a
βα
Zn7MT
ESI-MS3
K1 12.35
K2 12.47
K3 12.52
K4 12.37
K5 12.21
K6 12.05
K7 11.80

Reference
8
9

10

11

10

12

**superscript shows the number of cysteines in the peptide
***Explanations:
1 determined by analysis of the pH dependent titration data
2 binding strength was determined using competitors and fluorogenic dye
3 binding constant values were determined through competition of zinc binding to carbonic anhydrase
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A. Krȩżel and W. Maret, Dual nanomolar and picomolar Zn (II) binding
properties of metallothionein, J. Am. Chem. Soc., 2007, 129, 10911-10921.

12.

T. B. Pinter and M. J. Stillman, The zinc balance: Competitive zinc metalation of
carbonic anhydrase and metallothionein 1A, Biochemistry, 2014, 53, 6276-6285.

194

Appendix C: Supplementary Structures and Energies for Rh2
bound MT

Fig S. 4. Top: Apo-MT MD result. Cysteine S shown in yellow. Bottom: Potential Energy
trajectory over time. Reproduced from reference.1 Copyright 2018 American Chemical
Society.
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Fig S. 5. Apo-MT MD result. Cysteine S shown in yellow. H bond interactions are
indicated in blue. Reproduced from reference.1 Copyright 2018 American Chemical
Society.
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Fig S. 6. Top: Rh2MT MD result. Cysteine S shown in yellow. Rh shown in teal. Bottom:
Potential Energy trajectory over time Reproduced from reference.1 Copyright 2018
American Chemical Society.

197

Fig S. 7. Rh2MT MD result with Rh2 in the β-domain. Cysteine S shown in yellow. Rh
shown in teal. H bond interactions are indicated in blue. Reproduced from reference.1
Copyright 2018 American Chemical Society.
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Fig S. 8. Top: Rh2MT MD result with Rh2 in a conformation in the α-domain. Cysteine S
shown in yellow. Rh shown in teal. Reproduced from reference.1 Copyright 2018
American Chemical Society.
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Fig S. 9. Rh2MT MD result with Rh2 in a conformation in the α-domain Cysteine S
shown in yellow. Rh shown in teal. H bond interactions are indicated in blue. Reproduced
from reference.1 Copyright 2018 American Chemical Society.
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Fig S. 10. Top: Rh2MT MD result with Rh2 in an alternate conformation in the α-domain.
Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy trajectory over
time. Reproduced from reference.1 Copyright 2018 American Chemical Society.
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Fig S. 11. Rh2MT MD result with Rh2 in an alternate conformation in the α-domain.
Cysteine S shown in yellow. Rh shown in teal. H bond interactions are indicated in blue.
Reproduced from reference.1 Copyright 2018 American Chemical Society.
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Fig S. 12. Top: Rh4MT MD result with Rh2 in the β-domain and Rh2 in a conformation in
the α-domain. Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy
trajectory over time. Reproduced from reference.1 Copyright 2018 American Chemical
Society.

203

Fig S. 13. Rh4MT MD result with Rh2 in the β-domain and Rh2 in a conformation in the
α-domain. Cysteine S shown in yellow. Rh shown in teal. H bond interactions are
indicated in blue. Reproduced from reference.1 Copyright 2018 American Chemical
Society.
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Fig S. 14. Top: Rh4MT MD result with Rh2 in the β-domain and Rh2 in an alternate
conformation in the α-domain. Cysteine S shown in yellow. Rh shown in teal. Bottom:
Potential Energy trajectory over time. Reproduced from reference.1 Copyright 2018
American Chemical Society.
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Fig S. 15. Rh4MT MD result with Rh2 in the β-domain and Rh2 in an alternate
conformation in the α-domain. Cysteine S shown in yellow. Rh shown in teal. H bond
interactions are indicated in blue. Reproduced from reference.1 Copyright 2018 American
Chemical Society.
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Fig S. 16. Top: Rh4MT MD result with Rh4 in the α-domain. Cysteine S shown in yellow.
Rh shown in teal. Bottom: Potential Energy trajectory over time. Reproduced from
reference.1 Copyright 2018 American Chemical Society.
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Fig S. 17. Rh4MT MD result with Rh4 in the α-domain. Cysteine S shown in yellow. Rh
shown in teal. H bond interactions are indicated in blue. Reproduced from reference.1
Copyright 2018 American Chemical Society.
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Fig S. 18. Top: Rh6MT MD result with Rh2 in the β-domain and Rh4 in the α-domain.
Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy trajectory over
time. Reproduced from reference.1 Copyright 2018 American Chemical Society.
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Fig S. 19. Rh6MT MD result with Rh2 in the β-domain and Rh4 in the α-domain. Cysteine
S shown in yellow. Rh shown in teal. H bond interactions are indicated in blue.
Reproduced from reference.1 Copyright 2018 American Chemical Society.
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D. L. Wong and M. J. Stillman, Metallothionein: An Aggressive Scavenger—The
Metabolism of Rhodium (II) Tetraacetate (Rh2 (CH3CO2) 4), ACS Omega, 2018, 3,
16314-16327.
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Appendix D: Surfaces and Orbital Energies for GSH bound
to Rh2(OAc)4

Fig S1. Expanded views of Rh2(OAc)4 molecular orbital surfaces, part 1/2. Calculations
and image from A. Zhang in reference, 1 reproduced with permission from the Royal
Society of Chemistry.
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Fig S2. Expanded views of Rh2(OAc)4 molecular orbital surfaces, part 2/2. Calculations
and image from A. Zhang in reference, 1 reproduced with permission from the Royal
Society of Chemistry.
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Fig S3. Expanded views of Rh2(OAc)4(H2O)2 molecular orbital surfaces, part 1/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Fig S4. Expanded views of Rh2(OAc)4(H2O)2 molecular orbital surfaces, part 2/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Fig S5. Expanded views of [Rh2(OAc)4(GS)(H2O)]- molecular orbital surfaces, part 1/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Fig S6. Expanded views of [Rh2(OAc)4(GS)(H2O)]- molecular orbital surfaces, part 2/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Fig S7. Expanded views of [Rh2(OAc)4(GS)2]2- molecular orbital surfaces, part 1/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Fig S8. Expanded views of [Rh2(OAc)4(GS)2]2- molecular orbital surfaces, part 2/2.
Calculations and image from A. Zhang in reference, 1 reproduced with permission from
the Royal Society of Chemistry.
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Table S1. Transition contributions for excited states (ES) with oscillator strength (f)
greater than 0.001. Calculations from A. Zhang in reference, 1 reproduced with
permission from the Royal Society of Chemistry
Rh2(OAc)4
ES

Transition

Contribution

Energy [eV

f

(nm)]
72 → 80

0.12995

78 → 80

0.67953

71 → 80

0.13086

77 → 80

0.67956

72 → 80

0.68665

78 → 80

-0.12489

71 → 80

0.68635

77 → 80

-0.12557

16

69 → 80

17
20

1

2

14

15

1.5418 (804.16)

0.0037

1.5426 (803.75)

0.0037

4.7555 (260.72)

0.0229

4.7676 (260.06)

0.232

0.69654

5.1009 (243.06)

0.0140

68 → 80

0.69633

5.1094 (242.66)

0.0142

62 → 81

0.14182

5.3426 (232.07)

0.0643

63 → 80

-0.14773

66 → 82

-0.12428

70 → 80

0.61243

79 → 87

-0.11805

79 → 88

0.14491
Rh2(OAc)42H2O

ES

Transition

Contribution

Energy [eV

f

(nm)]
1

2

86 → 90

0.10876

87 → 91

0.17148

88 → 90

0.65326

80 → 90

0.10439

87 → 90

0.65256

2.2561 (549.55)

0.0034

2.3078 (537.23)

0.0027
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6

7

15

88 → 91

0.19584

76 → 92

-0.11427

84 → 92

-0.20679

87 → 90

-0.22219

88 → 91

0.61712

74 → 92

-0.12927

83 → 92

0.20788

87 → 91

0.62609

88 → 90

-0.19353

72 → 91

0.13910

75 → 92

-0.11732

86 → 90

0.61760

88 → 90

-0.10257

89 → 99

0.20974

3.1246 (396.80)

0.0018

3.1860 (389.15)

0.0019

5.2099 (237.98)

0.1489

[Rh2(OAc)41GS]ES

Transition

Contribution

Energy [eV

f

(nm)]
1

2

4

153 →166

-0.12239

161 →166

-0.30150

165 →166

0.57168

165 →167

-0.11791

153 →167

-0.12419

161 →167

-0.20202

161 →169

0.10319

163 →166

0.44851

163 →167

0.12743

165 →167

0.35148

153 →167

-0.13409

161 →167

-0.15160

162 →169

0.14879

2.0002 (619.85)

0.0013

2.3540 (526.69)

0.0029

2.5712 (482.20)

0.0013
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6

13

14

15

163 →166

-0.37276

163 →167

-0.12279

163 →169

0.14540

165 →166

0.13916

165 →167

0.43725

161 →166

0.23994

161 →169

0.32872

162 →169

-0.10429

163 →166

0.10738

163 →167

-0.24660

163 →169

0.34638

165 →166

0.20374

165 →169

-0.13194

153 →167

0.19539

154 →166

-0.10185

156 →166

-0.16372

161 →167

0.42275

163 →166

0.12060

164 →166

0.26718

165 →167

0.31264

153 →167

-0.10584

161 →167

-0.24010

164 →166

0.58547

165 →167

-0.15724

138 →166

0.13137

152 →166

0.22820

154 →166

0.23745

156 →166

0.46218

157 →166

0.12203

160 →166

-0.10821

161 →167

0.15066

2.7976 (443.18)

0.0016

3.8002 (326.26)

0.0704

3.8639 (320.88)

0.3938

4.0651 (305.00)

0.0569

221

163 →166

-0.10670

164 →166

0.19565
[Rh2(OAc)42GS]2-

ES

Transition

Contribution

Energy [eV

f

(nm)]
1

2

9

232 → 245

-0.12926

235 → 242

0.13289

235 → 244

-0.14224

236 → 242

0.42475

236 → 244

-0.21641

239 → 242

-0.21184

239 → 244

0.15268

240 → 242

0.29186

240 → 244

-0.11257

234 → 245

-0.12280

235 → 242

0.31121

235 → 244

0.16534

236 → 244

-0.17550

238 → 242

0.28945

238 → 244

0.22085

239 → 242

-0.23043

240 → 242

-0.19450

240 → 244

-0.20986

232 → 245

0.12454

233 → 244

0.14644

234 → 244

-0.14958

235 → 244

0.17043

235 → 245

0.22699

236 → 242

0.15648

236 → 244

0.33913

2.3396 (529.93)

0.0029

2.3866 (519.50)

0.0021

2.9522 (419.98)

0.0035
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12

1.

236 → 245

-0.15082

238 → 245

0.25701

239 → 242

-0.11774

239 → 244

-0.13665

240 → 245

-0.10547

241 → 244

-0.11128

241 → 242

0.67072

3.4198 (362.55)

0.7178

D. L. Wong, A. Zhang, A. S. Faponle, S. P. de Visser and M. J. Stillman,
Glutathione binding to dirhodium tetraacetate: a spectroscopic, mass spectral and
computational study of an anti-tumour compound, Metallomics, 2017, 9, 501-516.
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Appendix E: Copyright Permissions
In Chapter 1 and 7, all figures were made by Ms. Daisy Wong and are unpublished
elsewhere, except for Figure 1-10 which was used with permission from the American
Chemical Society from the article “Kinetic Analysis of Arsenic-Metalation of Human
Metallothionein: Significance of the Two-Domain Structure” by Ngu et al. and their
permission requirements have been followed as described below.
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The figures used in Chapters 2, 3, 4, and 6 were created by Ms. Daisy Wong and
published in Royal Society Journals, and their permission requirements have been
followed as described below.

The images used in Chapter 6 are open for public use under the American Chemical
Society AuthorChoice License:
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